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ABSTRACT
Selectins are a small family of adhesion molecules that are critical for immune cell trafficking. In
our laboratory, mice lacking all combinations of selectins have been generated. Previous work
from our laboratory has demonstrated that, in the absence of selectins, human tumors
transplanted subcutaneously into Rag2'- mice grow significantly larger. This implicates selectins
and the innate immune system in tumor immune surveillance. We have extended the xenograft
tumor model to immunocompetent C57BL/6 mice. Similarly to previous experiments, we found
that many syngeneic tumors grow significantly larger in the triple selectin knockouts (ELP / )
than in ELP+' control mice. The difference in tumor growth is most apparent in ELP'- and single
L-selectin knockout (L-/ ) mice. P-selectin also contributes to selectin-dependent tumor
suppression, while E-selectin does not appear to be involved. Since selectins are known to play a
role in immune cell traffic, we explored recruitment defects in selectin knockout mice, and
discovered that natural killer (NK) cell recruitment to tumors in Matrigel is impaired. NK cells in
ELP-' and L'/ mice appear otherwise normal and functional. NK cells express L-selectin and
selectin ligands, and are known to be tumoricidal. In mice depleted of NK cells, either
pharmacologically by TM-P1 antibody injection, or genetically in NK-deficient GrzA-Ly49A
transgenic mice, tumor growth is also significantly enhanced. Tumor growth increase seen in the
absence on NK cells is not enhanced further by the absence of both NK cells and selectins,
arguing that selectins and NK cells may act in the same pathway to suppress tumor growth. The
ability of NK cells to clear tumors in selectin-deficient mice is defective. These results suggest
that NK cells act to suppress tumor growth in this system and dependent on selectins to do so.
Thus, this work contributes to the understanding of the role of selectins and NK cells in the
process of tumor immunosurveillance.
Thesis supervisor: Richard O. Hynes
Title: Professor of Biology
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Chapter I
CHAPTER 1.
INTRODUCTION
The contents of this chapter were written by Olga Sobolev, with editing by Richard Hynes.
Chapter 1
Chapter 1
History of immune surveillance
Cancer is a complex process that involves not only tumor cell-intrinsic oncogenic and tumor
suppressor events, but is also greatly influenced by the tumor microenvironment. A tumor
develops in the context of a specific tissue in a living organism, where tumor cells dynamically
interact, through both direct contact and soluble secreted factors, with the extracellular matrix,
tissue stromal cells, blood and lymphatic vessels, and the immune system [Weinberg R et. al.,
2006]. This thesis focuses on tumor interactions with the immune system.
The idea of the immune system interaction with developing tumors dates back a century, and has
had a turbulent history. In 1909, Paul Ehrlich was one of the first to propose that the immune
system acts as a sentinel, surveying the body for nascent malignancies and repressing them
[Ehrlich P, 1909]. The idea of immune control of neoplastic disease then had to await the
advances in the developing field of immunology, until in the 1960s it was resurrected by Lewis
Thomas and Macfarlane Burnet, who formulated this concept in several publications and gave it
the name of "immune surveillance" of cancer [Burnet FM, 1957; Thomas L, 1959; Burnet FM,
1970]. A great advance in tumor immunology at that time was the discovery that the newly
available inbred mouse strains could be immunized against syngeneic tumors induced by
carcinogens, viruses, or other means [Old LJ et. al., 1964]. This provided a key cornerstone for
the cancer immunosurveillance hypothesis, demonstrating that tumor cells have signatures
distinct from normal cells and can be recognized by the immune system.
With these heartening results, there followed a wave of experiments to test the logical
predictions of the immune surveillance hypothesis. If immune surveillance existed and was
indeed successful, then immune-compromised animals should exhibit greater susceptibility to
tumors than their immune-competent counterparts. Mice were thymectomized, or treated with
anti-lymphocyte serums or chemical agents to remove immune cells; the results obtained by
these methods were inconclusive [Grant GA et. al., 1965; Sanford BH et. al., 1973; Stutman O,
1975]. If differences were detected, they were mostly in susceptibility to virally induced tumors
or to lymphomas, both of which could be attributed to higher susceptibility of immune-deficient
hosts to infection: either the host is unable to fight off the virus, or the increased infection load
Chapter 1
over-stimulates the immune system and leads to its dysregulation [Klein G, 1973; Stutman O,
1975]. The identification and characterization of the athymic nude mouse with a genetic
immunologic impairment provided researchers with a new model for studying tumor
immunosurveillance [Flanagan SP, 1966; Pantelouris EM, 1968]. Studies of both spontaneous
and induced tumors in the nude mice were extensive, thorough, and failed to demonstrate any
significant differences in tumor progression between immunocompetent and nude mice [Rygaard
J et. al., 1974; Outzen HC et. al., 1975; Stutman O et. al., 1979]. Based on the limited
understanding of the immunologic defects in the nude mouse available at the time, the failure of
these experiments to uphold the central prediction of the immunosurveillance hypothesis was
highly convincing and left the hypothesis in disrepute for several decades.
In retrospect, there are several important caveats to the early experiments. First, the nude mice
are not completely immunocompromized. They have a detectable population of T cells, as well
as other lymphocyte subsets that can develop extrathymically and were not known at the time,
such as natural killer (NK) cells and y8 T cells [Ikehara S et. al., 1984; Hayday AC, 2000].
Therefore, it is not possible to predict the functional effect of the nude mutation on tumor
formation. Second, the original nude mice were on a genetic background that rendered them
particularly susceptible to carcinogen-induced tumors, thus high rates of carcinogen-induced
transformation may have overwhelmed host immunological defense mechanisms [Heidelberger
C, 1975; Dunn GP et. al., 2002]. When the experiments were later repeated in nude mice on the
Balb/c background, which does not share this problem, nude mice did form more carcinogen-
induced tumors than controls [Svane IM et. al., 1996]. Third, the duration of the largest
spontaneous tumor formation studies, which lasted 3-7 months, may not have been sufficiently
long to detect tumor formation differences [Dunn GP et. al., 2002].
The immune surveillance hypothesis was revived with the development of better immune-
deficient mouse models in the 1990s. Several key discoveries using knockout mice contributed to
its resurrection. First, it was demonstrated in several mouse backgrounds and in several
carcinogen-induced and spontaneous tumor models that endogenous interferon gamma (IFNy)
protects the host against tumor growth [Dighe AS et. al., 1994; Kaplan DH et. al., 1998; Street
SE et. al., 2002]. The same results were obtained by removing IFNy with antibody treatment
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[Dighe AS et. al., 1994], overexpressing a dominant-negative IFNy receptor subunit [Dighe AS
et. al., 1994], using IFNy knockout mice [Kaplan DH et. al., 1998; Street SE et. al., 2002], or
mice missing STAT 1, a transcription factor important for IFNy signaling [Kaplan DH et. al.,
1998]. IFNy is secreted by activated immune cells, in particular cytotoxic T cells and NK cells.
Its role in tumor suppression, therefore, pointed to the importance of the immune system in the
control of tumor growth. The second key finding was the observation that granzyme-/ mice were
more prone to carcinogen-induced and spontaneous tumor formation [van den Broek MF et. al.,
1996; Smyth MJ et. al., 2000; Street SE et. al., 2001]. Perforin is a component of cytolytic
granules in cytotoxic T cells and NK cells that is important for lymphocyte killing of many
different target cells, including tumor cells, in vitro [Russell JH et. al., 2002]. This implicated
another component of the immune system in controlling tumor growth. Finally, the existence of
cancer immunosurveillance was definitively established by using Rag-' mice. Recombination
activating genes 1 and 2 (Rag l and 2) are expressed exclusively in the lymphoid compartment
and are necessary for adaptive immune receptor rearrangement. Mice deficient in either Rag l or
Rag2 therefore completely lack natural killer T (NKT), T and B cells [Shinkai Y et. al., 1992].
These mice provided the first immune-deficient mouse model where carcinogenesis experiments
could be unequivocally interpreted [Dunn GP et. al., 2002; Diefenbach A et. al., 2002]. Studies
in Rag-'/ mice demonstrated that the absence of adaptive immune cells led to increased
spontaneous and induced carcinogenesis [Shankaran V et. al., 2001], at last validating the
immune surveillance hypothesis.
Immune surveillance is now widely accepted as a real phenomenon that exists in both mice and
humans [Dunn GP et. al., 2002; Diefenbach A et. al., 2002; Dunn GP et. al., 2004; Stagg J et. al.,
2007; Swann JB et. al., 2007]. A dissatisfying aspect of the immune surveillance hypothesis as
originally stated is that it does not take into account or explain the fact that tumors actually do
develop, in the presence of a functioning immune system and despite tumor immune
surveillance. Therefore, the theory has recently been modified into a three-step model of "tumor
immunoediting" that better corresponds to the observed clinical and experimental data [Dunn GP
et. al., 2002]. The new model consists of three steps: elimination, equilibrium, and escape. The
elimination phase corresponds most closely with the initial idea of immune surveillance, and
includes the detection and elimination of cancer cells by the immune system. The elimination
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phase can be complete, in which case the tumor disappears, or incomplete, if only a portion of
the cells is eliminated. The tumor cells that have not been eliminated enter a state of dynamic
equilibrium, where the immune system is removing tumor cells, while the tumor cells continue to
evolve under this selective pressure, accumulating further changes. The equilibrium, again, can
be resolved in any of three ways: the immune system may finally succeed in eliminating the
tumor, the tumor may remain in this state of equilibrium or as yet poorly defined "dormancy"
indefinitely, or the tumor may enter the escape phase. In this last case the tumor has found a way
to resist, avoid, or suppress the anti-tumor immune response in such a way that the immune
system is no longer able to contain tumor growth, and a progressively growing tumor results
[Dunn GP et. al., 2002; Dunn GP et. al., 2004; Stagg J et. al., 2007; Swann JB et. al., 2007].
The three "E's" of tumor immunoediting: elimination
Let us now take a closer look at what is known so far about the three proposed stages of tumor
immunoediting, and the open questions that remain. The first phase, tumor elimination, is
probably the best-studied of the three, as it has existed in the guise of immune surveillance for
many years and much information on the subject has been generated. Putting together the data
generated in various mouse models, this first phase is thought to proceed in four steps [Dunn GP
et. al., 2002; Kim R et. al., 2007]. As a small solid tumor arises and begins growing, it induces
pro-inflammatory changes in its environment that lead to the recruitment of innate immune cells
such as NK, NKT, y6 T cells, macrophages and dendritic cells (DCs) into the tumor site [Kim R
et. al., 2007]. NK, NKT, and y6 T cells can specifically recognize tumor cells and become
activated, secreting IFNy and killing tumor targets [Street SE et. al., 2004]. Second, the apoptotic
and necrotic tumor cells that have been killed by innate effector cells are taken up by immature
DCs, which mature under the pro-inflammatory conditions in the tumor and migrate to the
tumor-draining lymph node. Third, the infiltrating NK cells and macrophages continue
generating inflammatory cytokines and killing tumor cells through cytokine secretion and
contact-dependent mechanisms in the tumor. At the same time DCs that have migrated from the
tumor to the draining lymph node present tumor antigens and appropriate co-stimulation to naive
CD4÷ T cells. This leads to clonal expansion of CD8÷ cytotoxic T cells that are specific for the
tumor antigens. Last, tumor-specific CD4÷ and CD8÷ T cells home to the tumor, where the
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cytotoxic T cells eliminate the remaining tumor antigen-expressing tumor cells [Shankaran V et.
al., 2001; Dunn GP et. al., 2004; Kim R et. al., 2007].
The elimination phase, despite being well studied, is still poorly understood and poses many
unanswered questions. First, it is not clear how exactly the unmanipulated immune system can be
activated in the developing tumor, in the first step of the elimination phase. Many of the
cytotoxic cells that can recognize tumor cells directly, such as NK and NKT cells, are not tissue-
resident, and therefore likely need some other danger signal to reach and contact the tumor
initially. Conversely, most tissue-resident and tissue-patrolling cells, such as macrophages and
DCs, that may reside next to the tumor or encounter it in the early stages, do not have the
receptors to recognize tumor cells as a danger. In the absence of danger signals, they will not
promote an immune response and instead may promote tolerance to tumor antigens [Kim R et.
al., 2007]. Some recent studies indicate that tumor cells might in fact generate danger signals that
would be recognized by the tissue-patrolling cells and activate them. Uric acid released from
dying cells [Shi Y et. al., 2003], potential endogenous toll-like receptor (TLR) ligands such as
the heat shock proteins [Ohashi K et. al., 2000; Bandholtz L et. al., 2003], and unusual
extracellular matrix derivatives such as low-molecular-weight hyaluronan [Powell JD et. al.,
2005] are some candidate factors. However, the initial steps of immune recognition of cancer are
still an open and controversial question.
Second, the cell adhesion events involved in tumor elimination are not well understood. It isn't
clear how the early innate immune cells, and later the adaptive immune cells, transition from the
circulation to the tumor. The immune cells in the blood, prior to reaching the actual tumor cells,
must somehow distinguish tumor vasculature from all other blood vessels in the body and exit
the circulation specifically at that place. It is known that several features of tumor-associated
vasculature are different from normal vasculature, including overexpression of receptors for
angiogenic growth factors, markers of vasculogenesis, upregulation of coagulation cascades,
aberrant expression of adhesion molecules and molecular consequences of hypoxia; some of
these differences are being investigated for the potential of targeted tumor therapy and imaging
[Bazan-Peregrino M et. al., 2007; Ocak I et. al., 2007]. It is possible that circulating immune
cells may recognize some of these changes and use them to enter the tumor. Other adhesion
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events associated with tumor elimination involve contact between cytotoxic cells and tumor
cells, immune cell traffic from the tumor to the draining lymph node, and immune crosstalk at
the lymph node in the context of cancer. The adhesion molecules and signals that are involved in
leukocyte traffic in the process of tumor elimination remain poorly studied at this time. This
thesis focuses on the role of one family of leukocyte adhesion molecules, the selectins, in tumor
immunoediting.
Third, the role of both innate and adaptive immune cells in tumor elimination is not at all
straightforward. While there is definitive evidence for tumor-protective roles of the immune
system, there is also clear evidence for the tumor-promoting role. Innate immune cells,
particularly macrophages, have been implicated in both tumor promotion and tumor suppression
[Vakkila J et. al., 2004; Allavena P et. al., 2008]. As early as the 19th century it was proposed
that cancer is linked to inflammation, and in the recent years it has become a generally accepted
hypothesis [Coussens LM et. al., 2002; Balkwill F et. al., 2005]. Cancers associated with chronic
inflammation include lung, esophageal, gastric, pancreatic, liver, cervical, prostate, bladder and
colorectal cancers, which are among some of the most lethal in adults [Vakkila J et. al., 2004].
Macrophage infiltration is a hallmark of cancer-associated inflammation, and in the 1970s it was
found that tumor-associated macrophages (TAMs) promote tumor progression [Coussens LM et.
al., 2002; Mantovani A et. al., 2002; Balkwill F et. al., 2005]. TAMs are implicated in promoting
tumor angiogenesis and growth by producing vascular endothelial growth factor (VEGF), basic
fibroblast growth factor (bFGF), TNF and CXC chemokines [Mantovani A et. al., 2002]; they
are also implicated in promoting metastasis, both by secreting chemoattractants (such as EGF)
for cancer cells [Ahmed F et. al., 2002; Goswami S et. al., 2005], and by breaking down the
basement membrane around the pre-invasive tumors, thereby presumably enhancing the ability
of tumor cells to escape into the surrounding tissues [Goswami S et. al., 2005; Bronte V et. al.,
2005]. On the other hand, macrophages can also secrete factors that damage tumor vasculature
and lead to the hemorrhagic necrosis of the tumor, and kill tumor cells by various cytotoxicity
mechanisms including secretion of reactive nitrogen intermediates, members of the TNF family,
and antibody-dependent cellular cytotoxicity [Mantovani A et. al., 1977; Allavena P et. al.,
2008]. Interestingly, it has recently been demonstrated that inflammation can promote both
cancer and cancer immunoediting in the same mouse tumor model [Swann B et. al., 2008].
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For the adaptive immune system, the case is similarly unclear. While cytotoxic T cells are
implicated in tumor suppression, a different T cell subset, regulatory T cells, promote tumor
growth by suppressing the immune response to tumors [Ghiringhelli F et. al., 2005; Kim R et. al.,
2007]. The activation of regulatory T cells is likely due to immature DCs in the tumor
microenvironment, which also inhibit the maturation of other DCs and thus prevent activation of
cytotoxic T cells in two ways [Mahnke K et. al., 2002; Wakkach A et. al., 2003; Ghiringhelli F
et. al., 2005]. NKT cells also exist in two functionally distinct subsets; the well-characterized
invariant type I NKT cells have potent immune stimulatory effects, while the less characterized
non-invariant type II NKT cells are sufficient to suppress immune surveillance in various mouse
models of cancer [Kronenberg M, 2005; Terabe M et. al., 2005].
It has been suggested that part of the answer to the paradox of the variable tumor-suppressive
and tumor-promoting effects of the immune cells on tumor may lie in the influence of the tumor
itself. Immune-suppressive cytokines such as IL-10, IL-6, M-CSF and TGF-13 are often present
in the tumor microenvironment, and favor immature DCs and regulatory not cytotoxic T cells
[Kim R et. al., 2005]; tumors also favor the development of tumor- and metastasis-promoting
macrophage subsets [Mantovani A et. al., 2002; Allavena P et. al., 2008]. As described here,
then, it is still not entirely clear what role the immune system plays in tumor elimination; the
process is likely much more complex and variable than the simple four-step elimination program
proposed above.
The three "E's" of tumor immunoediting: equilibrium
If the tumor fails to be completely eliminated by the immune system, it may enter a period of
equilibrium where the immune system keeps tumor growth in check and attempts to eliminate
the remaining tumor cells, while new tumor cell variants arise carrying more mutations that
provide them with increasing resistance to immune attack [Dunn GP et. al., 2004; Kim R et. al.,
2007; Swann GB et. al., 2007]. Currently, the equilibrium phase is the most hypothetical of the
three phases, and its existence in itself is a subject of some debate.
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The ideas behind the equilibrium phase of tumor immunoediting come from two clinical
observations. Evidence suggests that tumors, particularly micrometastases that linger after the
removal of a primary tumor, can remain detectable but dormant for at least 10 years before
relapse of the disease [Callaway MP et. al., 1989; Stewart TH et. al., 1991; Demicheli R et. al.,
1996]. This has been noted for melanoma, low-grade lymphomas, and breast cancer, among
others [Callaway MP et. al., 1989; Stewart TH et. al., 1991; Demicheli R et. al., 1996]. In a
similar vein, there is also clinical evidence of tumor transmission with organ transplants. Tissues
from apparently tumor-free donors who have been successfully treated for cancer often give rise
to cancer in the immune-suppressed recipients, as has been reported for incidences of donor-
derived lung cancer, sarcoma, melanoma, and other malignancies [Kauffman HM et. al., 2002;
Morath C et. al., 2005; Detry O et. al., 2005; Cankovic M et. al., 2006]. In such cases one
explanation could be that the immune-controlled equilibrium-phase tumors in the donor grow out
in the recipient, where immune suppression that is necessary to prevent graft rejection shifts the
equilibrium towards tumor growth. These observations, while suggestive, do not definitively
prove that the equilibrium phase exists.
One of the predictions of the equilibrium phase is that it is an active process that selects for
tumor variants with enhanced ability to resist immune elimination. This hypothesis has been
tested in mice and seems to hold up. Tumors that develop in immune-deficient mice and are then
transferred into immune-competent recipients are rejected more readily than tumors that develop
in immune-competent mice before transfer, suggesting that an active immune system does select
for immune-resistant variants in a growing tumor [Svane IM et. al., 1996; Shankaran V et. al.,
2001; Street SE et. al., 2002]. In a more sophisticated recent study, immune-competent mice
were treated with a single low dose of a carcinogen. A few animals developed tumors, while
most remained free of detectable tumors for -200 days after carcinogen injection, at which point
they were treated with immune-depleting or control antibodies. Animals treated with control
antibodies remained largely tumor-free, while many of the immune-suppressed mice did develop
observable tumors; furthermore, similar to previous findings, spontaneously escaping tumors
were more immunogenic than tumors from immune-suppressed animals [Koebel CM et. al.,
2007]. This would suggest that in this mouse model there exists a time when tumor cells persist
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without expansion, and that expansion is controlled by the immune system. These mouse data
lend support to the existence of an equilibrium phase in the process of tumor immunoediting.
The three "E's" of tumor immunoediting: escape
If the tumor fails to be eliminated initially or at the equilibrium phase, it may eventually escape
from immune suppression and proceed to grow. There are many examples documenting that
tumors may grow despite the presence of active anti-tumor immunity. In humans, the growth of
melanomas clearly results in the priming of a tumor-specific immune response, even though the
tumor continues to grow [van Oijen M et. al., 2004]; similar findings have been reported for
prostate cancer [Scanlan MJ et. al., 2004]. In mice, concomitant immunity may be the best
example: a mouse challenged with a given tumor will reject subsequent challenges with that
same tumor at a distant site, even as the initial immunizing tumor continues to grow [Kurt RA et.
al., 1995; Kurt RA et. al., 2000; Blohm U et. al., 2002]. This suggests that tumors can
overwhelm, evade or subvert the immune response. The escape phase of tumor immunoediting is
fairly well understood, and multiple mechanisms by which tumors evade the immune system
have been discovered.
One of the earliest evasion mechanisms to be identified was the loss of antigen processing in
tumors. Many tumor cells stop displaying self-peptides in their major histocompatibility class I
(MHC class I) molecules. Since cytotoxic T cells recognize their targets through T cell receptor
interaction with MHC class I, loss of self-antigen presentation renders such tumor cells
"invisible" to the adaptive immune system. Loss of self-antigen presentation by multiple
mechanisms has been reported: MHC class I protein itself might be lost [Algarra I et. al., 2000;
Marincola FM et. al., 2000], or there might be deficiencies in immunoproteasome components
such as LMP2 and LMP7, or the immune peptide transporter TAPI [Seliger B et. al., 2000].
Some tumors overproduce inhibitors of T cell responses, such as indoleamine 2,3-dioxygenase
(IDO) or galectin-1 [Uyttenhove C et. al., 2003; Rubinstein N et. al., 2004]. The adaptive
immune system is additionally suppressed, as has already been mentioned, by the influence of
the tumor microenvironment, which promotes the generation of immune-suppressive immature
DCs and regulatory T cells.
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Loss of MHC class I, while making tumor cells invisible to cytotoxic T cells, at the same time
marks them as targets for NK cells, which can detect and respond to the lack of MHC class I
presentation. Tumors, however, have other means of evasion. For example, some tumors have
been found to secrete a soluble form of MIC proteins, which belong to a family of NK cell-
activating molecules. Soluble MIC proteins both prevent NK cell recognition of tumor cells by
saturating the receptor, and hyperactivate the NK cells, leading to receptor downregulation and
decreased overall cytotoxicity [Groh V et. al., 2002]. Cancer cells are also frequently resistant to
cytotoxic mechanisms. Some cancer cells lose components of the IFNy signaling pathway
[Kaplan DH, 1998]; others have inactivating mutations in the death receptors FAS and TRAIL
[Shih MS et. al., 2001; Wohlfart S et. al., 2004; Takahashi H et. al., 2006]; still others
overexpress antiapoptotic molecules FLIP and BCL-XL [Kataoka T et. al., 1998; Hinz S et. al.,
2000]. Understanding how to promote the existing immune response to tumor and overcome
tumor immune evasion is currently a major goal of cancer immunotherapy [Swann JB et. al.,
2007; Rosenberg SA et. al., 2008].
Immune cells and cell adhesion in tumor elimination
Many questions remain about the interactions of the immune system with tumors, some of which
have been outlined above. Mouse models have been key to advances in tumor immunology up to
this point. In our laboratory it was discovered that selectin-deficient mice additionally lacking the
adaptive immune system (Rag2-') have a defect in rejection of subcutaneously injected tumors,
and that this defect transfers with bone marrow transplants [Taverna D et. al., 2004]. Selectins
are cell adhesion molecules that are important for immune cell recruitment, both into tissues and
into lymphoid organs [Ley K et. al., 2007]. The tumor result in selectin-deficient mice indicated
that, first, selectins play a previously unrecognized role in tumor immunoediting, and, second,
that innate immune cells are involved in immune suppression of tumors in this system. Both of
these findings were very interesting, the first because very little is known about the involvement
of adhesion molecules in the immune interactions with tumors, and the second because the role
of the innate immune system in cancer is unclear and most of the data suggest that it may
actually be more pro- than anti-tumorigenic.
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This thesis aims to investigate the role of selectins, and the innate immune cells that might be
using these selectins, in tumor suppression. The subsequent chapters are structured in the
following manner:
* In Chapter 2, I will describe selectins and their role in immune cell recruitment. I will
also describe the selectin-deficient mice and the tumor system we used for the majority of
our experiments, which is subcutaneous cell injection. Finally, I will discuss the
experiments we performed to optimize the system and to confirm that selectin-mediated
tumor suppression is a real phenomenon that holds up for many tumor cell lines in
multiple mouse strains, and seems to be particularly dependent on L-selectin.
* In Chapter 3, I will describe the experiments we performed to investigate which innate
immune cells use selectins for tumor entry. It was found that, first, there is clearly a
tumor-specific immune response in our system, and, second, that while many immune
cells have slight defects in infiltrating the tumor in selectin-deficient mice, the defect in
NK cell recruitment is particularly profound.
* In Chapter 4, I will provide an overview of NK cells, including their role in anti-tumor
responses and the available data on molecules involved in NK cell migration. This will be
followed by a detailed characterization of NK cells in selectin-deficient mice, including
overall NK cell numbers, development, and functionality in in vitro cytotoxicity and
cytokine secretion assays. Finally, I will discuss several attempts at exploring the role of
selectins in NK cell adhesion to tumor vasculature.
* In Chapter 5, I will review several in vivo models of NK cell depletion, and possible in
vivo functional assays. I will then describe the consequences of NK cell depletion for
subcutaneous tumor growth, and some data suggesting that NK cells require the presence
of selectins in order to suppress tumors.
20 Chapter 1
In Chapter 6, I will summarize the work described in this thesis, the unanswered
questions that resulted from this study, and possible directions of future research that
could be undertaken to answer these questions.
Chapter 1
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CHAPTER 2.
SUBCUTANEOUS TUMOR GROWTH IS ENHANCED IN
SELECTIN-DEFICIENT MICE
The work in this chapter was conceived by Olga Sobolev and Richard Hynes. Selectin-deficient
mice were generated previously in the Hynes lab. The work described here follows on earlier
research by Daniela Taverna. The contents of this chapter were written by Olga Sobolev, with
editing by Richard Hynes.
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INTRODUCTION
The selectin family of proteins
Selectins are a subfamily of C-type lectins, molecules that bind to carbohydrate determinants and
need calcium to do so [Drickamer K, 1988; Vestweber D et. al., 1999; Sperandio M, 2006]. They
are found in all mammalian species, and seem to have been well conserved during recent
mammalian evolution since they share considerable amino acid sequence identity among human,
mouse, rat, and bovine receptors [Tedder TF et. al., 1995]. Selectins play a key role in the first
step of leukocyte recruitment to tissues from the blood stream, by mediating the initial tethering
and rolling of leukocytes along the endothelium [Vestweber D et. al., 1999]. There are three
selectin molecules, designated by prefixes which were chosen according to the cell type where
the molecules were first identified: L-selectin on leukocytes, E-selectin on activated
endothelium, and P-selectin in platelet storage granules and also on activated endothelial cells.
L-selectin was the first of the selectins to be identified. It was defined by a monoclonal antibody
MEL 14 that blocked leukocyte binding to high endothelial venules (HEV) in mouse lymph
nodes [Gallatin et. al., 1983], which are normally used by leukocytes to home to the lymph nodes
from the blood. Subsequent cloning of the MEL 14 target molecule led to the identification of L-
selectin [Lasky LA et. al., 1989; Siegelman MH et. al., 1989]. L-selectin is constitutively
expressed on the surfaces of most leukocytes, and is shed upon cell activation in some leukocytes
such as T cells and neutrophils by proteolytic cleavage of the membrane-proximal domain by
cell-surface proteases acting in cis [Vestweber D et. al., 1999; Smalley DM et. al., 2005].
Very similarly to L-selectin, E-selectin was discovered using an antibody that had been raised
against cytokine-activated human endothelial cells and blocked neutrophil binding to activated
endothelium [Bevilacqua MP et. al., 1987]. It was also cloned and found to have a structure very
similar to L-selectin [Bevilacqua MP et. al., 1989], putting it in the same family. E-selectin
induction upon endothelial activation occurs on the transcriptional level, reaching maximal level
of E-selectin protein expression on the cell surface 3-4 hours post activation and declining to
basal levels after 16-24 hours [Bevilacqua MP et. al., 1989]. Some of the factors that stimulate E-
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selectin expression are physical forces such as high shear stress, bacterial stimuli such as LPS,
and many pro-inflammatory cytokines and chemokines including VEGF, HMGB 1, TNF-a, IL-
13 and others, while factors such as IL-4, glucocorticoids and TGF-P counteract the signals that
promote E-selectin expression [Vestweber D et. al., 1999].
P-selectin was initially found as a membrane protein in the a-granules of platelets, where it is
displayed on the surface of activated platelets within seconds of activation [Hsu-Lin S et. al.,
1984; McEver RP et. al., 1984]. Cloning and structural studies also assigned it to the selectin
family [Johnston GI et. al., 1989]. Later P-selectin was also discovered in the Weibel-Palade
bodies, an endothelial cell storage granule, from which P-selectin is mobilized to the surface
within minutes of endothelial cell activation [Bonfanti R et. al., 1989; Johnston GI et. al., 1989;
Geng J-G et. al, 1990]. The stimuli that induce P-selectin expression include histamine,
thrombin, IL-3, IL-4, superoxide and oncostatin M (an IL-6 family cytokine) [Yao L et. al.,
1996; Vestweber D et. al., 1999]. Within an hour of activation P-selectin is cleared from the
membrane by protease-dependent shedding or by endocytosis. Internalized P-selectin molecules
can be recycled [Subramaniam M et. al., 1993; Vestweber D et. al., 1999].
The structure of selectins
The selectin family molecules are quite distinctive in their structure. They are all type I
transmembrane proteins that consist of an N-terminal 120-amino acid domain that shares some
features with the lectin domains of C-type animal lectins, followed by a -35-40-amino acid
epidermal growth factor (EGF) - like domain, and two to nine short consensus repeats of -60-
amino acids each, homologous to SUSHI domains (also called CCP domains) found in
complement-binding proteins (Figure lA). All selectins are anchored in the membrane by a
single transmembrane region, which is followed by a short cytoplasmic tail of 17-35 amino acids
[Bevilacqua MP et. al., 1989; Johnston GI et. al., 1989; Lasky LA et. al., 1989; Siegelman MH
et. al., 1989].
Although the domains that comprise the extracellular parts of selectins are found in many
proteins, the selectins are the only known example where these three domains are found in
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immediate juxtaposition, suggesting that this spatial relationship is important for selectin
function. Indeed, studies using chimeric selectins, as well as mutagenesis and crystallography
studies of the lectin and the EGF-like domains, demonstrated that both domains are important for
selectin interactions with their ligands [Graves BJ et. al., 1994; Kansas GS et. al., 1994; Somers
WS et. al., 2000]. The SUSHI domains have not been shown to be directly involved in ligand
binding; however, as mentioned above, their number in selectins varies, thus giving selectin
molecules different lengths, which seems important for their function. P-selectin has the most
SUSHI domains, varying between nine in human P-selectin and six in bovine. Removal of
increasing numbers of SUSHI domains has no effect on ligand binding or specificity but causes
impaired P-selectin function, which has led to the hypothesis that P-selectin must extend a
sufficient distance from the cell surface to properly mediate leukocyte rolling under shear stress
[Patel KD et. al, 1995]. L-selectin has the fewest SUSHI domains, only two in all the mammalian
species where it has been studied. However, the physical location of L-selectin on leukocytes
may make length considerations less important for this molecule. It is located on the tips of
microvilli which extend from the leukocyte body and facilitate L-selectin interaction with the
endothelium [Vestweber D et. al., 1999]. The importance of this localization for L-selectin-
mediated leukocyte tethering to the endothelium, but not for rolling itself, has been demonstrated
[von Andrian UH et. al., 1995; Finger EB et. al., 1996].
The cytoplasmic tails of selectins have been implicated both in structural functions of linking
selectins to the cytoskeleton, and in signaling events. Structurally, selectins must be anchored to
the cytoskeleton in order to withstand the shear stress on the molecule as the leukocyte uses it to
tether and roll along the wall of the blood vessel. The terminal 11 of the 17 amino acids in the
cytoplasmic tail of L-selectin have been demonstrated to bind directly to a-actinin, and this
binding interaction is important for L-selectin mediated rolling in vivo but not for ligand
recognition [Kansas GS et. al., 1993; Pavalko FM et. al., 1995]. P- and E-selectins don't appear
to bind a-actinin. E-selectin has been shown to co-precipitate cytoskeletal proteins such as a-
catenin, vinculin, paxillin, filamin, and even focal adhesion kinase (FAK), but only in studies
where crosslinking was used [Yoshida M et. al., 1996]. Therefore, the structural role for the
cytoplasmic tails of P- and E-selectins is less clear. In P-selectin, the tail is necessary for sorting
into the secretory pathway [Disdier M et. al., 1992]. All three selectins are also able to signal
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through their cytoplasmic tails. Selectin signaling will be discussed in detail in the section on the
Functions of selectins in immune cell recruitment from blood into tissue.
Selectin ligands
Selectin ligands are composed of a scaffold protein modified by certain carbohydrates. The
carbohydrate epitopes for selectins are sulfated, sialylated and fucosylated oligosaccharides
found at the nonreducing termini of core 2-dependent O-linked, and recently also on N-linked,
glycans (Figure IB) [Rosen SD, 2004; Mitoma J et. al., 2007]. The tetrasaccharide 6-sulfo sialyl
Lewisx has been identified as a minimal recognition determinant for all three selectins [Alon R
et. al., 1995; Rosen SD, 2004], and some of the enzymes that are responsible for generating and
modifying the sugars that selectins recognize are known [Rosen SD, 2004; Sperandio M, 2006].
The dependence of selectin function on properly generated carbohydrate ligands is illustrated in
patients with leukocyte adhesion deficiency syndrome II (LADII). In this disease a defect in
fucose metabolism results in failure to synthesize sialyl Lewisx and related structures, which
leads to inability to recruit neutrophils to sites of inflammation [Harlan JM, 1993; Becker DJ et.
al., 1999].
While determining the sugar epitopes for selectin binding has been challenging, it has proven
even more difficult to identify which of the glycoproteins decorated with the above-mentioned
oligosaccharides are the physiological selectin ligands. One difficulty is that selectin-binding
oligosaccharides can transfer selectin-binding activity to many different carrier proteins, even
BSA [Berg EL et. al., 1991; Varki A, 1997]. Furthermore, depending on the techniques used to
measure binding, low affinity binding interactions that will not withstand shear stress in vivo can
be mistaken for physiological ligands [Varki A, 1997]. Despite these challenges, some proteins
have been identified. The best-established ligand for all three selectins is P-selectin glycoprotein
ligand-1 (PSGL-1). This sialomucin is broadly expressed on leukocytes, and on some
nonhematopoetic cells such as the epithelium of the fallopian tubes and sporadically on the
endothelium in some pathologic tissues [Laszik Z et. al., 1996]. In vitro binding studies and in
vivo antibody-blocking experiments, as well as studies in PSGL-1 knockout mice, have clearly
demonstrated that PSGL-1 is a physiological ligand that can play a role in the function of all
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three selectins, although it is particularly important for P-selectin function [Moore KL et. al.,
1995; Ramos CL et. al., 1998; Yang J et. al., 1999; Xia L et. al., 2002]. Other ligands for
selectins that are established as likely to be physiologically relevant include glycosylation cell
adhesion molecule-i (GlyCAM-1) and CD34 in lymph nodes, mucosal vascular addressin-1
(MAdCAM-1) in mucosal lymphoid tissues and Peyer's patches, and E-selectin itself for L-
selectin; ESL-1 and CD44 on leukocytes for E-selectin; and GPIb-V-IX on platelets for P-
selectin, as well as some other glycolipids and sulfatides [Romo GM et. al., 1999; Vestweber D
et. al., 1999; Khan AI et. al., 2003; Rosen SD, 2004; Sperandio M, 2006].
Functions of selectins in immune cell recruitment from blood into tissue
Selectins play a key role in the first step of the complex process of leukocyte exit from the blood
and entry into tissue. This process is crucial both for homeostatic tissue surveillance and
leukocyte recirculation, and for proper immune response in the case of injury or infection (Figure
2A, B). A leukocyte in the bloodstream recognizes activated (such as in inflammation) or
specialized (such as in HEVs) endothelium, tethers to it, and rolls along it, which allows the
leukocyte to slow down and sample the endothelial environment prior to firm adhesion,
cytoskeletal changes, and extravasation into tissue. Selectins mediate the crucial tethering and
rolling steps [Lawrence MB et. al., 1991; Ley K et. al., 1991; von Andrian UH et. al., 1991; Patel
KD et. al., 2002]. P-selectin in the predominant leukocyte rolling receptor on acutely inflamed
endothelia [Ley K et. al, 1995]. E-selectin mediates slow rolling and contributes to the transition
from slow rolling to firm arrest [Olofsson AM et. al., 1994; Smith ML et. al., 2004]. L-selectin is
essential for leukocyte rolling in HEVs and effective transmigration into secondary lymphoid
organs; it also influences leukocyte adhesion during inflammation [Warnock RA et. al., 1999;
Rosen SD, 2004]. The role of selectins in leukocyte recruitment from the blood into the tissue is
twofold. They are important as the initial physical tethers between the leukocyte and the
endothelium. They are also signaling receptors that contribute to the activation of leukocyte
integrins, aj3-dimeric adhesion receptors that mediate firm leukocyte adhesion to the
endothelium and the subsequent extravasation [Lawrence MB et. al., 1991; Hynes RO, 2002].
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Upon encounter of a leukocyte with specialized or activated endothelium, L-selectin on the
leukocyte microvilli contacts the selectin ligands on the endothelium, while P- and/or E-selectin
on the endothelium interact with leukocyte selectin ligands such as PSGL-1. Binding takes place
under dynamic conditions, where continuous shear forces are exerted on the leukocyte by the
blood, which flows at an average velocity that is 10 times higher than the speed of a rolling
leukocyte. To achieve and maintain stable rolling under these conditions, selectin binding to
ligands needs to comply to some requirements, namely: rapid, although not necessarily high-
affinity, bond formation; high tensile strength during binding; and fast dissociation rate. Selectins
meet all of the requirements. Their on rates have been calculated to be on the order of 105-106
M"'* s1', with Kd's in the range of 1001xM-200nM, and koff of > 1-10 s-1 [Vestweber D et. al.,
1999]. Interestingly, the strength of ligand binding for selectins changes during the bond lifetime.
Ligand binding under shear stress induces movements in the ligand-binding loops of the lectin
domain and a 520 change in the orientation of the EGF-like domain. Shear forces essentially
stretch the selectin molecule into a more extended conformation. This conformational change
leads to stronger selectin-ligand binding, the so-called "catch bond" effect [Yago T et. al, 2004;
Phan UT et. al., 20061. After reaching a certain shear threshold the bond properties change again,
weaken, and "slip" [Smith ML et. al., 2002]. A leukocyte thus rolls along the blood vessel at a
steady rate, catching hold of the endothelium and releasing when the shear forces become
exceedingly strong. However, signaling events determine whether the leukocyte will eventually
adhere and extravasate into tissue or let go and rejoin the bloodstream.
Successful leukocyte adhesion and transmigration require integrin activation, which in turn
depends on two signals: first, a signal from leukocyte chemokine receptors if the appropriate
chemokine is immobilized on the endothelial surface, and, second, a selectin signal. Leukocyte
rolling along the endothelium gives the chemokine receptors time to encounter their respective
ligands. In the meantime, selectins are actively signaling as well [Vestweber D et. al., 1999;
Sperandio M, 2006]. L-selectin signaling is the best studied. As mentioned already, L-selectin
associates with cytoskeletal proteins including the ERM family members, and through them L-
selectin ligand binding leads to an increase in cytosolic calcium, srk-tyrosine kinase p56 1ck
activation, and phosphorylation of a number of targets including L-selectin itself, MAPK, and
small GTPases Ras and Rac2 [Laudanna C et. al., 1994; Brenner B et. al., 1996; Brenner B et.
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al., 1997]. E-selectin crosslinking leads to E-selectin clustering and subsequent association,
through the intracellular domain, with small GTPases Ras and Raf, and MAPK/ERK kinase
(MEK). These proteins trigger the downstream signaling towards MAPK and c-fos, This leads
to changes in the shape of the endothelial cells [Kaplanski G et. al, 1994; Hu Y et. al., 2000]. P-
selectin crosslinking causes phosphorylation of the cytoplasmic tail and leads to changes in the
shape of endothelial cells, but the mechanism is not yet understood in detail [Kaplanski G et. al,
1994; Crovello CS et. al., 1995]. The case is much clearer for the signaling of PSGL-1, the main
P-selectin ligand, which contributes to leukocyte activation upon binding P-selectin. Recent
findings suggest that in mouse neutrophils the cytoplasmic domain of PSGL-1 forms a complex
with Nef-associated factor 1, which is then phosphorylated by Src kinase, activates PI3K and
thus leads to integrin activation [Wang H-B et. al., 2007]. PSGL-1 also interacts with the ezrin-
radixin-moesin (ERM) family proteins; PSGL-1 crosslinking leads to signaling through Syk and
PKC and thus to integrin activation [Blanks JE et. al., 1998; Urzainqui A et. al., 2002; Atarashi
K et. al., 2005].
Selectin-null mice
Much of what is known about selectins and their in vivo functions was established through
studies in selectin-null mice. Mice lacking single selectins, all combinations of two selectins, and
finally all three selectins have been made [Mayadas TN et. al., 1993; Arbones ML et. al., 1994;
Labow MA et. al., 1994; Frenette PS et. al., 1996; Robinson SD et. al., 1999]. Selectin genes lie
within a 300kb region of mouse chromosome 1 (11), thus double and triple selectin knockouts
were generated by successive rounds of gene targeting in the same ES cells [Frenette PS et. al.,
1996; Robinson SD et. al., 1999]. The mice are viable and fertile, but do exhibit a number of
defects in leukocyte recruitment, as well as alterations in hematopoiesis.
Mice lacking L-selectin have normal numbers and proportions of circulating leukocytes.
However, the pattern of leukocyte circulation is altered. The lymph nodes are fewer, smaller and
less cellular, although their structure is preserved. The spleen is enlarged by about 25%.
Leukocyte homing studies demonstrated that in the absence of L-selectin leukocytes are
defective in entry into lymph nodes and Peyer's patches, but enter the spleen in greater numbers
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[Arbones ML et. al., 1994]. In studies of leukocyte recruitment to sites of injury (in vivo
observation of leukocyte rolling in exteriorized mesenteric vessels) [Ley K et. al., 1993;
Weninger W et. al., 2003] or inflammation (thioglycollate injection into the peritoneum)
[Arbones ML et. al., 1994; Tedder TF et. al., 1995] L-selectin-deficient mice show severe defects
in leukocyte rolling and migration.
Mice lacking P-selectin, on the other hand, have normal leukocyte recirculation and homing to
lymphoid tissues, but altered leukocyte numbers, with about a 3-fold increase in the number of
circulating granulocytes. The mice are also severely defective in injury-induced leukocyte rolling
in the mesenteric vessels, and have a defect in leukocyte recruitment to thioglycollate at early
time points that they overcome at later time points [Mayadas TN et. al., 1993]. Mice deficient in
E-selectin alone didn't show any clear defects in leukocyte rolling or recruitment, unless infused
with P-selectin blocking antibodies [Labow MA et. al., 1994; Weninger W et. al., 2000]. This
suggested overlapping functions for P- and E-selectin. Interestingly, mice missing both
endothelial selectins exhibited a much more dramatic phenotype than either one alone. PE-null
mice have 4-fold higher peripheral leukocyte counts. Neutrophil numbers are particularly
affected, but to a lesser degree so are the numbers of monocytes, eosinophils and lymphocytes.
Leukocytosis, particularly with respect to high neutrophil numbers, is present even in neonates. It
is due to increased granulocytopoiesis in the bone marrow and in the spleen. Erythropoiesis is
partly translocated to the spleens of double-null mice, and spleen size and cellularity are
increased 2-fold. Cytokine levels are elevated in the circulation. Leukocyte rolling and
recruitment to thioglycollate-induced peritonitis is severely compromised in spite of elevated
numbers of circulating leukocytes. Finally, PE-null mice succumb to spontaneous skin and eye
infections by gram-positive bacteria, which leads to ulcerative dermatitis and severe
conjunctivitis. Clearly, the endothelial selectins cooperate in regulating leukocyte homeostasis
and function [Frenette PS et. al., 1996; Frenette PS et. al., 1997; Bullard DC et. al., 1996].
Angiogenesis is not affected in PE-null mice [Hartwell DW et. al., 1998].
Triple selectin knockout mice combine the features of the L-selectin and the PE-selectin null
models and also show cooperation among the three selectins, as the phenotypes are often
exacerbated. They have small lymph nodes and aberrant leukocyte recirculation, gross
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splenomegaly, increased circulating cytokine levels, and the numbers of circulating leukocytes
are significantly higher than these in PE-null mice. Leukocyte rolling is almost completely
abolished, while leukocyte recruitment to sites of injury and inflammation is severely impaired
[Robinson SD et. al., 1999].
The creation of selectin-null mice confirmed and expanded previous knowledge of selectin
function, demonstrated a predominant role for P-selectin in inflammatory leukocyte recruitment
and for L-selectin in homeostatic leukocyte circulation, and opened a way for detailed in vivo
studies of selectin function in inflammation and disease. For example, P-selectin involvement in
asthma and allergy, and in atherosclerosis has been studied [Andr6 P, 2004]. A role for E-selectin
that is constitutively expressed in small skin vessels in promoting peripheral tolerance has been
proposed [Amatschek S et. al., 2007]. Also, the role of selectins in promoting cancer and
metastasis could now be addressed.
A role for selectins in metastasis and tumor progression
It has been known for a relatively long time that tumor cells express aberrant glycosylation
patterns [Kannagi R et. al., 2004; Witz IP, 2008]. Notably epithelial cancers often express
sialylated fucosylated selectin ligands, which in some cases are used clinically as tumor markers
[Hoff SD et. al., 1989]. An example is the antibody CA19-9 that recognizes sialyl Lewis-a
epitope and is used in the diagnosis of gastrointestinal and pancreatic cancer [Nakayama T et. al.,
1997]. Selectin ligands have also been shown to be expressed and in some cases correlate with
the progression of hepatocellular carcinoma, head and neck squamous cell carcinoma, lung and
breast cancer [Witz IP, 2008].
The best-established role for selectins in cancer is in the process of cancer metastasis. The
malignancy of a tumor is defined by the ability of the tumor cells to exit from the primary tumor
mass into the circulation and disseminate to distant sites in the body, in the process of metastasis.
Much evidence indicates that, once tumors cells enter the bloodstream, they form microemboli
by interacting with platelets and leukocytes [Pantel K et. al., 2004]. The coat of leukocytes and
platelets could in theory physically protect the metastatic tumor cell from damage by the shear
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forces in the bloodstream and from recognition and elimination by the immune system, provide
adhesion signals and growth factors for survival, and aid in lodging at a distant site, either
mechanically through the large size of the emboli or by using leukocyte rolling and adhesion
mechanisms. The questions therefore have been, do tumor cells expressing selectin ligands
metastasize better, and do selectins contribute to tumor cell metastasis?
The answer seems to be yes, to both. Studies in breast and colon cancer cells have demonstrated
that tumor cells manipulated to express high levels of selectin ligands are more metastatic, while
cells where the levels of selectin ligands have been reduced (for example by using siRNA to
downregulate the fucosyltransferase enzyme critical for ligand generation) become less
metastatic [Hiller KM et. al., 2000; Zipin A et. al., 2004; Witz IP, 2008]. Selectin ligands do
seem to contribute to the metastatic ability of tumor cells. But is this process mediated by
selectins? Studies in P-selectin knockout mice showed that fewer of the injected colon carcinoma
cells were able to arrest in the lungs and that the tumor cells were surrounded by fewer platelets
[Kim YJ et. al., 1998]. Interestingly, metastasis was also reduced in mice lacking L-selectin, and
the reduction of metastasis in P- and L-selectin double-knockout mice was greatest, indicating
synergy [Borsig L et. al., 2002]. The mechanisms of selectin-mediated metastasis are still not
altogether clear, but it seems that P-selectin promotes metastasis through tumor cell-platelet
interaction, while a recent paper indicates that L-selectin facilitates metastasis via induction of as
yet unidentified L-selectin ligands on endothelial cells and that these ligands in turn promote pro-
malignancy leukocyte-endothelial interactions at the docking sites of the tumor emboli in the
lung [Borsig L et. al., 2002; Laubli H et. al., 2006].
Despite extensive studies on the involvement of selectins in promoting tumor metastasis, little is
known about their role in the growth and progression of primary tumors. The work of Dr
Taverna in our laboratory clearly indicated that selectins are involved in this process. While
studying tumor metastasis of human cancer cell lines from a subcutaneous (s.c.) site in selectin-
null, Rag2- mice, Dr. Taverna discovered that primary tumors grow significantly larger in the
absence of selectins. She also demonstrated that the tumor phenotype largely transfers with the
bone marrow, that both leukocyte and endothelial selectins contribute to it synergistically, and
that bone-marrow derived endothelial cells do not contribute to the phenotype [Taverna D et. al.,
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2004]. This implicated the cells of the innate immune system (since the adaptive immune system
is lacking in Rag2-" mice) in selectin-dependent tumor suppression. This thesis reports
experiment to elucidate the cells involved in this process and the mechanism of it. In the
following chapter, we begin the investigation by confirming Dr. Taverna's finding, and
establishing the experimental system with mouse tumor cell lines in fully immune-competent
animals.
RESULTS
Human tumor growth is enhanced in unilaterally injected selectin-null Rag2 mice
As described in the introduction, the work of Dr. Taverna demonstrated that LS 180 human colon
cancer cells give rise to larger subcutaneous tumors in selectin-null Rag2-" mixed background
mice, as compared to selectin-sufficient Rag2- littermate controls [Taverna D et. al., 2004]. We
began our studies on the mechanism of selectin-dependent tumor suppression by setting up the
system with the cells and mice that were used in Dr. Taverna's experiments. It was important to
familiarize ourselves with the subcutaneous tumor model in order to learn the necessary
experimental techniques, to develop a set of expectations in terms of the advantages and
limitations of our experimental system, and to optimize it if necessary.
Briefly, the experimental design involved injecting tumor cells suspended in a physiological
solution into the flank of a mouse, and dissecting the resulting tumor for analysis three weeks
later (Figure 3A; for details please consult the Materials and Methods section, Appendix A). We
found that LS180 tumors injected into one flank of mixed background Rag2- ELP" or ELP +/+
mice did indeed give significantly larger tumors (p=0.002), as expected from Dr. Taverna's work
(Figure 3B). The data points were rather scattered, requiring the use of 10-15 of each control and
experimental animals in order to obtain a good data set. Such scatter is a common feature of s.c.
tumor models.
The differences we observed, although significant, were not as dramatic as previously seen.
Although tumor growth in Rag2- ELP' / + mice was comparable (mean tumor size of -200mg,
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Figure 3B), tumors in Rag2- ELP/ were smaller than reported (mean tumor size of -450mg,
Figure 3B, versus -600mg seen previously) [Taverna D et. al., 2004]. Several factors could have
contributed to the change. One confounding factor is that the Rag2- ELP " and ELP+/+ mice,
although littermates originally, have been bred as separate strains for several years since. The
animals were of a mixed C57BL/6 - 129S4 origin. Dr. Taverna's work demonstrated that the
selectin effect on tumor growth is likely mediated by an immune cell, since the tumor growth
phenotype largely transfers with bone marrow transfer. Given that the immune system and its
modifiers are known to differ significantly between inbred mouse strains, and that these
differences can affect the inflammatory response and lead to differential tumor progression
[Maria DA et. al., 2001; Ribeiro OG et. al., 2005], it is likely that separate breeding has led to
significant genetic drift and, as a consequence, tumor growth rate in Rag2- ELP" mice could
differ from tumor growth rate in Rag2- ELP +/+ animals. Another factor is that the LS 180 cells
have been passaged in vitro for several generations since Dr. Taverna's original experiments. It
is clear that laboratory tumor cell lines are not clonal but constitute mixed populations of tumor
cells, as established by Dr. Fidler's metastasis experiments [Fidler IJ et. al., 1977]. That being
the case, the cells could have drifted towards a less aggressive or more immunogenic in vivo
phenotype with successive passages. With the above caveats, we found the s.c. tumor system to
be functional in our hands and the reported selectin-dependent tumor suppression phenotype to
be robust.
In order to make the system more efficient, we attempted to grow tumors on both the left and the
right flank of the same mouse simultaneously. This would allow us to obtain twice as many data
points from the same number of animals; a significant improvement, given the abovementioned
tendency to wide scatter in tumor sizes in the s.c. tumor models. Unfortunately, we discovered
that this approach only increases the scatter in the data. When the same number of cells was
injected into both flanks of a mouse, the two tumors rarely grew to be the same size. What we
observed is that in most cases one tumor was much larger than the other, with no particular bias
to either the right or the left flank in the experimental population. This was true of tumors grown
both in the Rag2- ELP' and in the ELP +/' animals. As can be seen in Figure 3C, when tumor
sizes in opposite flanks of the same mouse are graphed against each other, the resulting points do
not fall along a diagonal in the middle, as we hoped, but scatter to either side. This could be due
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to interactions between the two tumors. It is known that a primary tumor can suppress distant
metastases, which often begin growing rapidly after the primary tumor is removed [Zetter BR,
1998; Guba M et. al., 2001]. By a similar process, one of the two tumors in our model could
suppress the other. We did not explore this phenomenon farther, but this experiment
demonstrated that the two-flank injections were not useful for our investigation, as the increase
in data "noise" within single mice obscured the differences between them. All further studies
were conducted with unilateral tumor injections.
Murine syngeneic tumor growth is unaltered in 129S4 selectin-null mice
To take the project farther and explore the immunology of tumor rejection in the endogenous
setting, we wanted to establish a model similar to the previous one but using immune-competent
mice with syngeneic tumor cell line injection. Selectin-null animals in our laboratory have been
back-crossed for 6-9 generations into pure 129S4 (kindly provided by Dr. Jaenisch), Balb/c
(Taconic), and C57BL/6 (Taconic) mouse strains. We obtained a number of tumor cell lines
syngeneic to these mouse strains (for details on the cell lines and their provenance please consult
Appendix A) and tested their subcutaneous growth in the presence or absence of selectins.
The first cells we tested were the F9 teratocarcinoma cells of the 129S4 origin [Berstine EG et.
al., 1973]. Briefly, tumors were injected into the right flank at 1*104 cells/mouse, and dissected
and weighed 3 weeks later (for detailed methods please see Appendix A). We saw no significant
difference in tumor growth between ELP +/+ 129S4 controls and the ELP- 129S4 experimental
mice (Figure 4). If anything, tumors seemed to grow slightly larger in control animals.
Teratocarcinomas are very aggressive and poorly differentiated tumors; it is possible that the cell
numbers we injected were too high and the tumor growth rate too rapid for any selectin-
dependent tumor growth differences to be detectable. However, since the initial result was
discouraging and only two of the selectin-deficient mouse strains were available in the lab on the
129S4 background, we moved on to analyze syngeneic tumors on other backgrounds.
Syngeneic tumor growth is enhanced in male Balb/c selectin-null mice
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Next we tested the CT26 Balb/c colon carcinoma cells [Brattain MG et. al., 1980], with the same
injection and analysis protocol as previously described for F9 cell injection. We discovered that
tumors did grow larger in ELP-/- Balb/c mice than in ELP +/+ Balb/c controls. The difference was
not dramatic, but statistically significant in the male (p=0.02), and not in the female mice (Figure
5A). Interestingly, the tumors in the female ELP+/+ Balb/c controls and in the ELP /' Balb/c
experimental mice also appeared larger than tumors in the male mice of the same genotype
(Figure 5A). We hypothesized that the difference could be due to the origin of the cells. If the
cells came from a female mouse, it is possible that their growth could be enhanced in the
presence of female hormones. In addition, cells of female origin could express or display
antigens that the male immune system would recognize and react against. Either of these
possibilities would lead to reduced tumor growth in the males. We tested two separately prepared
DNA samples from CT26 cells by PCR for the male-specific SRY (sex-determining region Y)
gene, using tail DNA from male and female Balb/c mice as controls. PCR for E-selectin was
performed simultaneously to control for DNA quality. We found that CT26 cells do not contain
SRY, and therefore the cell line is indeed of female origin (Figure 5B).
To test whether the adaptive immune system is involved in selectin-dependent control of CT26
tumor growth, using only male mice, we injected CT26 cells into either Balb/c or into Balb/c-
nude animals. Nude mice bear a mutation that, among other phenotypes, precludes proper
development of the thymus and therefore leads to the absence of mature T cells [Pantelouris EM,
1968]. CT26 tumor growth was no different in nude mice than in Balb/c controls. Therefore, the
control of CT26 tumor growth in our system does not seem to depend on T cells. This is
reminiscent of Dr. Taverna's finding that selectin-dependent control of human tumor growth
does not require T or B cells.
Growth of three syngeneic tumor lines is enhanced in C57BL/6 selectin-null mice
Three different syngeneic tumor cell lines were available to us on the C57BL/6 background.
MC38GFP cells derive from a C57BL/6 colon adenocarcinoma. They have been modified in the
laboratory of Dr. Varki to express GFP by stable transfection followed by two rounds of FACS
sorting for GFP fluorescence [Borsig L et. al., 2002]. B16FO cells originate from a C57BL/6
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melanoma [Briles EB et. al., 1978]. Lastly, LL/2 cells (also known as LLC) come from a Lewis
lung carcinoma [Bertram JS et. al., 1980]. We tested all the cell lines in C57BL/6 mice with and
without selectins, following the protocol described above for F9 cells.
The MC38GFP cells were injected at 5X higher numbers than the other cell lines tested, at 5*104
cells/mouse, because the cell line grows poorly at lower cell numbers (Dr. Varki, personal
communication). We found that MC38GFP cells gave rise to significantly (P=0.00063) larger
tumors in ELP " C57BL/6 mice than in ELP'+/ C57BL/6 controls (Figure 6).
The growth of B 16FO cells was measured by a different method from most of the other cell lines
described here. B16FO tumors do not grow as a solid mass, but rather as a thin gelatinous capsule
with a soft interior that resembles instant pudding in consistency. They also tend to attach
inextricably to the inner layer of the mouse skin. For these reasons, they are very difficult to
dissect and weigh accurately. Therefore, instead of dissection and weight measurement, B 16FO
tumor growth was assessed by measuring tumor length (L) and width (W) with calipers and then
calculating the surface area by multiplying these two values together (surface area = L*W).
Tumor surface area was found to be significantly larger (p=0.0005) in ELP / C57BL/6 mice than
in ELP'+/ C57BL/6 controls. Tumors were also measured in mice lacking single selectins (Figure
7). No individual selectin was seen to contribute significantly to the phenotype in this case.
LL/2 tumors, injected at 5*104 cells/mouse, only gave rise to tumors in approximately 10% of
ELP÷/+ C57BL/6 controls. Tumors grew with much greater frequency (about 90% at the highest)
in selectin-deficient mice and were larger (Figure 8A, B). Since only 6 out of 56 control mice
developed tumors, the statistical significance of the size difference could not be established.
However, chi2 analysis of tumor incidence indicated that tumor frequency was significantly
higher in the absence of selectins (p=0.00009 for ELP"/ and p=0.002 for L'/ mice). The tumors
were largest and most frequent in ELP" mice. Out of the single selectin knockouts, the L'/ mice
were most similar in tumor growth to the triple knockouts, the P" mice and the PE- double
knockouts showed a mild tumor enhancement, and the E" animals didn't develop any detectable
tumors. These data suggest that the lack of selectins on lymphocytes and not on endothelial cells
is largely responsible for enhanced tumor growth in this system, which is consistent with
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previous findings that tumor growth phenotype transfers with the bone marrow [Taverna D et.
al., 2004]. To investigate the involvement of the adaptive immune system in tumor rejection in
this cell line, we tested LL/2 tumor growth in Rag2' " mice. Tumor growth in animals lacking the
adaptive immune cells was, if anything, slightly inhibited (Figure 8C), which is once again
consistent with Dr. Taverna's findings that selectin-dependent control of human tumor growth
does not require T or B cells.
DISCUSSION
The results from this chapter lay the foundation for subsequent studies in this thesis in three
ways: we confirmed the work of Dr. Taverna with human cell lines and validated the
experimental protocol; we extended the studies to fully immune-competent mice and established
that the phenomenon of selectin-dependent tumor suppression holds for many tumor cell lines of
different origins and in different mouse backgrounds, confirming the importance of researching
this problem and giving us an assortment of mice and cell lines with which to do so. We also
confirmed that the adaptive immune system is not necessary for tumor suppression in this system
and established that L-selectin contributes the most to the phenotype, focusing our future
research on the role of selectins (particularly L-selectin) in recruitment of innate immune cells to
tumor.
The initial work with LS 180 cells recapitulated previous findings that human tumor cells give
rise to larger subcutaneous tumors in selectin-null mice, as compared to selectin-sufficient
control animals. This set of experiments allowed us to familiarize ourselves with the model and
discover its limitations. One of the challenges of working with subcutaneous tumors, as we found
out, is large scatter in the data, which necessitates the use of large numbers of animals in order to
observe significant differences between the experimental groups. We attempted to circumvent
this problem by injecting tumors into both flanks of each mouse. Theoretically that would have
allowed us to use half as many animals to obtain the same amount of data. However, this
modification proved more harmful than helpful, because the two tumors within the same mouse
appeared to interact, one suppressing the other. This led to increased data scatter. We did not
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investigate the mechanism of this phenomenon, but for all subsequent experiments in this thesis
only single-flank tumor injections were used.
Having validated some of the previous findings and familiarized ourselves with the methods, we
proceeded to extend the system to fully immune-competent mice. This in turn necessitated a
switch to syngeneic mouse tumor cell lines. We investigated the growth of five different mouse
cell lines in three different pure backgrounds. F9 teratocarcinoma cells syngeneic to 129S4 mice
showed no significant tumor growth differences in the absence of selectins. CT26 colon
adenocarcinoma cells syngeneic to Balb/c background gave significantly larger tumors in
selectin-null male mice, but not in females. The effect could be due to the origin of the cells,
which are derived from a female mouse. MC38GFP colon adenocarcinoma, Bl6FO melanoma,
and LL/2 Lewis lung carcinoma cells syngeneic to C57BL/6 mice all showed increased tumor
growth in selectin-null mice. Summarizing all the data on this subject (Table 1), tumor
overgrowth in the absence of selectins was observed with two human and four murine tumor cell
lines in two different purebred mouse backgrounds and one mixed one. Only one tumor strain of
seven tested failed to show this phenotype. Overall, syngeneic tumor injection data confirm that
selectin-dependent tumor suppression is a real and important phenomenon that is well worth
investigating.
Looking at a wide variety of tumor cell lines and mice also allowed us to choose the best
experimental system for farther experiments. The F9 cells were obviously not useful. The CT26
cells we discarded because, first, the phenotype only held for male mice, for reasons that were
not entirely clear and could complicate the experiments, and, second, because the separation in
tumor size between mice with and without selectins was significant but likely too small to work
with reliably. The MC38GFP cells, although they demonstrated a very clear growth difference,
also contained two complicating factors. They expressed high levels of GFP, which can be
immunogenic in mice [Stripecke R et. al., 1999; Bubnic SJ et. al., 2005], and they also expressed
selectin ligands [Kim YJ et. al., 1998]. We were concerned that, first, the immune response to
tumor could be skewed by strong GFP expression on tumor cells, and, second, that our study of
selectin roles in immune cell recruitment to tumors could be complicated by the possibility of
immune cells interacting directly with the tumor cells via tumor-expressed selectin ligands.
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Therefore, this cell line was also discarded. The two cell lines used for the remainder of this
thesis are B16FO and LL/2 cells in C57BL/6 mice. Both exhibited clear enhancement of tumor
growth in the absence of selectins. Also, fortuitously, C57BL/6 mice have long been the main
background used in immunological studies, and many mice with immune cell deficiencies exist
on this background, which greatly facilitated our studies of tumor immunology later on.
Using the B 16FO and the LL/2 cell lines, we explored the contribution of individual selectins to
the tumor phenotype. Both cell lines demonstrated that L-selectin makes the greatest individual
contribution to the ELP /- phenotype, while P-selectin contributes more modestly, and E-selectin
hardly at all. These findings confirm those of Dr. Taverna, who demonstrated by bone marrow
transfer experiments that immune cells contribute more to tumor suppression than do the
endothelial cells. Yet another finding from the syngeneic tumor studies was that adaptive
immune cells did not appear necessary for selectin-dependent tumor suppression. We observed
this in two different mouse models: with CT26 cells in Balb/c nude mice, which are athymic and
therefore lack mature T cells, and with LL/2 cells in C57BL/7 Rag2-/' mice, which lack B, T and
NKT cells because of inability to rearrange the B and T cell receptor genes. These data agree
well with Dr. Taverna's human cell line experiments, which were all conducted in Rag2-' mice.
Taken together, the data on tumor growth in mice missing individual selectins and the data on
the role (or rather the lack thereof) of adaptive immune cells in control of subcutaneous tumor
growth allowed us to focus further experiments more precisely. We were looking for innate
immune cells that use L-selectin (with possible contributions from endothelial or perhaps platelet
P-selectin) to control tumor growth.
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Figure 1. Structure of selectins and their ligands (adapted from Vestweber D et. al., 1999 and
Alon R et. al., 2007) (A) Domain structure of selectin molecules. (B) Structure of 6-sulfo sialyl Lewis X,
the main carbohydrate epitope for selectin, and its assembly onto o-linked and N-linked glycans.
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Figure 2. Selectins play an important role in the adhesion cascade in lymphoid and inflamed
tissues (adapted from Khan AI et. al., 2003) (A) L-selectin plays a key role in the first steps of
leukocyte recruitment to lymphoid tissues including lymph nodes and Peyer's patches. P-selectin may
contribute slightly. (B) All three selectins participate in leukocyte rolling and recruitment in inflamed or
injured tissues, but P-selectin is particularly important in these processes.
Chapter 2
A
POmRow
ALl mx
ONIlynrlw"
Alasb sma•wm
AL cru~fri
Rig Qfeal )
ROLn ROING ROWNo
3 4 5
I PSOL. bbI
b L.Nlectik &
PSO• : P.intb in& f
I ?
ourin ud 4
ik
L-~~I Oý I ý 1 4I0=0 I
Illlpimi • +lArm'•Imml•',I• m . . . .. ..
,,.,,, Ire
Addifti I"~- "
Chapter 2
Chapter 2
B
Inject
tumor cells
N
\ i -~
LS180 tumor growth in mixed Rag2- mice
800
600
S 400
S200
C
LS180 tumor growth on opposite flanks of the same Rag2-' mouse
* Rag2 - Linear regression Rag2, R2=-0.8067
* Rag2-ELP Linear regression Rag2-ELP, R2= - 1.6838
0 50 100
Right flank
150
LS 180
200 250 300
tumor weight (mg)
Figure 3. Human IS 180 tumor weight is increased in ELP- mice when tumors are injected into
one flank. (A) A schematic of the experimental design is shown above, where tumor cells are injected
subcutaneously into the flank of a mouse and dissected for analysis 3 weeks later. (B) LS180 human
colon carcinoma cells give significantly larger tumors in mixed background Rag2- mice that lack selectins.
Data are presented as tumor weights in individual animals; the horizontal black bars indicating the mean
value for the data set (*p=0.002 by students' t test). (C) Tumor cells injected into both flanks of a
mouse simultaneously do not show significant difference between mice with or without selectins, due to
high variation in tumor size on the opposite flanks of the same animal.
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Figure 4. Syngeneic tumor weight is slightly reduced in ELPF 129S4 mice.
F9 syngeneic teratocarcinoma cells injected subcutaneously into the right flank of 129S4 mice at
1*104 cells/ mouse and dissected for analysis 3 weeks later grow smaller in 129S4 ELP-/- mice as
compared with 129S4 controls, although the difference is not significant. Data are presented as tumor
weights in individual animals; the horizontal black bars indicating the mean value for the data set.
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Figure 5. Syngeneic tumor weight is increased in ELP Balb/c males but not females, and is
unaffected by the absence of mature T cells. (A) CT26 syngeneic tumor growth is enhanced in Balb/c
ELP/ - male mice as compared with Balb/c controls (*p=0.02 by students' t-test), but not in Balb/c ELP-
female mice. Data are presented as tumor weights in individual animals; the horizontal black bars
indicating the mean value for the data set. (B) CT26 cells are female in origin, by PCR for the SRY gene.
E-selectin PCR was performed simultaneously to control for DNA quality. (C) CT26 tumor growth in
Balb/c mice is not affected by the lack of functional T cells, as demonstrated by tumor injection into
athymic nude mice.
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MC38GFP tumor growth in C57BL/6 mice
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Figure 6. MC38GFP syngeneic tumor weight is increased in ELP-/ C57BLU6 mice.
MC38GFP colon adenocarcinoma cells of C57BL/6 origin were injected subcutaneously into the right
flank of C57BL/6 mice at 5*104 cells/ mouse and dissected for analysis 3 weeks later. Tumors were
found to grow significantly larger in C57BL/6-ELP'-" mice as compared with C57BL/6 controls. Data are
presented as tumor weights in individual animals; the horizontal black bars indicating the mean value for
the data set (*p=0.00063 by students' t test).
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B16FO tumor growth in selectin-null C57BL/6 mice
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Figure 7. B16FO syngeneic tumor size is increased in ELP'- C57BU6 mice.
B 16FO syngeneic melanoma cells injected subcutaneously into the right flank of C57BL/6 mice at 1*104
cells/ mouse grow significantly larger in C57BL/6-ELP -/ mice as compared with C57BL/6 controls
(p=0.0005 by students' t test). B16FO tumor size does not appear to be affected by the absence of any
one selectin. Tumor size was calculated at day 23 after tumor injection by measuring the length (L) and
width (W) of the tumor mass with calipers, then multiplying the resulting values together to obtain
tumor surface area (L*W=tumor surface area, mm2). Data are presented as box-whisker plots, the central
line denoting the mean, the shaded gray boxes and the lines denoting the 90th, 75th, 25th and the 10th
percentiles.
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Figure 8. LUJ2 syngeneic tumor weight and incidence are increased in selectin-null C57BU6
mice, but slightly reduced in Rag2-/ mice. 1*104 Lewis lung carcinoma cells (LL/2) syngeneic to
C57BL/6 were injected subcutaneously into the flanks of either C57BL/6 control mice or C57BL/6 mice
lacking one or more selectins. Three weeks post injection, tumors were dissected out and their weight (A)
and incidence (B) were measured. The absence of all three selectins, and particularly of L-selectin in
single knockouts, significantly augments tumor weight and incidence (p=0.00009 for ELP- and p=0.002
for L-" mice by chi2 analysis). P-/- and PE"/- mice show some enhancement of tumor growth, while the
absence of E-selectin has no effect. Results are presented as a box-whisker plot, the central line denoting
the mean, the shaded gray boxes and the lines denoting the 90th, 75th, 25th and the 10th percentiles. (C)
The absence of B and T cells in Rag2-/ mice leads to a slight decrease in tumor weight and incidence.
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Table 1
Mouse Increased tumor
background size in ELP-/- mice?
A375SM*Mixed Rag2-/-  A375SM* Yes; p=0.0001
human melanoma
LS180*LS180* Yes; p=0.0001
human adenocarcinoma
LS180
C57BL/6 Rag2-/-  Yes; p=0.002human adenocarcinoma
129S4 F9 No
murine teratocarcinoma sliaht size decrease. NS
C57BL/6 MC38GFPYes; p=0.0006
murine colon adenocarcinoma
B16FO
Yes; p=0.0005murine melanoma
LL/2 (LLC)LL/2 (LL Yes; p=0.00009 (X2)
murine Lewis lung carcinoma
LL/2 (LLC) No (BL/6 vs. Rag2-/-)C57BL/6 Rag2 -/-
murine Lewis lung carcinoma slight size decrease, NS
Table 1. Numerous human and murine tumor cell lines exhibit increased subcutaneous
growth in selectin-null mice. When injected subcutaneously, two human cell lines of different
developmental origin give rise to significantly larger tumors in ELP -/- mice, as compared to ELP+ /+
controls. The same phenomenon is observed in 4/5 murine cell lines of different origins tested in 3
different mouse backgrounds. As demonstrated with two human and two mouse cell lines in mice
missing either all adoptive immune cells (Rag2-/-) or functional T cells (nude), the adaptive immune
system does not appear to be necessary for selectin-dependent tumor suppression.
* from Taverna D. et. al., 2004
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CHAPTER 3.
NATURAL KILLER CELL RECRUITMENT
TO TUMORS IN MATRIGEL IS IMPAIRED
IN SELECTIN-DEFICIENT MICE.
The work in this chapter was conceived by Olga Sobolev and Richard Hynes. The contents of
this chapter were written by Olga Sobolev, with editing by Richard Hynes.
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INTRODUCTION
Innate immune cells in cancer and their expected recruitment to subcutaneous tumors
The simplest hypothesis to explain increased tumor growth in mice lacking selectins, in view of
well established role for selectins in immune cell recruitment to tissue from the blood, would be
that selectins help some type of tumoricidal immune cell reach the tumor and eliminate it, or at
least limit its growth. In the absence of selectins the said immune cell would fail to reach its goal
and the tumor would grow unchecked. Initial experiments in tumor growth led us to conclude
that the adaptive immune system is not necessary for selectin-dependent tumor suppression (see
Chapter 2). We therefore focused on investigating innate immune cell recruitment to tumors.
There are many more kinds of innate immune cells than of adaptive, and their roles in
tumorigenesis are much less understood.
The innate immune system includes macrophages, dendritic cells (DCs), neutrophils, natural
killer (NK) cells, tissue-resident mast cells and their blood-borne counterparts basophils, and
eosinophils. It also includes cell fragments, namely platelets, and humoral factors such as
complement. Theoretically, any of the above, or any combination thereof, could be responsible
for selectin-dependent tumor suppression. Since L-selectin appears to be singly responsible for
the largest part of the phenotype, and is only expressed on leukocytes, we decided to disregard
the complement system and platelets, unless further data implicating them should arise.
Eosinophils are very poorly studied in the context of tumorigenesis, although eosinophil
infiltrates were first described in tumors over a hundred years ago [Wharton Jones T, 1846].
There is some clinical data from the 70s and 80s that describes tumor-associated tissue
eosinophilia in many epithelial cancers and correlates such infiltrates with better prognosis in
cervical cancer [Lowe D et. al., 1981]. However, the field hasn't progressed much since these
correlative human studies. Since there are no good tools to study the role of eosinophils in
mouse, we decided not to focus on these cells in the initial experiments. Basophils have not been
associated with cancer, but mast cells have become more prominent in tumor biology in the last
couple of years. They are found in the stoma surrounding certain tumors, and seem to be
particularly associated with mammary adenocarcinoma [Conti P et. al., 2007; De Nardo DG et.
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al., 2007]. Mast cells have been proposed to be both tumor-promoting and to play a role in tumor
rejection; on balance, recent evidence from mouse models supports their role in promoting tumor
progression [Coussens LM et. al., 2002; Ribatti D et. al., 2003]. However, when we began this
project mast cells were almost as poorly studied in cancer as basophils and eosinophils.
Therefore, we initially decided to focus on NK cells, DCs, macrophages and neutrophils. All of
these have been observed in tumors and suggested to play some functional role in tumor
immunity, although whether that role was to support or suppress tumors was often unclear and
varied depending on the experimental system [Coussens LM et. al., 2002; Dunn GP et. al., 2004].
As we considered the kinetics of innate immune cell recruitment to tumors, we largely had to
rely on what is known about the subject in cases of infection. In most instances immune cell
recruitment to tumors was not studied dynamically, but assayed at a fixed time point fairly late in
tumor progression. At such a time one finds a large number of macrophages, particularly near
tumor edges, as well as a few T cells, some NK cells, and perhaps DCs [Coussens LM et. al.,
2002; Taverna D et. al., 2004]. What are the kinetics of recruitment that lead to this end state?
From infection studies it is well established that neutrophils respond very quickly and enter the
tissue within minutes to a few hours after injury [Issekutz AC et. al., 1980]. Selectins certainly
contribute to this process [Vestweber D, 1992; Smith CW, 1993]. However, neutrophils do not
survive long in tissue but die within a few days of tissue entry. In our system, since tumor cells
are delivered along with tissue damage by the injection needle, we might well expect an early
wave of neutrophils. Macrophages and DCs reach the site of inflammation after neutrophils,
within the first day, and then continue to enter the tissue until inflammation is resolved [Ryan
GB et. al., 1977; Doherty DE et. al., 1988]. Therefore, we would expect to see macrophage and
DC infiltration into the tumor that would continue and then perhaps plateau. Since macrophages
and DCs are seen in later-stage tumors, we wouldn't expect them to disappear. NK cell kinetics
are best studied in viral infections. In such cases they appear within the first three days after
infection, and disappear around day 7, when T cells begin to replace them [Morris MA et. al.,
2004; Prlic M et. al., 2005]. NK cells are also sometimes observed in later-stage tumors; putting
that together with infection data, we would provisionally expect NK cells to build up over the
first 3-5 days and then perhaps linger in the tumor (Figure 6).
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Matrigel as a physical substrate to study immune cell recruitment
From inflammation, viral infection and tumor studies, our expectation was that most of the
immune cells of interest will begin appearing in the tumor within the first week after injection.
Our interest in analyzing the early time points of immune cell recruitment to tumor presented a
technical challenge. Namely, at the fairly low tumor cell numbers used in our experiments,
palpable tumor masses only appear after about two weeks post tumor injection. Before that time
it is nearly impossible to identify the site of injection, much less extract immune cells from the
nascent tumor. We needed a physical substrate in which to embed tumor cells and trap any
infiltrating immune cells.
One such substrate that is widely used for in vivo angiogenesis studies is Matrigel. It is a
commercial preparation (BD Biosciences) of solubilized basement membrane extracted from
EHS (Engelbreth-Holm-Swarm) mouse sarcoma, a tumor rich in ECM proteins. Its major
components are laminin, followed by collagen IV, heparan sulfate proteoglycans, and entactin
[Kleinman HK et. al., 1982; Kleinman HK et. al., 1986]. One property makes Matrigel
particularly suited to our purpose: it is liquid at 40C, so that tumor cells can be mixed into it, and
polymerizes quickly at 370C to form a solid "plug" at the site of injection (in our case under the
skin) that can be dissected, dissociated, and analyzed for cellular content.
However, Matrigel also presented some potential concerns that we had to be aware of in
planning our experiments. One concern was that Matrigel is known to promote tumor growth,
and has even been used specifically to augment tumor growth in immunosuppressed mice
[Pretlow TG et. al., 1991; Sterling-Levis K et. al., 1993]. With enhanced tumor growth, would
selectin-dependent mechanisms of tumor suppression still play a role, or would the growth-
promoting properties of Matrigel overwhelm them? This question we could only resolve
experimentally. Matrigel likely promotes tumor growth by several mechanisms. Firstly, it
consists of a rich mix of matrix molecules, which are known to provide anti-apoptotic and
growth-promoting signals to the cells that come into contact with them, mainly through integrins
[Giancotti FG, 1997; Hynes RO, 1999]. Matrigel also contains many growth factors [Vukicevic
S et. al., 1992]. Therefore, our second concern was that Matrigel and the growth factors it
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contains would lead to chemotaxis of immune cells into the plugs independently of tumor cell
presence or absence and distort our data. This concern could be somewhat mitigated by using
growth factor-reduced Matrigel; however, it is an issue that we kept in mind when designing the
experiments described in this chapter.
RESULTS
LL/2 tumor growth in Matrigel
For the study of immune recruitment to tumors we decided to use LL/2 cells. This cell line gives
the clearest difference in tumor growth between C57BL/6 ELP+/+ and ELP/- mice in our hands
(Chapter 2, Figure 8A, B). Matrigel is known to promote tumor growth [Pretlow TG et. al., 1991;
Sterling-Levis K et. al., 1993]; therefore, we first wanted to check whether the selectin-
dependent phenotype is preserved when LL/2 cells are co-injected with Matrigel. We found that
LL/2 tumors do indeed grow larger and have a 100% incidence in all mice when co-injected with
Matrigel. However, the phenotype of increased tumor growth in mice lacking L-selectin alone, or
all three selectins, is preserved (Figure 1). P-selectin, similar to what is observed for LL/2 cells
injected alone, plays a smaller individual role than L-selectin. Interestingly, E-selectin also
contributes to suppression of tumor growth in this system, while no such effect is seen when
LL/2 cells are injected alone. Overall, the data suggested that although the presence of Matrigel
altered the system somewhat, it was still useful for investigating the immune mechanisms of
selectin-dependent tumor suppression.
Tumor growth in selectin-null mice is most affected in the first two weeks post injection
In order to choose the best time frame for studying immune cell recruitment to tumors, we
considered several variables. As described in the introduction, we attempted to predict
approximate time courses for the expected infiltration of various immune cells of interest into the
tumor. That suggested to us that we should look somewhere in the first week post tumor
injection. However, we could also compare the actual rates of tumor growth in selectin-null and
control mice and establish experimentally when tumor growth is most affected by the lack of
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selectins. The time when tumor growth rate differs the most between selectin-null and control
animals would, by our hypothesis, be the time when the immune system is most actively fighting
the tumor and therefore the most relevant time in which to look for immune recruitment defects.
To study the rates of tumor growth we performed much the same experiment as usual (Appendix
A), but instead of waiting for the endpoint we followed tumor growth by monitoring mice every
other day and measuring either the diameter, or the surface area (surface area = tumor length *
tumor width), of any tumors detected. In this way we studied the growth of B16FO tumors in
C57BL/6 L-/ and L+/+ mice, and of LS 180 tumors in Rag2- ELP /' and ELP+/+ mice. In both
cases we observed that once palpable tumors appeared, at approximately 16-18 days post
injection, their growth curves were nearly identical in control and selectin-deficient mice (Figure
2A, B). Therefore, it appears that the difference in tumor growth must lie somewhere in the first
two weeks post tumor injection. Unfortunately, tumors are too small to detect by palpation in
that time period, and we could not measure their growth.
We would have liked to conduct similar studies with LL/2 cells, which we planned to use in the
actual immune recruitment experiments, but could not do so because the tumor incidence for
LL/2 cells is only -10% in control animals and thus we could not compare growth rates of
control and selectin-null mice. To circumvent this problem and look at the earliest time points
with LL/2 cells we engineered tumor cells to stably express Renilla luciferase [Bhaumik S et. al.,
2002] by infecting them with retrovirus containing Renilla followed by a puromycin selection
cassette (for detailed methods see Appendix A). Luminescence was detected using the NightOwl
imaging system (Berthold Technologies). The cells luminesced strongly in vitro, particularly
when incubated with higher concentrations (10 tg/mL) of the Renilla luciferase substrate,
coelentrazine (Figure 3A). As few as 10 cells were clearly detectable. However, in vivo no
luminescence could be detected if the substrate was injected intraperitoneally or intravenously,
perhaps because the nascent tumor did not yet have functional blood vessels that would allow the
substrate to reach it. At most 3 * 104 cells were detectable immediately after injection if LL/2-
Renilla cells were co-injected with the substrate; a week later tumors were only visible in mice
that have received 1*105-1 * 106 cells and only if the substrate was delivered subcutaneously to
the site of tumor injection (Figure 3B). Since we needed to see 1 *104 cells and track them for
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two weeks, this system didn't appear to have the desired sensitivity.
Despite our best attempts, we could not track the growth of LL/2 tumors and establish the best
timeframe for analyzing immune recruitment to them. However, data from LS 180 and B 16FO
tumors both indicated that the first two weeks post tumor injection probably encompassed the
key events in control of tumor growth. That, along with the prediction that innate immune cells
of interest are likely to be recruited to the tumor within the first week, focused our study on days
1-10 post tumor injection.
Immune response to Matrigel is tumor-specific
To explore the recruitment of immune cells to tumors in Matrigel, we injected C57BL/6 ELP+/+
and ELP / mice with Matrigel alone into the left flank and with Matrigel containing 1*104 LL/2
cells into the right flank. Matrigel plugs were removed at days 1, 3, 5, 7 and 10 post injection,
dissociated, and analyzed by FACS to quantitate neutrophils, tissue resident and inflammatory
macrophages [Geissmann F et. al. 2003], DCs, and NK cells (Figure 4A, B). We also analyzed
Matrigel plugs for CD8 and CD4 T cells, for two reasons. Firstly, NK cells are defined as
NK1.1 + cells that lack T cell markers, thus we were performing T cell stains in any case.
Secondly, T cells didn't appear to be necessary for selectin-dependent tumor suppression
(Chapter 2) but could still play a subtle role in this process, and we therefore wanted to see
whether they are present at the tumor.
Looking broadly at the collective recruitment of all the leukocytes we analyzed to the tumor in
Matrigel or to Matrigel alone, it is clear that in both the C57BL/6 ELP+/+ and in the ELP" mice
there is specific immune response to tumor. In C57BL/6 mice, there was an equal initial
recruitment of immune cells to both flanks on day one, probably in response to the injury of
injection itself. Subsequantly immune cell numbers in Matrigel alone rose slightly by day 5 and
then declined steadily, whereas in the tumor-containing Matrigel plug cell numbers remained
high until day 7 and only declined by day 10 (Figure 5A). In the ELP/" mice, immune cell
numbers were very high in both plugs on day 1, probably indicating an exceedingly robust injury
response. Immune cell numbers then declined in both plugs, but the rate of decline was much
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faster in the plug consisting of Matrigel alone, resulting in the presence of significantly more
immune cells in the tumor and Matrigel plug on days 5 and 7 (Figure 5B). In the L-"- mice, the
initial immune response was comparable to that of the C57BL/6 control mice in both plugs.
From there it declined slightly in both plugs until day 5, after which it continued declining in the
Matrigel alone plug but increased by days 7 and 10 in the Matrigel plug that contained LL/2
cells. The tumor-specific response was, again, significant on day 7 (Figure 5C).
Overall, it seemed that early on there was a non-specific immune response, which evolved into a
clear tumor-specific response in all mice by day 7 post injection.
Early inflammatory response to Matrigel is neither tumor-specific nor selectin-dependent
Focusing on particular aspects of the immune response in Matrigel, we will consider the cell
types in order of their expected appearance in the plugs (Figure 6). We will first discuss the
involvement of neutrophils, tissue-resident and inflammatory macrophages.
Neutrophils appear in high numbers in all Matrigel plugs, irrespective of the presence or absence
of tumor cells, at the earliest time point (day 1). This most likely represents a reaction to the
injury of puncturing the skin and injecting Matrigel. For the duration of the time course, the
presence of neutrophils, except for possibly day 7 in C57BL/6 and day 3 in L- mice, did not
appear to be tumor-specific. Neutrophil numbers gradually declined in all the plugs and the cells
were almost absent by day 10 post injection (Figure 7). Tissue-resident and inflammatory
macrophages were also recruited to the tumor at high numbers by day 1, and this recruitment
likewise was independent of the presence or absence of LL/2 cells (Figure 8A, B).
Interestingly, the early inflammatory response to Matrigel injection was unimpaired in L- mice
and actually significantly enhanced in ELP-" mice in the case of neutrophils and resident
macrophages (Figure 9A, B). This finding was quite unexpected, as it is known that neutrophils
use selectins in rolling and recruitment to sites of inflammation [Rosen SD, 2004]. Several
explanations could account for this surprising finding. It is possible that the defect in recruitment
is evident at a much earlier time point, a few hours post injection, and is remedied by the earliest
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time point in our experiment. It is also possible that in the case of sterile tissue damage, such as
our experiment causes, inflammatory cells mainly rely on some other molecules than selectins,
such as ca4 integrins, which are also known to mediate leukocyte rolling [Sriramarao P et. al.,
1994; Johnston B et. al., 1996], for exiting the blood vessel. In ELP-' mice, constitutively
increased numbers of circulating inflammatory cells [Robinson SD et. al., 1999] in conjunction
with the hypotheses proposed above may account for the enhancement of inflammatory cell
recruitment.
Phagocytic cell recruitment to Matrigel is tumor-specific but selectin-independent
Following macrophage response to Matrigel, later time points demonstrated that by day 5-7 it
was quite tumor-specific. In the plugs consisting of Matrigel alone, tissue-resident macrophage
numbers steadily declined in all mice, whereas in the plugs containing LL/2 cells they either
increased by days 7-10 (C57BL/6 and L--mice), or dropped slightly from a very high initial
value to a steady number (ELP -' mice). In either case, resident macrophage numbers were
significantly higher in Matrigel + LL/2 plugs than in Matrigel alone in all mice in the later part of
the time course (Figure 8A). Inflammatory macrophages behaved very similarly to tissue-
resident macrophages in that their numbers also declined steadily in all mice in the Matrigel
alone plugs, and increased in the Matrigel + LL/2 plugs to peak around days 5-7, contributing
significantly to the tumor-specific immune response. However, unlike resident macrophages,
inflammatory macrophage numbers declined by day 10 (Figure 8B).
Dendritic cells, as expected, were recruited with slower kinetics than macrophages, building up
in both Matrigel alone and Matrigel + LL/2 plugs at about the same rate over days 3-5 in
C57BL/6 and ELP-/ mice. From then on DCs remained in the Matrigel + LL/2 plugs until day
10, when they largely disappeared, but in Matrigel alone plugs DCs started disappearing much
earlier, after day 5. In the L/' mice, there was very little DC recruitment until day 7, at which
point DCs were specifically recruited to Matrigel + LL/2 plugs. Similarly to what we observed
for macrophages, in all mice DC numbers were significantly higher in tumor-containing plugs
than in Matrigel alone on day 7 (Figure 10A). Dendritic cells clearly contributed to the tumor-
specific immune response.
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Macrophages and DCs thus looked like promising candidates for the cell type that could be
involved in selectin-dependent tumor suppression; yet when we compared macrophage and DC
recruitment to tumor on day 7 between selectin-null and control mice, no significant differences
in recruitment of these cells in the presence or absence of selectins were found. We did see a
consistent tendency to fewer macrophages and DCs in ELP /' and L-' tumor-Matrigel plugs
(Figure 11A, B).
NK cell response to Matrigel is both tumor-specific and selectin-dependent
Next we looked at the recruitment of NK cells. As expected, it was not an early event, and
followed similar kinetics to DC recruitment. NK cells also built up in both Matrigel alone and
Matrigel + LL/2 plugs at a similar rate over days 3-5 in C57BL/6 and ELP -/ mice, then remained
in the Matrigel + LL/2 plugs until day 10, and declined in Matrigel alone after day 5. In the L'
mice, there was very little NK cell recruitment until day 7, at which point NK cells were
specifically recruited to Matrigel + LL/2 plugs (Figure 10B). In summary, NK cells also
contributed significantly to the tumor-specific immune response. Focusing more closely on day
7, we found that this NK cell response to tumors was significantly defective in both the ELP -/
and the L-' mice (Figure 11C), making them good candidates for involvement in selectin-
dependent tumor suppression.
T cell response to Matrigel is tumor-specific but likely not dependent on selectins
Lastly we analyzed T cell responses to tumor. T cells were the least numerous of all the cell
types we looked at in the plugs. CD4+ T cells were slightly more abundant. They were present in
the plugs irrespective of tumor cell content and with no consistent changes in all the mice
throughout the experiment. At day 7 in L'/ mice, but in no others, there was a significantly
higher number of CD4 ÷ T cells in the plug containing LL/2 cells (Figure 12A). CD8+ T cells
were the least numerous of all and thus the hardest to quantitate accurately, but their recruitment
pattern was interesting. CD8 + T cells were recruited to all plugs in ELP /' mice early on, but only
remained, and increased slightly by day 10, in the tumor-containing plugs. Similarly, in C57BL/6
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and in L- mice, CD8÷ T cells only built up around day 5 in tumor-containing plugs and remained
into day 10 (Figure 12B). Thus there was clearly a small but significant cytotoxic T cell response
to tumor. However, CD8÷ T cell recruitment to tumors was not significantly altered in the
absence of selectins.
DISCUSSION
In this chapter we attempted to determine which immune cell could be responsible for selectin-
dependent tumor suppression. To do so, we established a system of LL/2 tumor growth in
Matrigel, a physical substrate that would allow us to trap tumor-infiltrating leukocytes; narrowed
down the time in which selectin-dependent tumor suppression most likely takes place; identified
immune cells that are responsible for the tumor-specific response in Matrigel; and, finally,
ascertained which of the components of the tumor-specific immune response fail in the absence
of selectins.
In order to study immune cell recruitment to tumors in selectin-null mice, we needed a place and
a time to look at - in other words, a substrate in which to capture tumor-infiltrating leukocytes,
and some idea of when the leukocytes are likely to be exerting their tumor-suppressive effect.
For the place, we chose Matrigel, which on the one hand consists of actual tumor matrix, and on
the other hand has physical properties that would allow us to embed tumor cells in it easily and
analyze any resulting immune recruitment at many time points. We tested LL/2 cell growth in
Matrigel in selectin-null and selectin-competent mice, and found that tumor growth in Matrigel is
still greatest in selectin-null animals. Therefore, Matrigel was a reasonable system in which to
explore immune cell recruitment to tumors.
However, there are some caveats to this system that must be kept in mind. First, tumor growth in
Matrigel was enhanced in all mice. This is not unreasonable, since tumor matrix would provide
anchorage, growth factors, and thus growth and survival cues to the tumor cells co-injected with
it. This overall enhancement of growth did not appear to alter the selectin-dependent tumor
suppression phenotype, and therefore probably is not a big concern. Second, the profile of
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selectins that are involved in tumor suppression altered in Matrigel. L-selectin still appeared to
play a key role, P-selectin was involved, but E-selectin, which did not do so in LL/2 tumors
alone, contributed to the control of tumor growth in Matrigel. It is not clear how the presence of
Matrigel caused E-selectin involvement in tumor suppression. Perhaps the growth factors that
Matrigel contains led to upregulation of E-selectin on tumor-infiltrating blood vessels, whereas
tumor cells injected on their own are not able to do that. However achieved, the involvement of
E-selectin in Matrigel-imbedded tumor suppression may have altered the profile of the immune
cells present in the tumor in this system, compared to s.c. tumors alone.
For the best time to catch the immune cell responsible for selectin-dependent tumor suppression,
we chose to look at the first 10 days after tumor injection. The decision was based, first, on the
knowledge from inflammation literature that innate immune cells are typically early responders,
arriving at the site of damage within hours to days, and, second, on the studies of tumor growth
rates in mice with and without selectins. Analysis of the growth curves of B 16F0 and LS 180
tumors in selectin-deficient and selectin-replete mice demonstrated that the greatest effect of
selectins on tumor growth is in the first couple of weeks after tumor injection. Once the tumors
were established, they appeared to grow at similar rates in all animals. We were not able to
establish if this was also true specifically for LL/2 tumors, for technical reasons, but had to be
content with the assumption that this cell line likely behaves similarly to the ones we were able
to study. Therefore, we decided to focus on immune cell infiltration of tumors within the first
two weeks after injection.
Having established a model and a timeframe for the experiment, we proceeded to look at the
actual immune recruitment. Since we were interested specifically in the immune response to
tumors, all immune infiltrates were compared to the immune cell content of contralaterally
injected plugs consisting of Matrigel alone. Our first observation was that the immune system
responded quite strongly to the injection itself, presumably due to the tissue damage caused, and
that this early response was not tumor-specific. It consisted of about equal numbers of
neutrophils and macrophages, which is expected for an inflammatory response to injury.
Interestingly, ELP " and L" mice had no defect in mounting this early immune response. The
ELP / mice in fact generated a significantly enhanced early immune response. This is contrary to
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some earlier studies which demonstrated that L-selectin and P-selectin are key for efficient
neutrophil and monocyte recruitment to sites of inflammation [Mayadas TN et. al., 1993;
Arbonds ML et. al., 1994]. It is possible that the earliest time point we assayed is past the time
where the defect is most profound, which seems to be around 1-4 hours after injury or infection
[Mayadas TN et. al., 1993; Arbonds ML et. al., 1994; Frenette PS et. al., 1997]. The enhanced
inflammatory cell numbers in ELP -- mice could then perhaps be explained by increased number
of circulating myeloid cells in these animals [Robinson SD et. al., 1999]. It is also possible that
the model makes a difference. Most of the previous studies of inflammation in selectin-null mice
used severe inflammatory stimuli such as thioglycollate or Streptococcus pneumoniae injection
into the peritoneum [Mayadas TN et. al., 1993; Arbonds ML et. al., 1994; Bullard DC et. al.,
1996]. The defect in early inflammatory response may well be much milder, or altogether absent,
in the case of sterile, mild tissue damage such as caused by a subcutaneous injection.
Tumor-specific immune response was clearly observable in all mice around days 5 and 7 post
injection. It consisted of NK cells, macrophages, and DCs, listed in the order of relative
abundance in the tumor on these days. The recruitment of all of these cells was to some degree
defective in ELP -' and L-' mice. Inflammatory macrophages were not significantly affected in
the absence of selectins, but there was a definite downward trend in their numbers. Tissue-
resident macrophage numbers were significantly lower in L-' mice, while DC numbers were
significantly down in ELP /' animals. With respect to these differences, it must also be noted that
the time courses of immune cell recruitment for many cell types looked rather dissimilar in ELP
/ and L /- mice. This served as a reminder that, although these mice share the same tumor
phenotype, there are also substantial immunological differences between them. The most
dramatic difference in tumor-specific immune response we observed was in NK cells. While
very abundant in C57BL/6 LL/2 tumors on days 5 and 7, their numbers were down to about 30%
of control in both the ELP-" and the L-/- mice.
The immune response in all plugs, whether they contained tumor cells or not, declined by day 10
after injection, as tumor growth accelerated. However, it should be noted that by day 10 we
could observe some CD8+ T cells that were present in the plugs in a tumor-specific manner and
may have been slightly, although not significantly, reduced in numbers in ELP /' and L-/ mice. It
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is thus possible that cytotoxic T cells, although they do not appear to be necessary for the control
of tumor growth in our system (as demonstrated by the experiments in Rag2- mice), may still be
involved in the process somewhat, at the later stages of tumor growth.
In summary, in this chapter we have established that there is clearly a tumor-specific immune
response to subcutaneous tumors, that it consists mainly of NK cells, macrophages and DCs, and
that the recruitment of all of these cells to tumors in impaired to some degree in ELP " and L'
mice. Since NK cells were the most abundant cell type that contributed to the tumor-specific
immune response, and since it was also the cell type that was the most dramatically affected by
the absence of selectins both in the ELP " and in the L' mice, we established NK cells as our top
candidate and proceeded to investigate their role in selectin-dependent tumor suppression.
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LL/2 tumor growth in Matrigel
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Figure 1. LL/2 s.c. tumor growth with Matrigel is enhanced in all mice, but remains
greatest in ELP-/ and L-/ animals. LL/2 tumors grow larger and with 100% incidence in all
mice when co-injected with Matrigel. However, the phenotype of increased tumor growth in
mice lacking L-selectin or all three selectins is preserved. P-selectin, similar to what is observed
for LL/2 cells injected alone, plays a smaller role than L-selectin. Interestingly, E-selectin also
contributes to suppression of tumor growth in this system, while no such effect is seen when
LL/2 cells are injected alone. Results are presented as a box-whisker plot, the central line
denoting the mean, the shaded gray boxes and the lines denoting the 90th, 75th, 25th and the
10th percentiles.
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B16FO tumor growth rate
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Figure 2. Later-stage (- past day 18) growth rate of s.c. tumors is very similar in mice
with or without selectins. (A) The rate of B16FO tumor growth in C57BL/6 L-/- and L÷/+ mice
appears nearly identical in the later stages of tumor growth, past day 18-21. Data are presented
as average tumor surface area ± SEM. (B) The rate of LS180 tumor growth in Rag2-/ ELP -' and
ELP' + mice is also very similar in the later stages of tumor growth, past day 18-21. Data are
presented as average tumor diameter ± SEM.
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A In vitro luminescence of LL/2-Renilla cells
In vivo luminescence of LL/2-Renilla cells
Figure 3. LUi2 cells expressing Renilla luciferase luminesce well in vitro but are not sufficiently
bright for in vivo studies. (A) LL/2 cells stably infected with retrovirus carrying the Renilla luciferase
gene luminesce strongly in vitro in the presence of the substrate, coelentrazine. As few as 10 cells are
detectable, particularly with higher coelentrazine concentrations. (B) The LL/2 luminescence in vivo,
however, leaves much to be desired. Intraperitoneal or intravenous injection of coelentrazine didn't yield
any detectable luminescence. If tumor cells were co-injected with coelentrazine, 3* 104 cells were detectable
immediately after injection. A week later tumors were only visible in mice that have received 1 * 105-1 * 106
cells. Since we wanted to be able to see 1*10 4 cells and track them for two weeks, this system didn't
appear to have the desired sensitivity.
B
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B
Cell identification by FACS
Figure 4. Overview of experimental design. (A) A schematic of the experimental design is shown
above, where M atrigel containing LL/2 cells is injected s.c into the right flank while M atrigel alone is
injected s.c. into the left flank; Matrigel plugs are dissected and analyzed by FACS for their immune cell
content on days 1, 3, 5, 7 and 10 after injection. (B) A table demonstrating the markers that were used to
identify various immune cell types in FACS analysis of Matrigel contents. Cells are cited in order of their
expected appearance in the tumor, the earliest expected at the top of the list.
A
Cell type FACS markers
Neutrophil CD1lb-, CD1 c-, Grl+
Resident Mý CD11b low, CD11lc, Grl-
Inflamm. Mý CD 11b high, CDllc-, Grl+
DC CD11bhigh, CD11c +, Grl-
NK CD3-, NKI.1+
CD8+ T cell CD3+, CD8+
CD4+ T cell CD3+, CD4+
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Figure 5. Immune response to LU2 cells in Matrigel is tumor-specific. (A) In C57BL/6 mice, there
was clearly a greater immune response to Matrigel plugs containing LL/2 cells than to Matrigel alone,
particularly at day 7 (*p=0.0038 by students' t test). 4 to 10 mice were analyzed at each time point; data
are presented as a mean leukocyte number ± SEM. (B) Similarly in C57BL/6 ELP-' mice more leukocytes
were recruited to M atrigel plugs containing LL/2 cells than to M atrigel alone, again particularly at day s 5
and 7 (*p=0.033 and p=0.0014 by students' t test). (C) In C57BL/6 L-/- mice also more leukocytes were
recruited to M atrigel plugs containing LL/2 cells than to M atrigel alone on day 7 after tumor injection
(*p=0.0003 by students' t test).
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Figure 6. Predicted immune response to subcutaneously injected tumor. From what is known about
migration of our immune cells of interest and what is known about their presence in later-stage tumors, we
predict the following approximate time courses for immune cell recruitment to a subcutaneously injected
tumor. Neutrophils are likely to be recruited within hours, in response to the injury caused by the
injection, and we would not expect this early response to be tumor-specific. Subsequently neutrophil
numbers should decline. Tissue-resident macrophages are likely to appear next, perhaps followed by
inflammatory macrophages, on the order of a day or two after injection. A fair number of macrophages
would be expected to be present in the Matrigel plugs from that point on. NK cells and DCs are expected
to arrive later still, perhaps 3-4 days after tumor injection. Lastly, T cells might begin infiltrating the plugs
after a week.
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Figure 7. Neutrophil recruitment is early and does not appear to be tumor-specific. As expected,
neutrophils were found at high numbers in all the plugs, irrespective of the presence or absence of tumor
cells, at the earliest time point (day 1). For the duration of the time course, their presence, except for
possibly day 7 in C57BL/6 and day 3 in L-/- mice, did not appear to be tumor-specific (*p<0.05 by
students' t test). Neutrophil numbers gradually declined and the cells were almost absent in day 10 plugs.
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Figure 8. Tissue-resident and inflammatory macrophages are recruited later and contribute
significantly to the tumor-specific immune response. (A) Tissue-resident macrophages appeared in
the tumor fairly early, although not in such large numbers as neutrophils, and behaved very differently
depending on the presence or absence of LL/2 cells in the M atrigel plug. In the plugs consisting of M atrigel
alone, macrophage numbers steadily declined in all mice. In the plugs containing LL/2 cells, macrophage
numbers either increased by days 7-10 (C57BL/6 and L-/- mice), or dropped slightly from a very high
initial value to a steady number (ELP-" mice). In either case, resident macrophage numbers were
significantly higher in M atrigel + LL/2 plugs than in M atrigel alone in all mice in the later part of the time
course (*p<0.05 by students' t test). (B) Inflammatory macrophages were also recruited to all plugs by
day 1, and behaved very similarly to tissue-resident macrophages in that their numbers also declined
steadily in all mice in the Matrigel alone plugs, and increased in the Matrigel + LL/2 plugs to peak around
days 5-7, contributing significantly to the tumor-specific immune response (*p<0.05 by students' t test).
However, unlike resident macrophages, inflammatory macrophage numbers declined by day 10.
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Figure 9. Early inflammatory response is normal in L-'- and enhanced in ELP/- mice.
Unexpectedly, we discovered that the early inflammatory response (day 1) to subcutaneous injection is
normal in L-/- mice and enhanced in ELP -/- mice. Such was the case (A) for the recruitment of neutrophils
(*p=0.025 by students' t test) and (B) for the recruitment of tissue-resident macrophages (*p=0.048 by
students' t test) . Inflammatory macrophage numbers were also unaltered in L-' mice and slightly, although
not significantly, increased in ELP-/ mice (data not shown here, but compare day 1 time point in Figure 8B)
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Figure 10. DCs and NK cells are recruited later still and also contribute significantly to the tumor-
specific immune response. (A) Dendritic cells were recruited with slower kinetics, building up in both
Matrigel alone and Matrigel + LL/2 plugs at about the same rate over days 3-5 in C57BL/6 and ELP-
mice. From then on DCs remained in the M atrigel + LL/2 plugs until day 10, when they largely
disappeared, but in M atrigel alone plugs DCs started disappearing after day 5. In the L- mice, there was
very little DC recruitment until day 7, at which point DCs were specifically recruited to M atrigel + LL/2
plugs. In all mice, DC numbers were significantly higher in Matrigel + LL/2 plugs than in Matrigel alone in
on day 7 (*p<0.05 by students' t test). (B) NK cells behaved almost identically to DCs, the only
difference being that the NK tumor-specific response lasted into day 10 after tumor injection, even though
overall NK cell numbers declined by that time (*p<0.05 by students' t test).
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Figure 11. NK cell recruitment to tumor on day 7 is significantly impaired in both L-'/- and ELP-/
mice. Since tumor-specific immune response was most prominent at day 7, additional Matrigel
recruitment experiments were conducted focusing on this time point (a total of 10 mice per genotype).
Comparing the recruitment of the immune cells that contribute to the tumor specificity of the response on
day 7 after tumor injection in the presence and absence of selectins, we saw that: (A) Inflammatory
macrophages, although they contribute to tumor specificity, do not differ significantly in their recruitment
in the presence and absence of selectins. Tissue-resident macrophages are only significantly defective in
recruitment in L-" but not in ELP-" mice (*p=0.029 by students' t test). (B) Conversely, DC recruitment
is significantly defective in ELP-/- but not in L-" mice (*p=0.006 by students' t test). (C) Only NK cell
tumor-specific recruitment was consistently and significantly impaired in both the L- and the ELP-/ mice
(*p=0.0001 and p=0.0006, respectively, by students' t test).
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Figure 12. T cells are recruited very late and CD8+ T cells contribute to the tumor-specific
immune response at day 10. (A) Generally very few T cells were detected in the plugs. CD4 ÷ T cells
were present in the plugs irrespective of tumor cell content and with no consistent changes in all the mice
throughout the experiment. At day 7 in L-/ mice, but in no others, there was a significantly higher number
of CD4+ T cells in the plug containing LL/2 cells (*p<0.05 by students' t test). (B) CD8 ÷ T cells behaved
in a more interesting way, although, being the least numerous of all the cell types assayed, they were the
hardest to quantitate accurately. CD8' T cells were recruited to all plugs in ELP- mice early on, but only
remained, and increased slightly by day 10, in the tumor-containing plugs. Similarly, in C57BL/6 and in L-/'
mice, CD8+ T cells only built up around day 5 in tumor-containing plugs and remained into day 10
(*p<0.05 by students' t test). However, CD8+ T cell recruitment to tumors was not significantly altered in
the absence of selectins.
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Summary of changes in immune cell recruitment
to Matrigel + LL/2 on day 7 after injection
Change in Change inCell type FACS markers Cell %  in Changein
L% - vs. C57BUJ6? ELP-/- vs. C57BU6?
NK CD3-, NK1.1 30% 3-fold 3-fold 4
Resident Mý CD11b low, CDllc-, GrlV 20% 2-fold No change
Inflamm. M4 CDllbhigh, CD11c, Grl+  20% No change No change
Neutrophil CD11b-, CD11c-, Grl +  15% No change 2-fold
DC CDIlbhigh, CD 11c +, Grl1 5-10% No change 4-fold
CD4 + T cell CD3+, CD4+  2% No change No change
CD8 + T cell CD3+, CD8 + 1% No change No change
Figure 13. Selectin-dependent changes in immune cell recruitment to Matrigel + LUJ2 tumor
plugs on day 7 after tumor injection. The table summarizes any significant changes that were detected
in any of the cell types assayed between C57BL/6 mice and mice lacking selectins on day 7 after tumor
injection (n=10 mice per genotype). Cells are listed in order from highest to lowest cell number found in
tumors on day 7, with the most abundant cell type at the top of the table and the least abundant cell type
at the bottom. Downward-pointing arrows indicate a statistically significant (p-value at least <0.05 by
students' t test) decrease in recruitment to M atrigel + LL/2 tumor.
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CHAPTER 4.
CHARACTERIZATION OF NATURAL KILLER CELLS
IN SELECTIN-DEFICIENT MICE
The work in this chapter was conceived by Olga Sobolev and Richard Hynes. The contents of
this chapter were written by Olga Sobolev, with editing by Richard Hynes.
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INTRODUCTION
We found selectin-deficient mice to be specifically defective in natural killer cell recruitment to
tumors. This made NK cells our top candidate for mediating selectin-dependent tumor
suppression. NK cells are also a good candidate because they are known, and were in fact
discovered and named for, their ability to recognize and destroy tumor cells. As is described in
the following introduction, NK cells develop with a diverse repertoire of invariable activating
and inhibitory receptors, which enable NK cells to recognize targets that have either lost their
major histocompatibility cluster (MHC) class I molecule expression, which is present on all
normal cells in the body ("missing self' recognition), or gained the expression of viral or stress-
induced antigens that are not normally present on healthy cells ("altered self' recognition). Both
loss of MHC class I and the gain of inappropriate antigens are common for transformed or virally
infected cells. NK cells that have found a target can destroy it through a variety of mechanisms,
and can also aid the adaptive immune system in mounting an appropriate immune response.
However, it is still unclear what adhesion molecules are used by NK cells to traffic from blood to
tissue. In this chapter we characterize NK cells in selectin-deficient mice and test whether their
development, homeostasis, and functions are affected by the absence of selectins, as well as
attempting to explore the interaction of NK cells with tumor vasculature in in vitro assays.
The history and in vivo functions of a natural killer
NK cells were discovered in the 1970's, in the process of an investigation into T cell reactivity
against tumors. Mice were immunized with a particular tumor, their T cells were subsequently
harvested and tested for the ability to destroy in vitro the tumor cells that they have been
sensitized to. As a negative control, splenocytes from unimmunized mice were used. Very
surprisingly, the negative control proved to be quite efficient at eliminating tumor cells. This
ability was independent of T cells, but due to the presence of large granular lymphocytes that
seemed capable of killing tumor cells without any prior exposure or sensitization to them,
"naturally". Thus the name "natural killer", or NK, cells [Kiessling R et. al., 1974; Herberman
RB et. al., 1975].
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Shortly thereafter, NK cells were shown to effectively eliminate tumor cells from the circulation
of mice and rats [Riccardi C et. al., 1980; Barlozzari T et. al., 1983]. Studies in mice carrying the
homozygous beige mutation, which are defective in granule exocytosis and have a profound
defect in NK cell ability to kill tumor cells, develop virus-induced leukemia and carcinogen-
induced skin cancers at a higher frequency [Kirre K et. al., 1980; Talmadge JE et. al., 1980].
Mice specifically deficient in NK cells have impaired control of subcutaneous tumor growth and
experimental metastasis [Kim S et. al., 2000]. Recent breakthroughs in the NK cell receptor
biology have provided further confirmation for the importance of NK cells in tumor surveillance
in the mouse [Diefenbach A et. al., 2001; Cerwenka A et. al., 2001].
The evidence for the importance of NK cells in control of human tumors is of necessity more
correlative. Human NK cells are certainly able to kill many types of human tumor cells in vitro.
Patients with Chediak-Higashi syndrome, where NK cell degranulation and ability to kill tumor
cells are severely impaired, are susceptible to highly metastatic lymphomas [Ward DM et. al.,
2002]. NK cell function is often impaired in cancer patients, as assayed by in vitro tumor killing
and cytokine secretion assays [Kastelan K et. al., 1997; Koda K et. al., 1997]. Higher peripheral
blood NK activity in treated, apparently disease-free cancer patients correlates with longer
metastasis-free survival, while NK cell infiltration shows positive correlation with survival for
gastric, colorectal and squamous cell lung cancer [Yang Q et. al., 2006; Kim R et. al., 2007]. The
correlative evidence is compelling enough that NK cell therapies for cancer are being
investigated in clinical trials [Zamai L et. al., 2007].
Although NK cell research since their discovery has mostly focused on the role of NK cells in
tumor surveillance, they have other important functions that are worth mentioning. NK cells play
a key role in providing early defense against pathogenic organisms during the initial response
period while the adoptive immune system is being activated [French AR et. al., 2003]. They
recognize and respond to a variety of pathogens, including bacteria and protozoa, and are
particularly important in control of viral infections [Yokoyama WM et. al., 2002]. Humans with
selective NK cell deficiencies have particular difficulty in controlling herpes virus infection,
while mice are more susceptible to murine cytomegalovirus (MCMV) and several other viruses
[Orange JS, 2002; Yokoyama WM et. al., 2002]. NK cells play an important role during
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pregnancy, where their accumulation at the maternal-fetal interface is important for proper
remodeling of the placental blood vessels [Moffett A et. al., 2006]. They are also implicated in
other pathological processes, including autoimmunity and tissue inflammation [Baxter AG et. al.,
2002; French AR et. al., 2004].
NK cell development and life cycle
NK cells comprise the third major lymphocyte population after B and T cells [Trinchieri G,
1989]. They develop in the bone marrow, where they share a common early progenitor with T
cells. However, unlike other lymphocytes, NK cells do not undergo gene rearrangement but
instead express a repertoire of several families of invariable receptors. NK cell development
proceeds through several stages (Figure lA).
The first break between the common T/NK progenitor and a true NK progenitor (NKP) is the
expression of IL-2/15RI3 subunit (CD122). IL-15 has been demonstrated to be a critical cytokine
for NK cell development [Waldmann TA et. al., 1999]. IL-15 signaling and the transcription
factors Etsl and Id2 are known to be important for the T/NK to NKP transition [Yokoyama WM
et. al., 2004]. CD122 defines the first stage (A) of NK cell development.
The next major step of NK cell development involves a series of phenotypic changes that include
the acquisition of NK receptors. The receptors are gained in a particular order. The NKR family
receptors are the first to be expressed. Murine NK cells start expressing NKR-P 1C (NK1.1),
which is commonly used as an NK cell marker in mice, while human NK cells express NKR-
P1A [Yokoyama WM et. al., 2004]. The CD94/NKG2 receptors follow [Sivakumar PV et. al.,
1999]. NKR and CD94/NKG2 receptor expression but lack of other markers define the second
stage (B) of NK development.
At stage C, Ly49 receptors begin to appear. The Ly49 family consists of a dozen receptors which
appear on the NK cells in a stochastic process that may be influenced by specific transcription
factors [Raulet DH et. al., 2001]. The expression of Ly49 receptors does not require the presence
of CD94/NKG2 receptors, since cells expressing only Ly49 receptors exist. However, Ly49
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expression does require direct contact with bone marrow stromal cells [Roth C et. al., 2000]. The
interaction with stromal cells is not only necessary for Ly49 receptor expression, but also,
through the interaction of stromal MHC class I molecules with the Ly49 receptors, is required for
NK cell "education" or "licensing". Since NK receptor expression is stochastic, NK cells that do
not express any inhibitory receptors to self-MHC, and are therefore self-reactive, arise at a fairly
high frequency of 10-20% of all NK cells [Fernandez NC et. al., 2005]. However, such cells are
either rendered anergic in the bone marrow by excessive stimulation through the activating
receptors, or, alternatively, fail to be "licensed" by the engagement of the inhibitory receptors.
The precise mechanism is still controversial, but NK cell interactions with stroma are clearly
critical for this process [Fernandez NC et. al., 2005; Kim S et. al., 2005].
At stage D, having gained their receptors, NK cells proliferate vigorously. It is at this point
unclear whether this proliferation is triggered by the receptor expression and self-MHC
engagement. Interestingly, throughout stages B and C, when the receptor repertoire is being
generated and fine-tuned, NK cells express integrin av, but from stage D on they rapidly
downregulate it and express integrin a2 (DX5, CD49b) for all the subsequent, mature stages
[Kim S et. al., 2002]. It is tempting to speculate about the possible functions of integrin av in
NK cell interactions with bone marrow stromal cells.
Finally, NK cells exit the bone marrow and enter the circulation. Mature, functional NK cells are
characterized by increasing levels of integrin aM (Mac-1, CD 11 b) and CD43 expression. They
are now capable of killing target cells and secreting cytokines but have low proliferative capacity
unless challenged by pathogens [Kim S et. al., 2002; Yokoyama WM et. al., 2004]. NK cells
comprise 10-15% of all circulating lymphocytes. The lifetime of an NK cell in the blood is on
the order of seven to ten days [Yokoyama WM et. al., 2004; Gr6goire C et. al., 2007]. Following
activation by cytokines, resting NK cells from the blood can extravasate into tissues that contain
pathogen-infected or malignant cells [Smyth JM et. al., 2002]. At homeostasis the largest
numbers of NK cells are found in the blood, the red pulp of the spleen, and in the bone marrow,
however some also localize to the T cell zones in lymph nodes (Figure IB) [Gr6goire C et. al.,
2007; Baj6noff M et. al., 2006]. Specialized tissue-resident NK cell subsets exist in the lung, in
the liver sinusoids, and in the uterus [Gr6goire C et. al., 2007; van den Heuvel MJ et. al., 2005].
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NK cell receptors and target recognition
NK cells recognize their targets by two general mechanisms. The first mechanism, known as
"missing self' recognition, proposes that NK cells are typically kept in check by inhibitory
receptors that are specific for host MHC class I molecules bound to self-peptide [Ljunggren HG
et. al., 1990]. MHC class I molecules are constitutively expressed on all cells in the body, where
they present self-peptides. However, in cases of intracellular infection, MHC class I molecules
can also present pathogen peptides and are thus marked for recognition and elimination by
cytotoxic CD8+ T lymphocytes [Germain RN, 2004]. Many viruses have evolved mechanisms to
prevent MHC class I expression and evade recognition by CD8+ T cells [Farrell HE et. al., 1998;
Germain RN, 2004]. Tumor cells also frequently lose MHC class I expression [Garrido F et. al.,
1995]. Cells that do not express MHC class I are not recognized by CD8 + T cells, but they also
fail to interact with inhibitory receptors on NK cells [Farrell HE et. al., 1998]. Consequently NK
cell functions are not suppressed and the target is eliminated. NK cells can in consequence act
very much like mirror images of T lymphocytes [Versteeg R, 1992]. More recently a second
mechanism of target recognition by NK cells was discovered. The "altered self' recognition
depends on the activating NK receptors that bind molecules not normally expressed in healthy
tissues [Diefenbach A et. al., 2001; Smyth MJ et. al., 2002]. Some of the "altered self' ligands
have been discovered; they largely belong to a family of MHC class I -related molecules that are
induced on cells by viral infection or genotoxic damage [Diefenbach A et. al., 2001; Gomes AQ
et. al., 2007]. Hence, NK cells respond to disruption of normal cell physiology both by sensing
the absence of constitutive self and the presence of abnormal self (Figure 2A).
The inhibitory receptors that mediate NK cell target recognition by the "missing self'
mechanism were the first to be discovered. They belong to three families. The first to be cloned
were the Ly49 receptors in rodents, which are related in structure to C-type lectins and bind
directly to MHC class Ia molecules [Yokoyama WM et. al., 1989; Hanke T et. al., 1999]. There
are at least nine closely related Ly49 genes in mouse [Yokoyama WM et. al., 1993]. In humans
only a single non-functional Ly49 gene has been identified, but the same function is performed
by about ten killer cell immunoglobulin-like receptors (KIR), which also bind directly to MHC
class Ia molecules [Barten R et. al., 1999; Moretta A et. al., 1993; Colonna M et. al., 1995]. So
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far KIRs haven't been found in rodents. The third family of MHC class I binding NK receptors is
conserved between rodents and humans and consists of lectin-like CD94/NKG2 heterodimers.
There are three NKG2 genes; NKG2A and B are splice variants encoded by the same gene, while
NKG2C and E are the products of the remaining two genes [Houchins JP et. al., 1991]. All
NKG2 isoforms can associate with the unique CD94 chain to form a functional receptor [Lazetic
S et. al., 1996]. The CD94/NKG2 receptors also monitor MHC class Ia expression, but by an
indirect mechanism. They bind an MHC class Ib molecule that displays in its antigen-binding
groove the cleaved leader peptide of class Ia molecules [Braud VM et. al., 1998]. The class Ib
molecule, Qa-1 in humans and HLA-E in mice, does not traffic to the surface until a leader
peptide is bound, and therefore in essence reports on the overall MHC class Ia competence of the
cell [Long EO, 1998].
It is now known that the Ly49, KIR and NKG2 families all contain both inhibitory and activating
receptors with the same ligand specificity [Diefenbach A et. al., 2001; Smyth MJ et. al., 2002].
The cytoplasmic domains of all inhibitory NK-cell receptors contain an immunoreceptor
tyrosine-based inhibitory motif (ITIM). Ligand binding triggers tyrosine phosphorylation by src-
family kinases, which leads to recruitment and activation of phosphatases SHP- 1 and SHP-2
[Burshtyn D et. al., 1996; Kirwan SE et. al., 2007]. The activating receptors associate with an
immunoreceptor tyrosine-based activating motif (ITAM)-bearing adaptor molecule DAP 12, and
activate the ZAP70/SYK pathway upon ligand binding [Smyth MJ et. al., 2002; Kirwan SE et.
al., 2007]. The various "missing self' NK receptors are expressed in overlapping subsets of NK
cells such that most cells express a few inhibitory and activating receptors with different MHC
class I allele specificity [Raulet DH et. al., 2001]. Therefore, "missing self' recognition is a
matter of NK cells sensing alterations in the balance of activating and inhibitory signals. As
mentioned previously, the balance is set in the bone marrow, where developing NK cells are
educated to be unresponsive to self. If MHC class I is missing, the lack of inhibitory receptor
signaling will activate a subset of NK cells. However, if MHC class I levels are reduced, or only
a single allele of MHC class I is missing from a cell, very likely there exist subsets of NK cells
where this subtle MHC alteration will reduce inhibitory receptor signaling while leaving the
activating receptor signaling intact, shifting the overall balance towards NK cell activation and
target elimination [Diefenbach A et. al., 2001; Long EO, 2002].
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The "altered self' receptors are a recent and exciting addition to the NK receptor family. There
are two classes of "altered self' receptors to date. The immunoglobulin-like NKp receptor family
was discovered ten years ago. There are three human NKp's, designated NKp46, 44, and 30,
while mice have a single NKp46 receptor [Pessino A et. al., 1998; Vitale M et. al., 1998; Pende
D et. al., 1999; Biassoni R et. al., 1999]. The receptors are all activating, and, much like the
"missing self' activating receptors, signal by interacting with transmembrane ITAM-bearing
adaptor molecules such as DAP12, FcRy and CD3ý and activating the ZAP70/SYK pathway
[Cantoni C et. al., 1999; Pende D et. al., 1999]. The NKp's are clearly involved in recognition of
tumor and virally infected cells. Cytotoxicity against various tumor cell lines is significantly
blocked by blocking one or a combination of these receptors [Pessino A et. al., 1998]. However,
the tumor ligands for NKp's have remained elusive. The NKp's have also been implicated in NK
recognition of virally infected cells through hemagglutinin, in cases of flu and Sendai virus
infection [Mandelboim O et. al., 2001].
The best-characterized "altered self' receptor is NKG2D. Despite the name and the genomic
location in the NKG2 cluster, this C-type lectin differs dramatically from the other NKG2
proteins, does not associate with CD94, and does not recognize MHC class I [Diefenbach A et.
al., 2001]. Instead it can robustly activate NK cells upon binding to a family of MHC-related
molecules that are induced on tumor, infected, or stressed cells [Diefenbach A et. al., 2000;
Cerwenka A et. al., 2000; Gasser S et. al., 2005]. This receptor, its ligands and functions will be
discussed in detail in Chapter 5.
To summarize, target recognition by NK cells depends on the overall balance of activating and
inhibitory signals (Figure 2A). The various NK receptors are expressed stochastically in subsets
of NK cells such that most cells express a few inhibitory and activating receptors with different
MHC class I allele specificity, and at least one activating receptor for "altered self' [Raulet DH
et. al., 2001]. This renders NK cells exquisitely sensitive both to alterations in MHC class I
levels and repertoire on target cells, detected by reduction of inhibitory signals, and to
appearance of viral or damage-related molecules, detected by activating signals through the
"altered self' receptors.
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Mechanisms of target cell killing by NK cells
NK cells since their discovery have been best known for their ability to kill target cells. There
are, broadly speaking, three major ways in which NK cells mediate target cell killing. One way is
by the release of cytoplasmic granules that contain a number of proteins, such as perforin and
granzymes, which lyse target cells. NK cells can also express tumor necrosis factor (TNF) family
ligands, which, upon binding to appropriate receptors on target cells, cause target cell death by
caspase-dependent apoptosis. Lastly, activated NK cells can produce inflammatory cytokines
such as interferon gamma (IFNy) , that provide antiviral protection, restrict tumor angiogenesis,
and stimulate the adaptive immune system (Figure 2B).
The perforin/granzyme exocytosis is the principal pathway NK cells use to eliminate virus-
infected or transformed cells [Trapani JA et. al., 2000]. Upon encountering a potential target, the
NK cell forms an immune synapse with it. It is now generally accepted that in lymphocytes the
intracellular signaling events required for activation and effector function emanate from the
region of intercellular contact between the lymphocyte and its target that is referred to as the
immune synapse [Bromley SK et. al., 2001]. If an NK cell contacts a target cell that provides
more inhibitory than activating signal, an inhibitory synapse is formed, in which the central
region of NK cell LFA-1 (aLI32 integrin) interaction with its ligand ICAM-1 on the target cell is
surrounded by a ring of inhibitory NK cell receptors interacting with their ligands [Davis DM,
2002]. Such an interaction is relatively short-lived. An activating synapse forms in a similar way
but matures further; the activating NK receptor - ligand complexes move into the center of the
synapse, leaving a ring of LFA-1/ICAM-1 at the periphery. An activating synapse leads to NK
cell polarization: the microtubule network and the Golgi apparatus reorganize to face the target
cell, and cytotoxic granules are released specifically into the synapse [Bromley SK et. al., 2001;
Davis DM, 2002].
Perforin release in particular seems to be key for tumor target elimination. Perforin-deficient
mice have a 10-100-fold reduction in their capacity to clear MHC class I-deficient tumor cells or
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spontaneous methylcholanthrene (MCA)-induced tumors [Kaigi D et. al., 1994; van den Broek
MF et. al., 1995; Smyth MJ et. al., 1999; Smyth MJ et. al., 2001].
A large family of cell-membrane-bound and secreted cytokines of the TNF family are also able
to mediate apoptosis [Ashkenazi A, 2002]. NK cells can express at least three TNF-family
ligands: FAS ligand (FASL), TNF, and TNF-related apoptosis inducing ligand (TRAIL).
Sensitivity to these ligands depends on several parameters, such as target cell expression of the
corresponding death receptors and intracellular protective mechanisms against apoptosis. If a
tumor target expresses an appropriate death receptor, then encounter with the ligand on the NK
cell will lead to receptor clustering, assembly of a signaling complex around the cytoplasmic
tails of the receptors, caspase 8 activation and caspase-mediated apoptosis [Ashkenazi A, 2002].
TRAIL-mediated tumor killing by NK cells has been particularly well studied and there is good
evidence that it contributes to protection against metastasis and MCA-induced sarcoma
development in mice [Cretney E et. al., 2002; Takeda K et. al., 2002]. NK cell expression of
FASL also contributes to the suppression of tumor growth in vivo. Many tumor cells do not
express the FASL receptor, FAS, but NK cells directly cause FAS upregulation on targets and
then kill them in a FAS-dependent manner [Bradley M et. al., 1998; Screpanti V et. al., 2001].
Lastly, activated NK cells secrete a number of cytokines, such as IFNy, TNF, granulocyte-
macrophage colony-stimulating factor (GM-CSF), IL-5, IL-10 and IL-13, among others [Smyth
MJ et. al., 2002]. IFNy seems to be particularly important, as only mature functional NK cells
gain the ability to produce it, and are actually the major IFNy producers in the body [Loza MJ et.
al., 2002]. NK cell secretion of IFNy is involved in the suppression of viruses and other
pathogens; recent evidence suggests that it also contributes to NK cell effector functions in the
MCA-induced sarcoma model and in experimental metastasis assays [Biron CA et. al., 1999;
Street SE et. al., 2001; Smyth MJ et. al., 2002]. However, it has not been easy to dissect the
mechanism of antitumor effects of NK cell IFNy production. This cytokine has been proposed to
control cell proliferation and sensitivity to apoptosis and block angiogenesis [Hayakawa Y et. al.,
2002; Smyth MJ et. al., 2002]. NK cell IFNy also mediates activation of the innate and adaptive
immune system by stimulating the activity of phagocytes, promoting antigen presentation by
many cell types, and orchestrating leukocyte interactions with the endothelium [Smyth MJ et. al.,
2002]. The ability of NK cells to mediate innate-adaptive crosstalk has been an area of much
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recent interest and research. It will be discussed in Chapter 5, in the context of the role of NK
cells in controlling in vivo tumor growth in our system.
Adhesion molecules in NK cell migration and function
A lot is understood about NK cell recognition of, and interaction with, the target cells, but it is
much less clear how NK cells find their targets in the first place. As mentioned above, NK cells
normally reside in the blood and lymphoid organs (with the exception of lung, liver and uterus),
yet their targets, such as epithelial cancers, often arise in the peripheral tissue. The mechanisms
that govern NK cell trafficking and recruitment from blood to tissue are not well understood at
present [Gr6goire C et. al., 2007]. Furthermore, what little is known in the area is complicated by
the differences in adhesion molecule repertoire between human and murine NK cells, the two
main systems where NK cell migration has been studied. In this section I will briefly review
what is known about the roles in NK cell migration and function of the three families of
molecules that classically comprise the immune cell recruitment cascade: selectins, chemokines
and their receptors, and integrins.
NK cells do express L-selectin, PSGL-1, and some other selectin ligands, which they use for
tissue homing at homeostasis and in inflammatory situations (Figure 3B). L-selectin is expressed
on all human and murine NK cells, and the expression levels are downregulated with NK cell
activation [Uksila J et. al., 1997; Frey M et. al., 1998]. NK cell L-selectin interacts with
glycosylated L-selectin ligands on lymph node HEVs, and has been reported to be required for
mouse NK cell entry into lymph nodes in a murine model of lymph node metastasis [Frey M et.
al., 1998; Chen S et. al., 2005]. L-selectin may also be used for NK cell interactions with blood
vessels other than these in the lymph node. No in vivo studies have been done, but freshly
isolated human NK cells can roll on activated endothelial cells via L-selectin in vitro, and NK
cell binding through L-selectin stimulates adhesion through aLl2 integrin-ICAM-1 interaction
[Schneider MKJ et. al., 2002; Frey M et. al., 1998]. As L-selectin is downregulated, activated
human NK cells increase their surface expression of PSGL-1 modified to contain the L-selectin-
binding epitope PEN5. Human NK cells have been shown to use PSGL-1 to roll on immobilized
L-selectin [Andre P et. al., 2000]. They have also been demonstrated to roll on platelets using
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PSGL-1 interaction with platelet P-selectin, where PSGL-1 signaling promoted NK cell firm
adhesion through activation of aLP2 and aM32 integrins [Sheikh S et. al., 2004]. There is also
one report showing that immature human NK cells express selectin ligand Cutaneous
Lymphocyte Antigen (CLA) and that this expression is increased by treatment with
inflammatory cytokines, and one report of NK cell in vitro rolling on E-selectin via an
unidentified ligand [Tsuchiyama J et. al., 2002; Yago T et. al., 1998]. Overall, it is clear that NK
cells can use selectins for rolling and arrest in inflammatory conditions simulated in vitro, but it
is unclear whether the same is true in vivo and, if so, in what circumstances selectins are
important for NK cell recruitment.
Chemokines and chemokine receptors are also key for immune cell migration and recruitment.
NK cells in humans and mice express a plethora of chemokine receptors, some of which appear
and disappear at particular stages of NK cell activation [Robertson MJ et. al., 2002; Maghazachi
AA, 2003]. It has been extensively demonstrated that resting human NK cells can migrate in
vitro towards cytokine ligands for CXCR3, CXCR4, CX 3CR1, and to most of the CCL
chemokines (Figure 3A) [Robertson MJ et. al., 2002]. It is also clear that in vitro activation of
human NK cells promotes their chemotactic response and cytotoxicity by upregulation of CCR2,
CCR4, CCR7 and CCR8 [Robertson MJ et. al., 2002]. In vivo data for the role of various
chemokine receptors in NK cell migration are recent, sparse and often controversial. Several
chemokine receptors have been implicated in NK cell homeostatic trafficking. CCR7, which is
important for T cell lymph node homing, is expressed on human but not on mouse NK cells, and
may be important for human NK cell lymph node entry and localization in the T cell cortex
[Ferlazzo G et. al., 2004]. However, murine NK cells enter lymph nodes in the absence of any
CCR7 expression. Studies with human NK cells transplanted into mice have suggested that
CXCR4 plays a role in NK cell homing to and retention in the bone marrow [Beider K et. al.,
2003]. However, studies in mouse NK cells failed to confirm this finding [Abraham M et. al.,
2007]. Similarly, the role of CXCR3 in NK cell egress from the bone marrow is controversial,
with one study confirming and three denying such a role [Gr6goire C et. al., 2007]. Although it is
not a chemokine receptor, I will briefly mention that one of the five sphingosine-phosphate G-
protein-coupled receptors, S 1Ps, clearly does promote NK cell migration out of the bone marrow
and lymph nodes into the blood, spleen and lung [Walzer T et. al., 2007].
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Under inflammatory conditions, four chemokine receptors appear to play a key role in mouse
NK cell recruitment: CCR2, CCR5, CXCR3 and CX 3CR1 [Gr6goire C et. al., 2007]. These
receptors respond to a dozen different inflammatory chemokines, allowing for NK cell
recruitment in almost any inflammatory situation. It also allows for a lot of variation in the NK
response to inflammatory stimuli. Sometimes NK cell recruitment to the same tissue can be
mediated by different receptors. For example, human NK cell recruitment to the epithelium can
rely on CCR2, CCR5, or CXCR3, depending on the inflammatory condition [Hanna J et. al.,
2005; Ottaviani C et. al., 2006; Parolini S et. al., 2007]. In other cases, receptors can mediate
recruitment of particular NK subsets. For example, CXCR3 and CX3CR1 are expressed in an
almost mutually exclusive fashion, with CXCR3 present on less mature and CX3CR1 on more
mature NK cells [Gr6goire C et. al., 2007]. CX 3CR1 but not CXCR3 is required for NK cell
recruitment to CNS in mouse models of autoimmune encephalomyelitis, while CXCR3 has a
central role in NK cell recruitment to inflammatory lymph nodes [Huang D et. al., 2006; Martin-
Fontecha A et. al., 2004]. CX 3CR1 has also been implicated in NK cell recruitment to tumors
[Lavergne E et. al., 2003; Xin H et. al., 2005].
NK cells express multiple integrins, as has been demonstrated for both mouse and human NK
cells by antibody staining, microarray and proteomic analyses (Figure 3B) [Mocellin S et. al.,
2004; Hanna J et. al., 2004; Gr6goire C et. al., 2007]. Some of these integrins vary in interesting
ways during NK cell development (Figure lA), and some are widely used as NK cell markers, as
has been discussed previously. However, only a few integrins have been studied in terms of their
function in NK cells.
The P2 family of leukocyte-specific integrins are the best-studied NK integrin subset. NK cells
express all three a subunits associated with 12 integrin: aL, aM and aX (also known as CD11 a,
b and c) [Morris MA et. al., 2004; Gr6goire C et. al., 2007]. aLi32 integrin is highly expressed on
the surface of all NK cells. In in vitro assays, it has been demonstrated that NK cells require
aLP32 - ICAM-1 interaction for firm adhesion to and transmigration across endothelial cell
monolayers [Allavena P et. al., 1991; Allavena P et. al., 1997; Bianchi G et. al., 1993]. It is also
necessary for proper NK cell binding to and cytotoxicity against target cells [Matsumoto G et.
128
Chapter 4
al., 2000; Barber DF et. al., 2004]. Recent data from human studies suggest that the case may be
different for human NK cells, as NK cells from LAD 1 patients, who lack all 32 integrins, are
normal and fully functional in cytokine secretion and cytotoxicity assays [Castriconi R et. al.,
2007]. aM and aX integrins have not been shown to play an important role in NK cell migration
or cytotoxicity [Allavena P et. al., 1997; Bianchi G et. al., 1993]. Their expression pattern on NK
cells is suggestive though: aM integrin expression is acquired, while aX expression is decreased
upon NK cell maturation [Kim S et. al., 2002; Gr6goire C et. al., 2007].
NK cells also express several pi integrins, some of which have been shown to mediate NK cell
migration and matrix binding. The earliest studies showed that NK cells express integrins a4pl3
and a5P31 and can use them to bind to fibronectin, an important component of extracellular
matrix [Gismondi A et. al., 1991]. The in vivo role for this interaction is unclear, but it could
perhaps contribute to NK cell migration within tissues after exit from the blood vessel. Integrin
a43 1 interaction with its vascular ligand VCAM-1 is also important for NK cell migration. In
vitro it has been demonstrated to be of equal importance with the aL3P2 - ICAM-1 interaction in
mediating NK cell binding to and transmigration across endothelial cell monolayers [Allavena P
et. al., 1997; Bianchi G et. al., 1993]. A couple of in vivo studies confirm the in vitro findings.
Human NK cells required a4pl1 for bone marrow homing when transferred into mice [Franitza S
et. al., 2004]. An antibody-blocking study in mice showed that the a4pl - VCAM-1 interaction,
but not the aL32 - ICAM-1 interaction, is critical for NK cell infiltration under inflammatory
conditions of lung, liver, and B16 subcutaneous tumors [Fogler WE et. al., 1996].
Characterization of NK cells in selectin-deficient mice
Our findings in Matrigel assays (Chapter 3) have led us to hypothesize that NK cells may use
selectins to reach and eliminate the tumor. However, since NK cells haven't been characterized
in selectin-deficient mice, it was entirely possible that selectins may also play a role in any of the
aspects of NK cell biology reviewed above. Therefore, before proceeding with in vivo tumor
experiments, we investigated several aspects of selectin-deficient NK cells in vitro. First, we
wanted to make sure that the absence of selectins does not affect overall NK cell numbers,
development, or tissue distribution. As has been reviewed in the introduction to Chapter 3, the
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absence of L-selectin affects lymphocyte migration patterns, and the absence of P-selectin
disturbs leukocyte numbers. Second, the absence of selectins could potentially affect the ability
of NK cells to recognize and kill tumor targets, or to secrete cytokines. Therefore, we wanted to
confirm that selectin-deficient NK cells are functional. Third, we intended to investigate in vitro
whether selectins are directly involved in NK cell recruitment to tumor, as the Matrigel data have
led us to believe. To do so, we wanted to confirm that NK cells express L-selectin and PSGL-1,
to search for selectin ligands on the blood vessels in our subcutaneous tumors, and to assay
directly whether NK cells use selectins to bind to tumor vasculature by using the classic
Stamper-Woodruff lymphocyte binding assay [Stamper HB et. al., 1976].
RESULTS
NK cell development and activation are normal in L' and in ELP"/ - mice
First, we wanted to look at overall NK cell numbers in selectin-deficient mice. To do so, we
prepared single cell suspensions of blood, bone marrow, right inguinal lymph node and spleen
isolated from C57BL/6, L'" and ELP'" mice (please see Appendix A for methods). Three 8-10
week old animals of each genotype were used in the assay. Cells were counted, and stained for
various NK cell markers. They were then analyzed by FACS to establish the percentage of
NK1.1+, CD3- cells in the samples. From the cell count and the percent of NK cells, the number
of NK cells in the various organs was calculated. We found that mice lacking L-selectin had
approximately 3-fold fewer NK cells in the lymph node, while ELP/" mice had 2-fold more NK
cells in spleens (Figure 4A). NK cell numbers in the blood and in the bone marrow were normal
in the absence of selectins (Figure 4A). It seems that overall NK cells are affected in the
direction of the defects previously observed in selectin-deficient mice (smaller lymph nodes in
the L-selectin-null animals; much enlarged spleens in the ELP " mice) but the effect is mild.
Next, we looked at NK cell development and maturation in the absence of selectins. The samples
described above were analyzed for markers that change during NK cell development. As
described in the introduction to this chapter, integrin aV is normally high on bone marrow NK
cells and is downregulated as NK cells mature and leave the bone marrow. Analysis of aV
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expression on NK1.1+, CD3- cells demonstrates that this process is normal in selectin-deficient
mice (Figure 4B). Integrin ccaM2 is a marker of mature functional NK cells, which is usually
low on bone marrow NKs and is upregulated as they enter the circulation. NK cells from
selectin-deficient mice express normal levels of cMP32, with expected tissue expression patterns
(Figure 5A). Finally, we looked at the expression of a major NK cell receptor, NKG2D. Unlike
many of the "missing self' receptors, NKG2D should be expressed on every mature NK cell. We
found that in selectin-deficient mice NKG2D is expressed on all NK cells. Its expression levels
are normal in the bone marrow and blood, and slightly but significantly increased in the inguinal
lymph node NK cells of L' and ELP' mice (p=0.06 for L' and p=0.003 for ELP'- NK cells;
Figure 5B). Its expression is similarly increased in splenic NK cells of ELP'- mice (p=0.008;
data not shown). It seems that NK cells mature normally in the absence of selectins, and may
have some NK cell subsets that are more reactive than normal against certain tumor targets.
Selectin-deficient NK cells have normal cytokine secretion
We used two approaches to assay NK cell cytokine secretion. First, NK cells were isolated from
spleens of C56BL/6 and ELP" mice and activated overnight with cytokines (IL-2 and IL-15).
Supernatants from cytokine-stimulated NK cells were then collected and analyzed for IFNy
content using the mouse IFNy DuoSet ELISA Development System (R&D Systems). No
significant differences in IFNy secretion were found in ELP / mice (Figure 6A). Second, we
stimulated NK cells in freshly isolated unsorted splenocyte mixtures by 6-hour culture on anti-
NK1.1 antibody-coated plates. The antibody crosslinks an activating NK cell receptor, leading to
NK cell activation and IFNy production. Cells were treated with Brefeldin A while in culture to
prevent cytokine release into the medium. IFNy production in response to this stimulation was
assayed by FACS analysis for % intracellular IFNy staining in NKI.1 +, CD3- splenocytes. ELP/-
and L- NK cells showed no significant difference in IFNy production in response to stimulation
through the NK1.1 receptor. These data lead us to conclude that NK cells from selectin-deficient
mice are capable of normal cytokine production and secretion. In fact we observed a non-
significant but consistent trend towards enhanced IFNy response in NK cells from ELP / mice.
Selectins are not necessary for NK cell killing of tumor targets in vitro
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To test whether selectin-deficient NK cells are functional in tumor target killing in vitro, we
isolated NK cells from spleens of C56BL/6, L/ and ELP/" mice and activated them overnight
with IL-2 and IL-15. Increasing numbers of NK cells were then mixed with a constant number of
the classical NK cell target, Yac-1 lymphoma cells, to create different effector:target ratios, and
were co-cultured for 4 hours in a colorigenic cytotoxicity assay (please consult Appendix A for a
detailed experimental protocol). NK cells isolated from L/" and ELP " mice killed Yac-1 targets
very efficiently, and were in fact found to be slightly, though not significantly, better at killing
Yac-l targets than were the control NK cells (Figure 7A). Selectin-deficient NK cells appear to
be functional in tumor killing.
NK cells from L' and ELP / mice lack selectins throughout their lifetime and perhaps develop
mechanisms to compensate for the constitutive absence of selectins. To confirm that selectins are
not directly involved in NK target cell killing, we acutely blocked L-selectin on NK cells and
then tested NK cell ability to kill tumor targets in vitro. To do so, we isolated NK cells from the
spleens of C57BL/6 mice, activated them with cytokines overnight, and either treated or not
treated them with an L-selectin blocking antibody MEL 14. NK cells were treated with the
blocking antibody for 1 hour prior to exposure to LL/2 target cells and throughout the
cytotoxicity assay. No difference in the ability of NK cells to kill tumor targets was detected at
any effector:target ratio in the presence of the blocking antibody (Figure 7B).
Tumor cell recognition by NK cells is partly mediated by missing self mechanisms
We did not analyze extensively the precise mechanisms of tumor cell recognition in our system,
since a lot of data on the subject of NK cell killing of tumor cell lines exists already. However,
we did perform a few experiments that address this point and are worth a brief mention.
First, we performed a FACS analysis of MHC class I expression on some of our tumor cell lines.
C57BL/6 tumor cell lines LL/2 and MC38GFP were of particular interest, since they both
demonstrated strong dependence on selectins in subcutaneous tumor assays. Whole C57BL/6
splenocytes were used as a positive control. C57BL/6 mice express two major MHC class I
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molecules, H-2D and H-2K. No H-2D or H-2K expression was detected on MC38GFP cells,
while LL/2 cells were missing H-2K specifically (Figure 8A). We then tested whether the
absence of MHC class I is important for NK cell recognition of tumor target cells. Dr. Stern in
our laboratory had a retroviral construct for H-2K expression and used it to reconstitute the
missing H-2K to LL/2 cells. We found that LL/2 cells reconstituted with H-2K were two-fold
less susceptible to NK cell killing in cytotoxicity assays (Figure 8B).
NK cells express L-selectin and PSGL-1
Having established that NK cells from selectin-deficient mice are functional, we proceeded to the
analysis of NK cell adhesive properties. Although it has been reported previously that normal
NK cells do express L-selectin and PSGL-1 (Figure 3b), we wanted to confirm these data in our
mice. We also wanted to test whether the expression level of these adhesion molecules changes
with NK cell activation. To do so, we isolated NK cells from the spleens of C57BL/6 mice and
either analyzed them directly or cultured them overnight in the presence of activating cytokines
IL-2 and IL-15 (same activation protocol as was used for NK cell activation in cytotoxicity
assays). By performing FACS analysis for L-selectin and PSGL-1 expression on these cells, we
confirmed that all fresh and in vitro-activated NK cells express L-selectin, while some also
express the selectin ligand PSGL-1 (Figure 9). We also established that the level of expression of
these adhesion molecules did not change with overnight NK cell activation by cytokines. In the
process of these experiments, we also assayed integrin expression on fresh and activated
C57BL/6 splenic NK cells. These data confirm that NK cells express many integrins and show
that the expression of some of them varies with NK cell activation. However, as these results are
not directly relevant to the current project, they are presented separately in Appendix D.
Search for selectin ligands in tumor vasculature
In the previous section we confirmed that NK cells normally express L-selectin and PSGL-1, and
therefore have the potential for mediating selectin-dependent tumor suppression. We next looked
for possible selectin ligands in the tumor vasculature. To do so, we used thin cryosections of the
day 21 LL/2 tumors that have been removed for weighing from C57BL/6 selectin-replete and
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selectin-deficient mice at the end of tumor growth experiments described in Chapter 2, and
preserved for future study. We stained the tumor sections in parallel with lymphoid tissue
sections (spleen, inguinal lymph nodes) for the expression of P-selectin, E-selectin, and the
antibody against the common L-selectin sugar epitopes in the lymph node, the PNAd's. We did
not detect any expression of the abovementioned molecules in any of the tumor sections.
Stamper-Woodruff assay for NK cell adhesion to tumor vasculature
Taking a different approach to investigating possible NK cell interactions with the tumor
vasculature, we used NK cells themselves to probe for their selectin-dependent adhesion to
tumor blood vessels. A classic in vitro assay to test selectin-dependent adhesion has been
developed in the 1970's [Stamper HB et. al., 1976]. The Stamper-Woodruff assay involves
adding a suspension of freshly isolated leukocytes of interest to a frozen section of tissue, and
assaying leukocyte adhesion to the tissue blood or lymphatic vessels in the presence or absence
of selectin-blocking antibodies. We used freshly isolated or in vitro-cytokine-activated NK cells
and tested their adhesion to day 21 LL/2 tumors from C57BL/6 and ELP'" mice (preserved after
tumor growth experiments described in Chapter 2). NK cells were labeled with the CFSE dye
for ease of detection, while the blood vessels in tumor sections were visualized using the anti-
PECAM-1 antibody (for the detailed methods on the assay please consult Appendix A).
Unfortunately, despite repeated attempts we did not see any selectin-dependent adhesion of
C57BL/6 or ELP / NK cells to LL/2 tumor tissue from C57BL/6 or ELP"/ mice. Instead, NK
cells adhered very well to the tumor cells themselves, and perhaps this tumor adhesion
sequestered them from the blood vessels and interfered with the assay (Figure 10).
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DISCUSSION
The results from this chapter characterize NK cells from selectin-null mice and establish that
selectins do not dramatically alter overall NK cell numbers, development, cytokine secretion, or
the ability to bind and kill classical Yac-l NK target cells. The results also demonstrate that NK
cells are capable of killing LL/2 tumor cells in vitro, likely recognizing them by the lack of MHC
class I. Furthermore, we confirm that NK cells express L-selectin and the main selectin ligand
PSGL-1. These findings validate NK cells as good candidates for mediating selectin-dependent
tumor suppression. Unfortunately due to technical difficulties we were unable to demonstrate the
presence of endothelial selectins or selectin ligands on tumor vasculature, or to show direct
interaction between NK cells and tumor vasculature in Stamper-Woodruff assays.
In the Matrigel recruitment assays described in the last chapter, we found that NK cell
recruitment is tumor-specific and that NK cell recruitment to LL/2 tumors in Matrigel is severely
defective in selectin-deficient mice. On the one hand, this suggested that NK cells, which are
known to be tumoricidal, are an excellent candidate for mediating the selectin-dependent tumor
suppression phenomenon described in Chapter 2. On the other hand, NK cells have not been
studied extensively in selectin-deficient mice, leaving the possibility that their absence in the
tumor is not due to a recruitment defect but to a general defect in NK cell number in the absence
of selectins. Analysis of NK cell numbers in L'/ and ELP-' mice eliminated this possibility. In
the absence of selectins the numbers of circulating NK cells, which are likely the ones that
respond to and enter the tumor, are normal. Some differences in NK cell numbers have been
detected though: L-' mice have half as many NK cells in the lymph nodes, while ELP-' mice
have twice the normal number of splenic NK cells. These differences are consistent with the
known behavior of other leukocytes in selectin-deficient mice.
Next, we wanted to investigate whether NK cells from selectin-deficient mice are only defective
in their recruitment to tumors, or whether they have any other developmental or functional
deficits that could synergize with the recruitment defect and prevent NK-dependent tumor
elimination. Selectins could potentially be important for NK cell development and maturation.
Immature NK cells are less capable of target cell killing and cytokine secretion, and would be
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less capable of eliminating tumors. In this chapter we demonstrate that NK cells from selectin-
deficient mice express normal levels of maturation markers in an appropriate pattern, are capable
of killing Yac-1 tumor target cell in vitro, and have normal secretion of the main tumor-
protective NK cell cytokine, IFNy. They do not seem to be functionally defective; if anything,
their cytotoxic and sytokine-secreting capabilities are slightly enhanced.
It is also possible that selectins are involved directly in the adhesion of NK cells to tumor cells
and thus contribute to cytotoxicity. Many tumor cells are known to express selectin ligands,
which could bind to NK cell selectins. Although genetically selectin-deficient NK cells did not
appear to be defective in target cell killing, we wanted to eliminate the possibility that some
other mechanism compensates for the chronic lack of selectins in the L' and ELP/ mice,
masking the defect. We therefore acutely blocked L-selectin on selectin-sufficient NK cells with
an antibody. This did not affect NK cell cytotoxicity at all, confirming that selectins do not
directly affect NK cell ability to eliminate tumors.
In the process of testing NK cell function, we established that NK cells are capable of killing
LL/2 tumor cells, at least in vitro. This finding confirmed NK cells as a good candidate for
mediating selectin-dependent tumor suppression, as it agreed with the data on dramatically
enhanced LL/2 subcutaneous tumor growth in the absence of selectins (Chapters 2, 3).
Investigating the mechanism of LL/2 cell killing a little further, we established that LL/2 cells
lack one of the major MHC class I alleles, and that the reconstitution of this allele into the LL/2
cells significantly reduced the ability of NK cells to kill the tumor target. While not directly
relevant at this point, knowing something of the killing mechanism for a tumor cell line that
shows strong selectin-dependent subcutaneous growth differences could be used to test the in
vivo function of selectin-deficient NK cells at a later time.
By all the assays we tried, NK cells in selectin-deficient mice seemed normal and functional. The
only defect that we observed was defective NK cell recruitment to LL/2 tumors in Matrigel, as
described in Chapter 3. We therefore focused on investigating NK cell recruitment to tumors.
First, we confirmed that NK cells express L-selectin and the main selectin ligand PSGL-1. All
NK cells were found to express L-selectin, while only some expressed PSGL-1. It could be that
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PSGL-1 levels are low and are below the limit of detection by FACS with the antibody and the
staining protocol we used. It is also possible that PSGL-1 is only expressed by a particular subset
of NK cells.
Next, we tried to identify by antibody staining L-selectin ligands and PSGL-l-binding
endothelial selectins on the endothelium of day 21 LL/2 tumors, in order to establish a possible
mechanism of direct NK cell interaction with the tumor vasculature. We could not detect any
endothelial selectin or selectin ligand staining on day 21 LL/2 tumor blood vessels with the
available antibodies. There are many possible explanations for this failure. First, identification of
selectin ligands is a challenging undertaking; as described in the introduction to Chapter 2,
despite many years of searching very few selectin ligands are known, and even fewer have been
established as physiologically relevant. Our simple antibody staining approach for the known
lymph node carbohydrate ligands might not detect the tumor ligands, which might well be
different. Second, it is entirely possible that we were looking at the wrong time point. The
greatest immune recruitment differences in Matrigel are seen around day 7 after tumor injection;
in a tumor growing by itself we do not know the timing of immune cell recruitment. Day 21 after
tumor injection could well be too late for detecting the relevant adhesion molecule changes on
the tumor blood vessels.
Rather than continuing with the difficult search for the ligand, we tried a different approach.
Assuming the selectin ligand exists on tumor vasculature, we could probe for its interaction with
NK cell L-selectin and PSGL- 1 directly in Stamper-Woodruff assays. Unfortunately, this idea
met with a technical difficulty of a different nature. The NK cells did bind to tumor sections, but
to the tumor cells themselves and not to the blood vessels. One hypothesis is that the mechanism
of tumor cell recognition and binding is so strong and rapid that it sequesters NK cells from the
blood vessels. Another explanation could be that, once again, we are not looking at the correct
time point and the tumor vasculature no longer expresses the molecules needed for NK cell
recruitment by day 21 after tumor injection.
In summary, in this chapter we characterized NK cells in selectin-deficient mice and established
that they are present in normal numbers, develop appropriately, and are functional. We also
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established that NK cells can recognize and kill LL/2 tumors, partly through MHC class I-
dependent mechanisms. Furthermore, we confirmed that NK cells normally express L-selectin
and PSGL-1. Our inability to establish a direct in vitro link between NK cell selectin expression
and the failure in NK cell recruitment to the tumor in selectin-deficient mice indicated that the
system is complex, and involves many variables (such as the stage of tumor growth and the
precise timing of NK cell recruitment to tumor in a live animal) that are difficult to control in
vitro. Since in vitro tests failed to provide a satisfactory model for investigating the mechanisms
of NK cell recruitment to tumor, we proceeded to testing the role of this promising candidate in
selectin-dependent tumor suppression in vivo.
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Developmental stages of murine natural killer cells
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Figure 1. Natural killer cell development and homeostatic tissue distribution in mouse (adapted
from Di Santo JP et. al., 2006 and Gregoire C et. al., 2007) (A) Several stages of NK cell
development from a common hematopoietic stem cell (HSC) to a mature functional NK cell (mNK) have
been identified. The stages are defined my altertions in surface marker expression. Interestingly, many of
these markers are integrins. (B) NK cells are present in many lymphoid and non-lymphoid (liver, lung)
tissues of adult mice.
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Figure 2. NK cell activation and target killing (adapted from Smyth MJ et. al., 2002) (A) NK cells
recognize target cells that have either lost MHC class I expression (through activating and inhibitory
Ly49, KIR and NKG2 "missing self' recognition receptors) or gained expression of antigens not
normally expressed on healthy cells (through the NKG2D "altered self' recognition receptor). The
overall balance of inhibitory and activating signals is integrated by the NK cell to determine whether or
not it will be activated. (B) Activated NK cells can kill tumor or virally infected targets through perforin
and granzyme exocytosis, through death ligand expression, or through cytokine secretion.
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Summary of human and mouse data for
NK cell response to chemokines
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Figure 3. Mechanisms of NK cell migration (adapted from Morris MA et. al., 2004 and Gr6goire
C et. al., 2007) (A) Human and mouse NK cells respond to many chemokines by migrating towards
them (most data are for in vitro migration assays, some have been confirmed in vivo). (B) NK cells have
also been shown to express L-selectin, selectin ligand PSGL-1, and many integrins. The list represents
adhesion molecule expression as detected by microarray analysis in mouse NK cells. FACS data and
proteomics analysis in mouse and human NK cells have reported much the same results.
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Figure 4. NK cell development is normal in the absence of selectins. Blood, bone marrow, inguinal
lymph node and spleen of C57BL/6 and selectin-deficient mice were counted, and stained with antibodies
for FACS analysis to assess NK cell numbers and development. (A) The number ofNKl.1+, CD3- cells
in various organs was established for three 8-10 week old mice in each group. Mice lacking L-selectin had
lower NK cell numbers in the lymph node (p=0.00001 by students' t test), while ELP - - mice had more
NK cells in spleens (p=0.027). Data are displayed as a table of average NK cell number ±SEM, with the
p-value added where a significant difference was detected. (B) As described in the introduction to this
chapter, integrin aV is normally high on bone marrow NK cells and is downregulated as NK cells mature
and leave the bone marrow. Analysis of aV expression on NKl.1+, CD3- cells demonstrates that this
process is normal in selectin-deficient mice. Data are displayed as representative histograms of aV
expression by FACS in the bone marrow and spleen, gated on live NK1.1+, CD3- leukocytes.
NK cell numbers in C57BL/6 control and selectin-deficient mice
C57BL/6 L-/-  ELP-/-
Blood l1.1±0.32 *105 1.2±0.21 *105 1.2±0.24 *105(,100[tL)
Bone marrow
1.4±0.23 106 0.82±0.22 *106 1.8±0.19 * 106(1 femur)
Lymph node 0.65±0.04 *10s
2.210.11'105 2.4O0.06*105(1 inguinal) (p=O.OOOO1)
Spleen 3.8O0.4,1071.9±0.17*107 1.6±0.21 * 107
(1 whole) (p=0. 027)
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NK cell numbers in C57BL/6 control and selectin-deficient mice
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Figure 5. NK cells in selectin-deficient mice mature normally and express proper NK receptors.
Blood, bone marrow, inguinal lymph node and spleen of C57BL/6 and selectin-deficient mice were
stained with antibodies for FACS analysis to assess NK cell maturation. (A) NK cells from selectin-
deficient mice express normal levels of integrin aM 32, a marker Of mature functional NK cells. Data are
displayed as representative histograms of aM expression by FACS in the bone marrow and spleen,
gated on NKI.1+, CD3- cells. (B) NKG2D, a major NK cell receptor, is expressed at slightly but
significantly higher levels in the lymph nodes of selectin-deficient mice (p=0.06 for L-/ and p=0.003 for
ELP- NK cells). Data are displayed as representative histograms of aM expression by FACS in the
right inguinal lymph node, gated on live NK1.1+, CD3- leukocytes.
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Figure 6. Interferon gamma secretion is normal in selectin-deficient mice. (A) NK cells were
isolated from spleens of C56BL/6 and ELP-/ mice and activated overnight with IL-2 and IL-15.
Supernatants were analyzed for IFNy content using the mouse IFNy DuoSet ELISA Development
Sy stem (R&D Sy stems). No significant differences in IFNy secretion were found. (B) Whole splenocy tes
isolated from age and sex-matched C56BL/6, L-/-and ELP-/ mice were stimulated by 6-hour culture on
anti-NK1.1 antibody coated plates to crosslink an activating NK cell receptor. IFNy production in
response to this stimulation was assayed by FACS analysis for % intracellular IFNy staining in NKl.1',
CD3- splenocytes. ELP-/ - and L/-mice showed no significant difference in IFNy production in response
to stimulation through the NK1.1 receptor. Data are presented as bar graphs of average IFNy secretion
from, or % intracellular IFNy staining of, NK cells isolated from at least 3 individual mice +SEM.
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Figure 7. NK cells from ELP-•and L'/- mice are able to kill tumor targets, and target killing by
NK cells does not require L-selectin. (A) NK cells were isolated from spleens of C56BL/6, L-' and
ELP-' mice and activated overnight with IL-2 and IL-15. Increasing numbers of NK cells were then mixed
with a constant number of target Yac- 1 cells to create different effector:target ratios and co-cultured for 4
hours in a colorigenic cytotoxicity assay. NK cells isolated from L-/- and ELP-' mice were found to be
slightly, though not significantly, better at killing Yac-l targets than were the control NK cells. Data are
represented as average killing curves from at least 3 individual experiments, ±SEM. (B) To test whether
L-selectin on NK cells might play a direct role in promoting or inhibiting target cell killing, NK cells were
isolated from the spleens of C57BL/6 mice, activated with cytokines overnight, and either treated or not
treated with an L-selectin blocking antibody MEL14 for 1 hour prior to exposure to LL/2 target cells and
throughout the cytotoxicity assay. No difference in the ability of NK cells to kill tumor targets was
detected at any effector:target ratio in the presence of the blocking antibody. Data are represented as
average killing curves from at least 3 individual experiments, +SEM.
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C57BL/6 tumor cell lines lack MHC class I expression
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Figure 8. C57BU6 tumor cell recognition is partly mediated by missing self mechanisms. (A)
C57BL/6 tumor cell lines LL/2 and MC38GFP were analyzed by FACS for the expression of two major
MHC class I molecules, H-2D and H-2K. Whole C57BL/6 splenocytes were used as a positive control.
No H-2D or H-2K expression was detected on MC38GFP cells, while LL/2 cells were missing H-2K
specifically. Data are represented as a bar graph of percent of cells positive by FACS for H-2D and H-
2K expression. (B) To test whether the absence of MHC class I is important for NK cell recognition of
tumor target cells, we reconstituted the missing H-2K expression to LL/2 cells by retroviral infection
(performed by Dr. Stem). LL/2 cells reconstituted with H-2K were two-fold less susceptible to NK cell
killing, indicating that NK cell killing of LL/2 cells is partly mediated by "missing self' recognition. Data
are represented as killing curves from one experiment.
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Selectin and selectin ligand expression in C57BL/6 NK cells
Freshly isolated NK 1-day stimulated NK
................ isotype control
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Figure 9. Freshly isolated and in vitro-activated NK cells express L-selectin and selectin ligand
PS GIL1. NK cells were isolated from the spleens of C57BL/6 mice and either analyzed directly or
cultured overnight in the presence of activating cytokines IL-2 and IL-15. Cells were analyzed by FACS
for selectin and selectin ligand expression. All fresh and in vitro-activated NK cells express L-selectin,
while some also express the selectin ligand PSGL-1. The level of expression of these adhesion molecules
did not change with overnight cell activation. Data are presented as histograms of L-selectin and PSGL-1
expression by FACS, gated on live NKI.1+, CD3- leukocytes.
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NK cells do not interact with tumor blood vessels in
in vitro Stamper-Woodruff assays
LL/2 tumors from ELP-/- mice LL/2 tumors from C57BL/6 mice
Figure 10. NK cells do not co-localize with blood vessels in Stamper-Woodruff assays. NK cells
isolated from the spleens of C57BL/6 or ELP-/- mice were labeled with CFSE and incubated with thick
frozen sections of day 21 LL/2 tumors grown in either C57BL/6 or ELP-/ mice. In all cases NK cells did
not co-localize with blood vessels (labeled red with an anti-PECAM-1 antibody) but bound instead to
the tumor cells themselves (black area between blood vessels). The data demonstrate representative
fluorescence microscopy images from the assay at a 20X magnification.
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CHAPTER 5.
NATURAL KILLER CELLS ARE NECESSARY
FOR TUMOR ELIMINATION IN VIVO
AND REQUIRE SELECTINS FOR THIS PROCESS
The work in this chapter was conceived by Olga Sobolev and Richard Hynes. The TM-f31
hybridoma was provided by Toshiyuki Tanaka (Osaka University, Japan) and the RR4-7
hybridoma was a kind gift from Herman Eisen (MIT). The GrzA-Ly49A transgenic mice came
from Wayne Yokoyama (Washington University St. Louis). The Rael construct was provided
by David Raulet (Berkeley). The contents of this chapter were written by Olga Sobolev, with
editing by Richard Hynes.
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INTRODUCTION
Mouse models of NK cell depletion
From the experiments in immune cell recruitment to tumors, and from the literature, NK cells
seemed a good candidate for mediating selectin-dependent tumor suppression. Having
characterized NK cells in selectin-deficient mice and established that NK cell numbers,
development and in vitro function are not dramatically affected by the absence of selectins, we
proceeded to test the role of NK cells in tumor suppression in vivo.
To determine whether NK cells play any role in tumor suppression at all, we tested tumor growth
in two NK-deficient mouse systems: mice depleted of NK cells by using an antibody, and a
transgenic mouse model that is genetically NK-deficient.
There are several antibodies that are used for depleting NK cells, and all of them present some
technical challenges and specificity issues. Anti-asialo-GM1 antibody, directed against a cell
surface glycolipid, is fairly specific in depleting mouse NK cells [Young WW Jr. et. al., 1980].
However, the antibody has also been shown to have a slight reactivity with monocytes and
macrophages [Riser BL et. al., 1988]. The anti-NK1.1 antibody, directed against an NK receptor
variants NKR-P1B and C, is also commonly used for NK cell depletion [Schott E et. al., 2003].
One technical challenge to its use is that the NKR-P 1B and C receptor are only present in some
mouse strains but not in others, for example including C57BL/6 but excluding Balb/c [Koo GC
et. al., 1984]. The NK1.1 antigen is also expressed on some NKT cells and has been reported on
some cultured monocytes [Yu YY et. al., 1992; Vicari AP et. al., 1996]. An additional technical
problem to using the anti-asialo GM1 and the anti-NK1.1 antibodies is that their effects are
short-lived and the depletion has to be repeated every 2-3 days. We decided to use a different
antibody, directed against interleukin 2 receptor P (IL-2Rp). The antibody is designated TM-31
and has been demonstrated to specifically deplete NK cells for up to five weeks after a single
injection [Tanaka T et. al., 1993]. It isn't established yet how a single injection accomplishes this
long-term depletion, but it has been hypothesized that the antibody depletes NK cell precursors.
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As mentioned in the previous chapter, developing NK cells require IL-15 and express high levels
of the IL-15 receptor, which includes the same common P chain as the IL-2 receptor, and which
would therefore be recognized by the TM-p 1 antibody. Whatever the mechanism, a clean and
long-lasting depletion seemed an appealing NK depletion method. However, although it has been
demonstrated that this method does not affect NKT, CD3+, CD8+, CD4+, TCRap+ or TCRy8+
cell numbers, it should be kept in mind that, as with any antibody depletion, there could still be
some leukocyte population that is affected by this method besides NK cells. We therefore
decided to use the TM-p 1 antibody depletion in parallel with a different method of removing NK
cells, by using a genetically NK-deficient mouse model.
There are also several mouse models that are either defective in NK cell function or have
reduced NK cell numbers. The earliest NK cell-deficient mouse to be described was the beige
mouse. The beige is a spontaneous point mutant that has normal NK cell numbers but impaired
NK cell function because of a defect in exocytosis of the granzyme and perforin-containing lytic
granules [Roder J et. al., 1979]. The beige mouse was widely used in early NK cell studies.
However, there are some serious drawbacks to this model. First, the beige mutation affects not
only NK cells, but all granulocytes, which show defective chemotaxis and reduced bactericidal
activity [Gallin JI et. al., 1974]. Second, although NK cell cytotoxicity is affected, overall NK
cell numbers and cytokine production are not reduced [Tomida M et. al., 1982; Robertson SA et.
al., 1992], meaning that the NK cells in this model are still somewhat functional. A better model
are the mice lacking the common cytokine receptor gamma chain (IL2Ry-). These mice have
defective leukocyte development and lack NK cells, but also have severe B and T cell defects
[Cao X et. al., 1995; DiSanto JP et. al., 1995]. To circumvent the B and T cell complication,
these mice are typically used as a double Rag2-/ IL2Ry-" mutant and compared to Rag2-
controls [Goldman JP et. al., 1998]. We wanted an immune-competent model that would be
selectively defective in NK cells, and therefore decided not to use the IL2Ry- mice. The newest
NK-deficient mouse model, the GrzA-Ly49Atg mice, was discovered by a happy accident, in the
process of generating a transgenic model where every NK cell would express the Ly49A receptor
driven by the Granzyme A promoter [Kim S et. al., 2000]. The transgenic construct integration
disrupted the transcription factor Atf2, which proved to be critical for NK cell development [Kim
S et. al., 2006]. Atf2 disruption led to an NK cell-intrinsic defect that results in the accumulation
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of immature NK cells in the bone marrow and a -10-fold reduction in circulating NK cell
numbers [Kim S et. al., 2000]. The few NK cells that could exit the bone marrow were immature
by phenotypic markers, non-functional in cytotoxicity assays and defective in cytokine secretion
[Kim S et. al., 2000; Kim S et. al., 2006]. The numbers and function of other immune subsets
were not affected by the transgene [Kim S et. al., 2000]. The GrzA-Ly49Atg mice seemed a
clean and specific NK-deficient mouse model, and is the one we chose to use in our studies.
NKG2D and its ligands
By depleting NK cells in two different ways, with the TM-P1 antibody, and by using the
genetically NK-deficient GrzA-Ly49Atg mice, we could investigate whether NK cells contribute
to suppression of subcutaneous tumors in our system. That, however, would not answer the
question of whether NK cells use selectins to suppress tumor growth in vivo. To get at this
question, we took advantage of the special properties of the NK cell "altered self' receptor
NKG2D and one of its ligands, Rael.
As mentioned briefly in Chapter 4, NKG2D is the best-characterized "altered self' receptor in
NK cells. Despite the name and the genomic location in the NKG2 cluster, this C-type lectin
differs dramatically from the other NKG2 proteins, does not associate with CD94, and does not
recognize MHC class I [Diefenbach A et. al., 2001]. Instead it can robustly activate NK cells
upon binding to a family of MHC-related molecules that are induced on tumor, infected, or
stressed cells [Diefenbach A et. al., 2000; Cerwenka A et. al., 2000; Gasser S et. al., 2005]. The
NKG2D ligands are the MHC class I chain-related (MIC)A and MICB molecules, and a diverse
family of ligands shared by humans and mice called the retinoic acid early transcripts (RAETI),
which include human cytomegalovirus protein UL 16-binding (ULBP)1, 2 and 3 molecules,
murine UL16-binding protein-like transcript 1 (Multl), human and mouse retinoic acid early-i
(Rae 1) proteins, and murine minor histocompatibility antigen H60 [Raulet DH, 2004].
MIC proteins contain three MHC-like domains, but probably do not bind or present peptide [Li P
et. al., 1999]. Their expression is normally highly restricted to the intestinal epithelium, but is
upregulated in human epithelial tumors and on CMV-infected cells in vitro and in vivo [Groh V
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et. al., 1999; Groh V et. al., 2001]. MIC expression can also be moderately increased by heat
shock in some cell lines [Groh V et. al., 1996]. The ULBP's are glycosylphosphatidyl inositol
(GPI)-anchored cell surface proteins. The extracellular domain structure shows some structural
and amino acid similarity to the al and a2 domains of MHC class I molecules. The ULBP
mRNA is detectable in many normal tissues, however the ULBP proteins are only found on the
surface of tumor cells and, very recently, on cells stressed by proteasome inhibition [Pende D et.
al., 2002; Val6s-G6mez M et. al., 2008].
The Rae 1 proteins are a large family of MHC-like molecules that are normally expressed during
embryogenesis and extinguished after the embryonic stages, only to be re-expressed in cells
exposed to damage or undergoing malignant transformation [Diefenbach A et. al., 2001]. There
are ten human RAET1 genes; six are expressed and five of these have been shown to bind
NKG2D [Bahram S et. al., 2005]. The mouse Raela-e proteins are all expressed and have been
shown to bind NKG2D [Bahram S et. al., 2005]. The H60 protein is unique to mouse. It is
located next to the Rael genes on mouse chromosome 10, and exhibits the same domain
structure as the Rael proteins, although the amino acid sequences of Rae 1 and H60 are only
distantly related [Malarkannan S et. al., 1998; Diefenbach A et. al., 2000]. The murine Multl
protein, which is similar to the human ULBP proteins, is a fairly recent discovery; its role in
tumor surveillance and the factors that induce its expression are as yet poorly studied
[Carayannopoulos LN et. al., 2002].
In vivo roles for NKG2D in tumor surveillance
In mouse it has been clearly demonstrated that Rael molecules and H60 are constitutively
expressed on many tumor cell lines, and that their expression confers target susceptibility to NK
cell attack through NKG2D activation [Cerwenka A et. al., 2000]. It has also been demonstrated
that in several experimental settings Rael and H60 expression is necessary and sufficient to
induce in vivo rejection of experimental tumors in an NK cell-dependent manner [Cerwenka A
et. al., 2001; Diefenbach A et. al., 2001]. In man, several reports indirectly support the
conclusion that NKG2D and its ligands are important mediators of tumor rejection [Smyth MJ et.
al., 2004; Bahram S et. al., 2005]. There is also evidence that epithelial tumors shed soluble
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NKG2D ligands and that this results in NKG2D downregulation on immune cells, perhaps
indicating a mechanism of tumor immune evasion [Salih HR et. al., 2002; Wu JD et. al., 2004].
The mechanisms of Rae 1 induction are not yet clear; however, there is some evidence that in
mouse Rael, H60 and Multl are specifically induced by DNA damage sensing mechanisms
through the ATR and ATM pathways [Gasser S et. al., 2005].
NKG2D signaling pathways
Once bound to ligand, NKG2D signals through several mechanisms. In humans, it associates
with an adaptor molecule DAP 10 [Wu J et. al., 1999]. DAP10 contains a YxxM motif, which is
tyrosine phosphorylated upon ligand binding to NKG2D and recruits PI3K regulatory p85
subunit and Grb2; this signaling promotes target cell killing and provides costimulation for
proliferation and cytokine production, as well as contributing to NK cell survival by activating
AKT further downstream of DAP10/PI3K signaling [Chang C et. al., 1999; Cerwenka A et. al.
2003]. In mice, NKG2D exists in two splice isoforms that differ by 13 amino acids in the
cytoplasmic tail. The long (L) isoform associates with DAP10 and behaves like the human
NKG2D receptor in terms of downstream signaling, while the short (S) isoform associates with
both DAP10 and DAP 12, and can thus signal through PI3K and through the ZAP70/SYK
pathway that the MHC class I-specific NK receptors use. All cells that express NKG2D
constitutively carry the NKG2D-L isoform, while NKG2D-S is expressed in NK cells at low
levels and upregulated upon PolyI:C, IL-2 or LPS stimulation [Diefenbach A et. al., 2002;
Gilfillan S et. al., 2002].
There are several interesting and puzzling aspects to NKG2D signaling. One is, it is unclear why
so many NKG2D ligands are necessary, while most other NK receptors make do with one.
Another interesting feature of NKG2D is that, while most NK receptors exist in pairs of
activating and inhibitory receptors with the same ligand specificity, no inhibitory isoform of
NKG2D has been identified so far in any species. It seems to exist as a single, relatively non-
polymorphic gene. Furthermore, NKG2D signaling is relatively resistant to inhibition by
engagement of MHC class I molecules. MHC class I-expressing targets that display NKG2D
ligands are killed quite efficiently, and it takes very high levels of MHC class I expression on the
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target to overcome the NKG2D activation signal [Pende D et. al., 2001; Cerwenka A et. al.,
2003]. It will be interesting to follow future advances in NKG2D research.
For the purposes of investigating the role of NK cells in selectin-dependent tumor suppression,
what interested us most is, first, that NKG2D activation overrides any inhibitory signaling and
always leads to NK cell activation, and, second, the work of Dr. Raulet's laboratory
demonstrating that in mouse Rael ligand expression on subcutaneously injected tumor cells is
necessary and sufficient for NK-dependent tumor elimination [Cerwenka A et. al., 2001;
Diefenbach A et. al., 2001]. We decided to use the in vivo growth of matched tumor cell lines
that either do or do not express the Rael antigen as a test of NK cell function in selectin-deficient
mice.
NK cell functions in innate-adaptive crosstalk
Although the NKG2D-Rael interaction assay would tell us whether selectins are required for NK
cell elimination of tumors in vivo, it cannot answer the question of whether or not the effect is
cell-intrinsic. In the past few years it has become apparent that NK cells do not act in isolation
but influence and are influenced by many other immune cell types, and that their predominant
function might not be target killing so much as target recognition and subsequent activation of
the appropriate adaptive immune response.
The first paper to demonstrate the importance of NK cell interactions with other immune cells
was published in 1999. It showed that mouse NK cell-mediated immunity against MHC class I-
negative tumors was potentiated by dendritic cells (DCs) in vivo, and that in vitro cell-to-cell
contact between DCs and freshly isolated "resting" NK cells resulted in dramatic increase in NK
cell cytotoxicity and interferon production [Fernandez NC et. al., 1999]. This finding led to great
interest in the field of NK cell crosstalk with other immune cells, and a lot of progress has been
made lately in identifying the cell types and pathways involved in this crosstalk (Figure lA).
First, the initial mouse finding was generalized to human NK-DC interactions [Gerosa F et. al.,
2002; Ferlazzo G et. al., 2002]. The mechanism of NK cell activation required both cytokines
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and cell-cell contact. DC-derived cytokines IL-12 and IL-18 have been demonstrated to promote
NK cell cytotoxicity and IFNy production in human and mouse [Yu Y et. al., 2001; Andoniou
CE et. al., 2005]. Another cytokine, IL-15, seems to be secreted by DCs, bound to the IL-15
receptor a on the DC surface, and presented in trans to NK cells, promoting NK cell
proliferation in mouse and human [Koka R et. al., 2004; Ferlazzo G et. al., 2004]. Type I
interferon secretion by DCs in response to various viral and bacterial challenges also contributed
to induction of NK cell cytotoxicity [Dalod M et. al., 2003; Gerosa F et. al., 2005]. Optimal DC
activation of NK cells also required cell-cell contact, as reported initially. The exact pathways for
this are not yet fully understood and may be different for different DC subsets [Raulet DH,
2004]. One possibility is that cell-cell contact allows for the formation of an NK-DC immune
synapse and more efficient, directed IL- 12 and IL- 18 secretion towards the NK cell [Borg C et.
al., 2004; Semino C et. al., 2005]. Another set of data indicate that human DCs prestimulated
with IFNa express MICA and MICB NKG2D ligands, which contribute to NK cell activation in
co-culture experiments [Dokun AO et. al., 2001].
Second, it became clear that the influence was not one-way but mutual: as DCs were activating
NK cells, NK cells could reciprocally activate or kill DCs, depending on the context. In co-
culture with activated NK cells, immature human DCs undergo maturation, produce TNF and IL-
12, and upregulate costimulatory molecules such as CD86 [Gerosa F et. al., 2002; Piccioli D et.
al., 2002]. NK cell-secreted TNFa and IFNy, as well as cell-cell contact, are important for NK
cell-mediated DC activation [Piccioli D et. al., 2002; Vitale M et. al., 2005; Walzer T et. al.,
2005]. Several mechanisms for cell-cell contact dependency of DC maturation induced by NK
cells have also been proposed. Mouse IL-2-activated NK cells can trigger TREM2 receptor
signaling on bone marrow-derived DCs, thereby promoting CD86 costimulatory molecule
upregulation on the DC [Terme M et. al., 2004]. Triggering of the NKp30 receptor on NK cells
has also been implicated in NK-mediated DC maturation [Vitale M et. al., 2005].
Whereas low NK/immature DC ratios (1:5) lead to DC maturation, high NK:DC ratios (5:1) lead
instead to immature DC killing by NK cells [Wilson JL et. al., 1999; Piccioli D et. al., 2002;
Ferlazzo G et. al., 2002]. Lysis of immature DCs in vitro is mainly mediated by recognition
through the NKp30 NK receptor and to a lesser extent through the NKp46 receptor [Spaggiari
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GM et. al., 2001; Ferlazzo G et. al., 2002]. CD40 expression on immature DCs also seems to
contribute to lysis [Carbone E et. al., 1999]. As DCs mature, upregulation of MHC class I
molecules, in particular HLA-E, and expression of CD 1, mediate resistance to NK cell lysis
[Carbone E et. al, 2000; Ferlazzo G et. al., 2001; Della Chiesa M et. al., 2003]. The NK-mediated
killing of DCs has also been demonstrated in vivo, and seems to proceed by a pathway dependent
on TRAIL [Ruggeri L et. al., 2002; Hayakawa Y et. al., 2004]. Lysis of immature DCs by NK
cells has been proposed to be one of the checkpoints for preventing T cell activation in the
absence of microbial or viral signals necessary to induce DC maturation. In the absence of such
signals, lysis of immature DCs with the potential to present self-antigens could help in
preventing autoimmunity and regulate DC homeostasis [Raulet DH, 2004; Walzer T et. al.,
2005].
The new data on NK-DC cross-activation logically led to the investigation of the effects of this
interaction on T cell responses. The function of mature DCs is to migrate to lymphoid tissues and
activate T cells. Different T cell responses are activated depending on the type of maturation
stimulus to which the DC was exposed. Therefore, by contributing to DC maturation, NK cells
may well be influencing the strength and the type of the resulting adaptive immune response.
NK cells themselves are found in lymphoid tissues and also have the potential to interact directly
with T cells. In the last several years it has been demonstrated that NK cells do play a major role
in the development of protective T cell immunity against intracellular pathogens and cancer
(Figure IB) [Degli-Esposti MA et. al., 2005; Zingoni A et. al., 2005]. Such "helper" activity of
NK cells is mediated in part by the functional modulation of DCs described above, depends on
the production of TNFa and IFNy by activated NK cells, and is associated with the induction of
Thl and cytotoxic T lymphocyte (CTL) responses in human in vitro and mouse in vivo models
[Mailliard RB et. al., 2003; Martin-Fontecha A et. al., 2004; Zingoni A et. al., 2005]. There is
also some data to suggest that NK cells can stimulate CD4÷ T cells directly. T cell activation
requires three signals: antigen recognition, costimulatory molecules to indicate whether a given
antigen is danger or self, and cytokine signals to modulate the resulting immune response
towards the appropriate Thl, Th2, Thl7 or other activation pathway. Activated human NK cells
express MHC class II and can use it to present antigen to CD4÷ T cells [Phillips JH et. al., 1984;
Roncarolo MG et. al., 1991; Hanna J et. al., 2004]. Activated human NK cells also express
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costimulatory molecules such as CD86, 2B4, and OX40 and have been shown to use them to
stimulate T cell activation and proliferation, at least in vitro [Zingoni A et. al., 2004; Assarsson E
et. al., 2004].
However, the case is not altogether clear. First, while some T cells activate NK cells, others have
been shown to suppress NK cell activation. Cytotoxic activity, cytokine production,
proliferation, tumor rejection and bone marrow graft rejection by NK cells can all be inhibited by
the CD4+, CD25+ regulatory T cells [Romagnani C et. al., 2005; Smyth MJ et. al., 2006;
Ralainirina N et. al., 2007]. Conversely, NK cells have also been demonstrated to suppress T cell
responses, either through lysis of antigen-presenting DCs or through direct killing of activated
CD4+ and CD8+ T cells [Rabinovich BA et. al., 2003; Beilke JN et. al., 2005; Barber MA et. al.,
2007].
Part of the solution to the riddle of "killer" versus "helper" NK cells may lie in the recent
realization that there are different functional subsets of mature NK cells both in the mouse and in
the human. Several such subsets have been described. In both human and mouse, "killer" NK
cells, when exposed to particular cytokines such as DC IL-18 and T cell IL-2 can differentiate
into "helper" cells that are poorly cytotoxic but able to migrate toward lymph node homing
cytokines, highly secretory, and particularly good at stimulating DCs and T cells [Mailliard RB
et. al., 2005; Hayakawa Y et. al., 2006; Li Z et. al., 2007]. The "killer" and "helper" subsets are
distinct by phenotype, function and in vivo localization. It is also possible that the "helper"
subset can be further subdivided, as it has been reported that NK cells depending on stimulation
can produce either type 1 (NK1 cells) or type 2 (NK2 cells) cytokines and thus stimulate either
Thl or Th2 responses [Peritt D et. al., 1998; Katsumoto T et. al., 2004]. There is also a subset of
cells that are derived from NK cell progenitors and have phenotypic and functional markers of
both DCs and NK cells [Pillarisetty VG et. al., 2005]. This "NKDC" subset has been described to
have a role in tumor suppression and protection against pathogens [Chaudhry UY et. al., 2007;
Plitas G et. al., 2007].
Apart from communicating with the adaptive immune system, NK cells may also interact with
other innate immune cells. Very few data are available on the subject as yet, but there are some
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hints of NK-innate cell interactions in the literature. A couple of studies have shown that human
and mouse NK cells can engage in a reciprocal program of activation with macrophages [Tripp
CS et. al., 1993; Dalbeth N et. al., 2004; Siren J et. al., 2004]. This process, similar to what is
reported for NK-DC interactions, involves cell-cell contact and cytokine production by both cell
types [Dalbeth N et. al., 2004; Siren J et. al., 2004]. A subset of myeloid cells, named myeloid-
derived suppressor cells (MDSCs), that are often found in tumors, mediate T cell suppression
and promote tumor progression [Bunt SK et. al., 2006], have been implicated in NK cell
suppression in tumor-bearing mice in a recent publication [Liu C et. al., 2007]. A role for NK
cell-produced IL-5 in the recruitment of eosinophils to the lung has been demonstrated in a
mouse model of allergic inflammation [Walker C et. al., 1998].
Although it has become clear in the last decade that NK cells are an essential part of the innate-
adaptive crosstalk, and possibly important in innate-innate crosstalk, conflicting data and many
unanswered questions remain in this area. If NK cells do mediate selectin-dependent tumor
suppression in our system, the question of whether the effect is cell-intrinsic or not will be an
important one to answer.
Adoptive transfer of NK cells
Given the recent findings on the importance of NK cells interactions with other immune cells,
any observed defects in NK cell in vivo function need not be cell-intrinsic, but could instead be
due to the failure of some selectin-dependent immune cell (for example a DC or a T cell) to
activate NK cells, or to the failure of NK cells to activate a downstream selectin-dependent
effector (for example a cytotoxic T cell). To determine whether L-selectin and selectin ligands
on the surface of NK cells themselves are necessary for tumor suppression, NK cell adoptive
transfer experiments would have to be performed.
In transferring any cell one has to consider several points: the method of isolation, the
appropriate number of cells to transfer, and the timing and route of cell administration. NK cell
adoptive transfer is not a trivial undertaking by any of these criteria.
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NK isolation is challenging, because NK cells are a rare immune subpopulation, constituting at
most 5% of cells in the tissues from which they are typically isolated (such as the spleen).
Therefore, they are difficult to isolate with good purity and in high numbers. There are generally
speaking two ways of purifying a particular cell type from a mixed population: by depletion of
every other cell type, or by positive labeling and isolation of the cell type of interest. Both have
been described for NK cells. The original method of NK cell isolation by depletion involves a
long process with at least a week of in vitro culture of isolated NK cells prior to reconstitution.
This method is still commonly used for human NK cell isolation. In a mouse model of lung
metastasis, adoptive transfer of 20*106-10* 106 NK cells isolated by this method per mouse has
been shown to eliminate established lung metastases [Yang Q et. al., 2002]. However, in this
case the cells could be significantly altered by long ex vivo culture. The transfer of NK cells
immediately after depletion of other cell types is the most labor-intensive approach and is rarely
used, but it reduces the chance of activating or altering NK cells in the process of isolation. It
also gives good results, as indicated by a recent study where -2* 10 NK cells/mouse were
transferred and proved sufficient to demonstrate the role of NK cells in hapten-induced contact
hypersensitivity [O'Leary JG et. al., 2006]. Since this method can result in significant loss of NK
cells in the isolation process, tumor cells secreting Flt3 ligand are often injected into the donor
several days prior to NK cell isolation in order to boost donor NK cell proliferation and numbers
[Shaw SG et. al., 1998; O'Leary JG et. al., 2006]. The most common current method of NK
transfer is a positive selection of NK cells with beads directed against the DX5 antigen on NK
cells. It has been used to demonstrate the role of NK cells in a mouse model of autoimmune
encephalomyelitis, for example [Shi FD et. al., 2000]. In this case 10*106 cells were transferred.
The appeal of DX5 positive selection is that it is easy and fast, compared to other methods. The
down side is that in this method NK cells are being altered by DX5 binding and directly
manipulated, which increases the chance of their activation and possible changes in phenotype.
For the initial experiments, we decided to use a DX5 NK cell isolation.
Because of the scarcity of literature on NK cell transfers, it is difficult to guess how many NK
cells might be necessary to make a difference to subcutaneous tumor growth in our model. We
decided to begin with the minimal dose of 1*106 NK cells/mouse, and scale up if this did not
produce an effect. Similarly, few data are available on the lifespan of transferred NK cells in the
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recipient; the most appropriate timing for the transfer would have to be established
experimentally in our case. For the route of administration, it has been demonstrated in three
publications that cells injected into the venous circulation tend to home to the lung in the first
day after transfer, and have to be injected into the local arterial circulation of a particular organ if
homing to that organ is desired [Basse PH et. al., 1992; Matera L et. al., 2006; Gr6goire C et. al.,
2007]. In our case it is impossible to inject NK cells specifically into the arterial circulation of a
growing subcutaneous tumor; we will attempt to transfer NK cells via tail vein injection and
assay whether any of the transferred NK cells are detectable circulating in the peripheral blood.
RESULTS
Pharmacological or genetic depletion of NK cells significantly enhances tumor growth
To determine whether NK cells are necessary for suppression of tumor growth in our system, we
chose two methods of NK cell depletion. First, we depleted NK cells by injection of the TM-pl
antibody. As described in the introduction, this antibody has been shown to efficiently deplete
NK cells for several weeks with a single injection. Since the antibody has to be injected in a high
concentration of 1 mg/mouse, we purified it ourselves form hybridoma supernatants (for
detailed protocol please consult Appendix B). As a negative control we used an isotype-matched
rat IgG2b antibody RR4-7. The RR4-7 hybridoma was generated in the laboratory of Dr. Eisen to
recognize a VA8 variable region of the human T cell receptor and is unreactive to mouse. We
prepared the RR4-7 antibody from hybridoma supernatants in parallel with the TM-131 antibody.
C57BL/6 mice were injected once intraperitoneally (i.p.) with either 1 mg/mouse of the TM-11
antibody, or with the same amount of the RR4-7 antibody. Depletion was measured by regularly
taking small peripheral blood samples from antibody-treated mice and assaying them by FACS
for NKI.1+/CD3- cells. As an additional control and to assure ourselves that other immune cells
were unaffected by the antibody injection, we also monitored blood macrophage levels. In our
hands the TM-p 1 antibody selectively depleted NK cells by -95%, as compared to NK cell
levels in mice injected with the RR4-7 antibody (Figure 2A). Macrophage levels were not
affected by either antibody. The depletion became apparent within 3 days after antibody injection
and was maintained for at least 21 days, which is sufficient time for our tumor growth assays.
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Second, we obtained C57BL/6 GrzA-Ly49Atg mice that are genetically deficient in NK cells.
Since the mice are not truly NK cell-null but only have a defect in NK cell development, we
were somewhat concerned that, if challenged with a tumor, NK cells might recover. To test this
possibility, we monitored peripheral blood NK cell levels by FACS by regularly taking small
blood samples in a cohort of GrzA-Ly49Atg÷ and GrzA-Ly49Atg siblings injected
subcutaneously with LL/2 tumor cells. As an additional control, we also monitored overall T cell
numbers in the blood. GrzA-Ly49Atg ÷ mice, as compared to their Ly49Atg- littermates,
maintained their low level of NK cells even after 3 weeks of tumor challenge, while peripheral
blood T cell numbers were unaffected by the transgene or the tumor (Figure 2B).
Having established the methods of NK cell depletion, we proceeded to test tumor growth in NK-
depleted mice. For the tumor challenge we used the LL/2 cells, as they gave us the clearest
results previously in selectin-deficient mice (see Chapter 2). Male 8-12-week-old C57BL/6
mice were injected i.p. with the TM-Pl or the RR4-7 antibody three days prior to the
subcutaneous LL/2 cell injection. In a separate set of experiments, 8-12-week-old GrzA-
Ly49Atg÷ and GrzA-Ly49Atg" siblings were injected subcutaneously with LL/2 cells. In both
sets of experiments, LL/2 tumor weight was assayed at 3 weeks after tumor injection. At the time
of tumor removal NK-depleted animals were bled to check that the NK depletion had been
maintained throughout the experiment. Depletion of NK cells by either method significantly
enhanced tumor weight and tumor incidence (Figure 3A).
To test whether selectin-dependent tumor suppression proceeded through the same pathway as
the NK-dependent tumor suppression, or through a parallel pathway, in the LL/2 tumor model,
we depleted NK cells in the selectin-deficient mice. ELP / mice were crossed with the GrzA-
Ly49Atg÷ mice to generate mice lacking both selectins and NK cells. ELP"', Ly49Atg÷ or
Ly49Atg" siblings were then tested in LL/2 tumor growth assays. Alternatively, L'/ mice were
treated the TM-P1 or the RR4-7 antibody prior to LL/2 tumor injection. Depletion of NK cells by
either method in selectin-deficient mice did not significantly enhance tumor weight or incidence
over what is already observed in the absence of selectins alone (Figure 3B).
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NK cell in vivo function is defective in selectin-deficient mice
The NK cell depletion data indicated that NK cells are necessary for suppressing tumor growth,
and hinted that the selectin mechanism of tumor suppression and the NK mechanism of tumor
suppression may be in the same pathway. We next wanted to assess whether NK cell-dependent
tumor suppression was functional in the absence of selectins. To do so, we took advantage of the
work on the NK cell NKG2D receptor and its ligands on tumor cells that is described in the
introduction. Namely, the work from Dr. Raulet's laboratory demonstrated that, in mouse, Rael
ligand expression on subcutaneously injected B16 tumor cells leads to tumor rejection
specifically by NK cells [Diefenbach A et. al., 2001]. We obtained the Rael cDNA from Dr.
Raulet and used it to generate matched B16 tumor cell lines that contain a viral construct with
either the puromycin selection cassette alone (B 1 6-puro) or the selection cassette and Rae 1E
(B16-RaelE). The two cell lines, as well as the parental cells, were grown and selected in
parallel. Rael antigen expression was confirmed by FACS analysis (Figure 4A). We would
expect the B16-puro cells to grow in all mice, and the B16-Raels to be rejected specifically by
NK cells (Figure 4B).
To test the system, the cell lines derived above were injected subcutaneously either into
C57BL/6 mice treated with the control RR4-7 antibody, or into mice treated with the NK-
depleting TM-P1 antibody. In a parallel set of experiments, the tumor cells were injected into a
cohort of GrzA-Ly49Atg + and GrzA-Ly49Atg- siblings. Tumor growth was monitored by
measuring tumor surface area with calipers, as described for B16 cells previously in Chapter 2.
Mice treated with the control antibody all grew B16-puro tumors, while 9/10 mice completely
rejected B 16-Rae 1E tumors. B 16-Rae l1 rejection was completely abolished in mice treated with
the NK-depleting TM-P1 antibody (Figure 4C). Similarly, in the GrzA-Ly49Atg mice, B16-puro
tumors grew in all animals, while B16- Raels tumors grew only in GrzA-Ly49Atg+ mice (Figure
7A). The cell lines we generated behaved as expected in vivo.
Next, we used the B 16 cell lines to test NK cell function in selectin-deficient mice. If NK cells
require selectins for tumor rejection, we would expect both B16-puro and B16-Rael cells to
grow in selectin-deficient mice. If NK cells do not require selectins for tumor rejection, we
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would expect only the B16-puro cells to grow. B16-puro and B16-RaelE cells were injected into
the flank of 8-12-week-old ELP"/" mice. B16-puro tumors grew in 15/16 mice, while B16- RaelE
tumors grew in 18/18 mice (Figure 5A). ELP" mice thus demonstrated a severe defect in NK-
dependent tumor rejection. To test which individual selectins contribute to NK cell function,
B 16-puro and B 16-Rael E cells were also injected into mice missing single selectins. Similarly to
the tumor growth patterns we observed in selectin-deficient mice previously (Chapter 2), L-
selectin and P-selectin-null mice were both partially defective in B16- Rae 1E tumor rejection,
with some mice growing tumors while some mice were able to reject them, while E-selectin
alone did not seem to contribute greatly, as only one out of 5 mice tested grew a very small B 16-
Raele tumor while the other 4 rejected B16-RaelE tumors (Figure 5B).
Failure of NK-dependent tumor rejection in selectin-deficient mice is not rescued by T cells
As described in the introduction, NK cells interact with many other immune cells. Their role in
promoting cytotoxic T cell function is particularly well studied. We therefore wanted to explore
whether the failure of NK cell-dependent tumor rejection in selectin-deficient mice requires T
cell function. If selectin-deficient NK cells are unable themselves to reach the tumor in selectin-
deficient mice, as we hypothesize, they might still be able to activate T cells. This most likely
happens in the lymph nodes, and we found the NK cell numbers to be normal in the lymph nodes
of ELP" mice (Chapter 4). However, T cell numbers are greatly reduced in lymph nodes in the
absence of L-selectin [Arbon6s ML et. al., 1994]. Therefore, if the defect in selectin-deficient
mice is two-fold, both in NK cell function and in T cell function, some of the phenotype could be
ameliorated by the transfer of normal, selectin-sufficient T cells (Figure 6A). We isolated total
splenic T cells (Miltenyi Biotech T cell isolation kit) from the spleens of C57BL/6 mice and
transferred them at 5* 106 cells/mouse into ELP/" mice 3 days prior to the injection of B 16-puro
and B 16-Rael E tumor cells. All mice that received T cell transfers grew B 16-Rael tumors with
the same kinetics as untreated ELP" mice, indicating that normal T cells are not sufficient to
rescue NK-dependent tumor rejection in the absence of selectins (Figure 6B).
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Adoptive transfer of NK cells
To determine whether L-selectin and selectin ligands on NK cells themselves are sufficient for
NK-dependent tumor rejection, we planned a series of adoptive transfer experiments. In the
GrzA-Ly49Atg + mice, B 16-puro tumors grow and B 16-Rae 1 tumors also fail to be rejected
(Figure 7A). Since these mice have very low endogenous NK cell numbers, they could be
reconstituted with either C57BL/6 selectin-replete NK cells, or with NK cells missing L-selectin,
or the main selectin ligand PSGL-1, or both. L-selectin and P-selectin seemed to contribute the
most to NK-dependent tumor rejection (Figure 5B). We would expect GrzA-Ly49Atg+ mice
reconstituted with normal NK cells to reject B 16-Rae 1E tumors, and the mice reconstituted with
L-selectin and/or PSGL- 1-deficient NK cells to grow B 16-Rae 1E tumors, if the defect in NK-
dependent tumor rejection in the absence of selectins is cell-intrinsic and depends only on the
presence or absence of these adhesion molecules on NK cells themselves (Figure 7B).
The work on adoptive transfer is in progress. We can isolate NK cells fairly efficiently from
mouse spleens by using DX5-coated beads (Miltenyi Biotech; for detailed protocol of NK cell
isolation and transfer please consult Appendix A). This method typically results in isolation of
-70% pure NK cells, as assayed by FACS for % of DX5+, NK1.1 +, CD3 live leukocytes (Figure
8A). NK cells isolated by this method from the spleens of C57BL/6 CD45.1-congenic mice and
transferred by tail vein injection into C57BL/6 or ELP'" / recipients at 1*106 cells/mouse could be
detected in the blood, spleen and mesenteric lymph nodes of the recipients by FACS for
CD45.1 +, NKI.1 +, CD3Y cells for up to a week after transfer, after which NK cell numbers
declined (Figure 8B). The work on NK cell transfers into GrzA-Ly49Atg+ mice is ongoing; some
preliminary results and potential problems are presented in Appendix C.
DISCUSSION
The results from this chapter establish that NK cells are necessary for tumor suppression in our
system. The results also demonstrate that selectins are required for NK cells to reject the tumor
and suggest that selectin-dependent tumor suppression and NK-dependent tumor suppression lie
in the same pathway for controlling tumor growth. These findings agree with the hypothesis that
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selectin-dependent tumor suppression is mediated by NK cells. To prove the hypothesis
definitively, we would need to show that the presence of selectins on NK cells is sufficient to
confer tumor suppression. Adoptive transfer experiments to address this question are ongoing.
In this chapter we established that NK cells are necessary for tumor suppression in our system,
by demonstrating in two orthogonal mouse models of NK cell depletion that tumor growth is
significantly increased. While each method of depleting NK cells has its caveats and may
potentially affect other immune cell types, it is unlikely that two very different models would
share the same set of side effects. The tumor growth phenotype we observed is reminiscent of the
increase in tumor growth in selectin-deficient mice. However, it is formally possible that
selectins affect tumor growth by one mechanism, while NK cells affect it in a different way, with
the same observable outcome in both cases. If that were so, we might expect these effects to be
synergistic, and to observe tumors growing twice as large in the mice missing both selectins and
NK cells. Instead we do not observe an additive effect in the absence of both selectins and NK
cells, accomplished by two different methods. This agrees with, but does not prove that the
selectin effect and the NK cell effect on tumor growth are part of the same pathway.
Alternatively, it could be that we have reached the limit of the effective range of our system, and
the LL/2 tumors simply cannot grow much faster than they do in the absence of either selectins
or NK cells alone for physiologic reasons.
To address this issue from a different angle, we set up a system to test whether NK cells require
selectins to reject tumors in vivo. We generated tumor cells that would be particularly good
targets for specific rejection by NK cells. The system was validated in NK-deficient mouse
models, and then tested in selectin-deficient mice. We found that selectin-deficient mice clearly
do have defects in NK cell-dependent rejection of tumors in vivo. Similar to what is seen for
tumor growth is selectin-deficient mice (which can actually be observed in this data set as well,
by comparing the growth of B 16-puro cells in the various mouse strains), the defect in NK cell
function was the most profound in the absence of all three selectins. Of the single selectins, L-
selectin and P-selectin knockouts but not the E-selectin knockout demonstrated partial
impairment of NK cell-dependent tumor rejection. These data indicate clearly that some aspect
of NK cell function that contributes to tumor surveillance is impaired in the absence of selectins.
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From the in vitro data, we know that, in the absence of selectins, NK cells are functional
(Chapter 4), therefore the observed in vivo defect is probably not a cytotoxicity or a cytokine
secretion deficit. Matrigel recruitment data suggest that the defect is in the impaired NK cell
recruitment to tumor in the absence of selectins (Chapter 3).
However, other explanations are possible. While these data show an impairment of NK cell
function in the absence of selectins, they do not demonstrate that the impairment is direct or
necessarily NK cell-intrinsic. If the defect is indeed in NK cell recruitment, it could be that NK
cells themselves fail to reach the tumor because they need selectins to do so, or it could be that
an early immune cell that needs to reach the tumor and provide proper signals (for example
secrete particular cytokines) for subsequent NK cell entry, or for NK cell activation at the tumor,
fails to get there in the absence of selectins. As demonstrated in Chapter 3, macrophages and
dendritic cells, which are known to provide signals for NK cell activation in some contexts, are
also somewhat defective in their recruitment to tumors in the selectin-deficient mice, and the list
of cell types we assayed is by no means exhaustive, there could be defects in some other cells
such as eosinophils or mast cells that we have not looked for. The opposite case, where NK cell
recruitment defect does not in itself affect tumor growth but affects instead the recruitment or
activation of the true effector cell, such as a cytotoxic T cell, is also possible. The second
scenario, in particular with regards to T cells, is less likely by several pieces of evidence. First,
the original experiments of Dr. Raulet's group demonstrated that cytotoxic T cells are
dispensable and do not affect the growth of B 16 tumors expressing Rael antigens [Diefenbach A
et. al., 2001]. Second, our experiments demonstrate that T cell transfer into selectin-deficient
mice does not rescue that defect in NK-dependent tumor rejection. None of our data exclude the
first possibility though.
To establish definitively that NK cells are sufficient for mediating selectin-dependent tumor
suppression, and that they do so through a cell-intrinsic mechanism, experiments with adoptive
transfer of NK cells are required. By transferring normal NK cells into selectin-deficient mice,
we could test whether NK cells and the defect in their adhesion molecules are sufficient to
explain the selectin-dependent tumor suppression phenotype. Conversely, by transferring
selectin-deficient or selectin-replete NK cells into NK-deficient mice, we could determine
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whether selectins on NK cells are sufficient for NK-dependent tumor suppression. These
experiments are technically very challenging, and work on them is in progress. For now, we have
developed methods for reliable NK cell isolation at reasonable purity, and have established that
after adoptive transfer our NK cells do stay mostly in the lung on the first day after injection, as
has been reported, but enter the circulation and disseminate to the lymph nodes and spleen
subsequently. Therefore, there is a good chance that they will reach our model tumors. We have
also established that transferred NK cells begin to disappear from the circulation and lymphoid
organs after about a week in the recipient. This is consistent with the known half-life of NK
cells, which is reported to be on the order of a week (see Chapter 4, introduction). Whether we
can transfer sufficient numbers of NK cells to observe a difference in tumor growth, and whether
we can find the correct subset of NK cells to transfer, remains to be seen. If we cannot see an
effect on tumor growth, at the very least, with the tools we have now, we can perform transfers
of a 1:1 mix of selectin-sufficient and selectin-deficient NK cells into the same NK-deficient
mouse bearing a Matrigel tumor, and compare NK cell recruitment in this short-term assay. This
will answer the question of whether the defect in NK cell recruitment to Matrigel tumors in
selectin-deficient mice is intrinsic to NK cells or depends on prior recruitment of some other cell.
The challenges we have encountered in the adoptive transfer experiments and some preliminary
data can be found in Appendix C.
In summary, in this chapter we establish that NK cells are necessary for tumor suppression, that
they may act in the same tumor suppression pathway as selectins, and that selectin-deficient mice
have a clear defect in the ability of their NK cells to eliminate tumors in vivo. The data so far
have confirmed that NK cells play a part in selectin-dependent tumor suppression. We therefore
have at least a partial answer to the questions posed at the beginning of this work. Whether NK
cells are the only immune cell type that contributes to selectin-dependent tumor suppression, and
what is the exact mechanism of this phenomenon, remains to be discovered.
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Possible outcomes of NK cell interactions with dendritic cells
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B
Model of NK cell crosstalk with the adaptive immune system
in tumor suppression
Figure 1. The role of NK cells in innate-adaptive crosstalk (adapted from Degli-Esposti MA et. al.,
2005). A. The interaction of NK cells with DCs can lead to several outcomes, depending on the relative
numbers of interacting cells and the maturation state of the DC. Dendritic cells promote NK activation
and proliferation through both soluble and contact-dependent signals. Conversely, NK cells can promote
DC maturation, or mediate killing of immature DCs, while mature DCs are protected against NK-mediated
killing. B. Through activating DCs, or through direct interactions, NK cells can promote cytotoxic T cell
responses. This may be important in alerting the adaptive immune system to the presence of a tumor and
activating anti-tumor adaptive immune response.
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NK cells but not macrophages
are efficiently depleted by TM-f1 antibody injection
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Figure 2. NK cells can be efficiently and stably removed either by TM-PI antibody injection or by
using GrzA-Ly49Atg mice. A. As measured by the % NK1.1+/CD3 - cells in the blood, mice injected
with TM-PI1 NK-depleting antibody (1 mg/mouse i.p.) selectively lose NK cells but not macrophages as
compared to mice treated with the same dose of an isotype control antibody. Antibody removes NK cells
within 3 days of injection and maintains them at near undetectable levels for at least 3 weeks, the duration
of our tumor experiments. B. Similarly, GrzA-Ly49Atg+ mice that are genetically deficient in NK cells, as
compared to Ly49Atg littermates, remain depleted of NK cells even after 3 weeks of tumor challenge,
while T cells are unaffected. Results are expressed as percent of cells in NK-depleted animals as compared
to the appropriate controls ± SEM.
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NK cell depletion enhances
LL/2 tumor growth
*C
B NK cell depletion does not
significantly affect tumor growth
in the absence of selectins
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Figure 3. S electin-dependent enhancement of tumor growth can be phenocopied by removing NK
cells. A. LL/2 tumor weight was assayed at 3 weeks post injection in mice depleted of NK cells, either
pharmacologically by TM -31 antibody injection three days prior to tumor cell transfer, or genetically in
GrzA-Ly49Atg mice. Depletion of NK cells by either method significantly enhanced tumor growth. B.
Conversely, depletion of NK cells in selectin-deficient mice did not significantly enhance tumor growth
over what is already observed in the absence of selectins alone. Results are expressed as a box-whisker
plot, the central line denoting the mean, the shaded gray boxes and the lines denoting the 90th, 75th, 25th,
and 10th percentiles; plotted below are the corresponding tumor incidences (*p<0.05 by two-tailed
students' t test).
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Generation of B16 cells
expressing the Raele NKG2D ligand
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Figure 4. Generation and testing of B16 lines expressing the NKG2D receptor ligand Raele. A.
B 16 cells were infected with a viral construct containing either the puromycin selection cassette alone
(B16-puro) or the selection cassette and RaelE (B16-RaelE). The cell lines, as well as the parental cells,
were grown and selected in parallel. Rael antigen expression was confirmed by FACS analysis. B. A
schematic demonstrating NK-dependent rejection of B16 cells expressing Rael, but not of regular B16
cells. Based on the work of Dr. Raulet [Diefenbach A et. al., 2001]. C. The cell lines derived above were
injected subcutaneously into either C57BL/6 mice treated with a control antibody, or mice treated with
the NK-depleting TM -P 1 antibody. Tumor growth was monitored by measuring tumor surface area with
calipers (L*W=tumor surface area, mm2). Mice treated with the control antibody all grew B16-puro
tumors, while 9/10 mice completely rejected B16-Rael tumors. B16-RaelE rejection was abolished in the
absence of NK cells. Data are presented as average tumor growth curves for 5-10 animals+SEM.
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ELP-'- mice fail to reject B16-Raels cells in vivo
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Figure 5. Selectin-deficient mice are defective in B16-Raels tumor rejection and therefore
demonstrate defective in vivo NK cell function. A. B16-puro and B16-RaelE cells were injected into
the flank of 8-12-week-old ELP- mice. B16-puro tumors grew in 15/16 mice, while B16- Raele tumors
grew in 18/18 mice. ELP -/  mice demonstrated a severe defect in NK-dependent tumor rejection. B. B 16-
puro and B16-Rael e cells were also injected into mice missing single selectins to determine which selectins
are important for NK-dependent tumor rejection in this sy stem. Similarly to previous data, L-selectin and
P-selectin-null mice were both partially defective in B16- Rael tumor rejection, while E-selectin alone did
not seem to contribute greatly. Data are presented as average tumor growth curves+SEM. The number of
animals that developed tumors out of the total number of animals tested are indicated in boxes next to the
growth curves.
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A NK cells may activate cytotoxic T cells to kill tumor targets
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Figure 6. Selectin-deficient NK cells do not mediate tumor rejection through T cell activation.
A. NK cells are known to interact with DCs and T cells to enhance cytotoxic T cell responses. We
therefore hypothesized that, as presented above, efficient tumor elimination by selectin-null NK cells in
GrzA-Ly49tg+ hosts may depend on the ability of donor NK cells to activate T cells in the recipient,
which are normal, functional, and may or may not require selectins to reach and eliminate the tumor. B. To
test this hypothesis, we transferred 5* 106 CD3+ total splenic T cells/mouse into ELP-- animals 3 days
prior to B16-puro and B16- Rael tumor cell injection. If selectin-null NK cells are capable of acting
through a parallel pathway that involves T cell activation, than normal, selectin-sufficient T cells should
prevent B 16- Rael tumor growth in selectin-deficient mice. However, this does not seem to be the case,
as 5/5 animals that received C57BL/6 T cells grew B 16- Rael tumors. Tumor growth data for untreated
ELP-/ mice are shown for comparison. Data are presented as average tumor growth curves+SEM.
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GrzA-Ly49tg + mice fail to reject B16-Raele cells in vivo
W __ A91. W _-AdlL- i
300
250
200
150
100
50
V " 1 10 L3 L L0 V V 14 IV 10 L1 L2 L3 4.0 3V
days after tumor injection
B
NK transfer test to determine whether L-selectin and selectin ligands
on NK cells are sufficient to mediate tumor rejection
B16-Raele
r L........ .. a _
\ 
tumor 
cell
NK cells
TUMOR?
NK cells
No tumor
Figure 7. GrzA-Ly49Atg+ mice fail to reject B16-Raele tumors and can be used to test the function
of L-selectin on NK cells in vivo. A. B16-puro and B16-Rael cells were injected into the flanks of 8-12-
week-old GrzA-Ly49Atg+ NK-deficient and of GrzA-Ly49Atg control mice. B16-puro tumors grew in
all animals, while B 16- Rael tumors grew only in GrzA-Ly49Atg+ mice. These data once again confirm
the importance of NK cells for B 16-RaelE tumor rejection. Data are presented as average tumor growth
curves±SEM. B. A schematic of a test to determine whether L-selectin on NK cells is sufficient to ensure
NK-dependent tumor growth suppression. GrzA-Ly49Atg+ NK-deficient mice will receive adoptively
transferred NK cells from C57BL/6 or from L-' and/or PSGL-1-/- mice, and injected with B16- Rael
tumor cells. If L-selectin on NK cells is sufficient for NK-dependent tumor suppression, then mice that
received C57BL/6 NK cells should be able to reject B 16- Raels tumors, while mice reconstituted with L-
selectin-null NK cells should be unable to do so.
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Figure 8. NK cells can be isolated to reasonable purity and adoptively transferred. A. NK cells
were isolated from mouse spleens by using DX5-coated beads (Milteniyi Biotech). This method typically
resulted in isolation of -70% pure NK cells, as assayed by FACS for% of DX5', NK1.1 + , CD3- live
leukocytes. B. NK cells were isolated by the above method from the spleens of CD45.1-congenic mice
and transferred by tail vein injection into C57BL/6 or ELP- recipients at 1*106 cells/mouse. NK cells
were monitored in the blood, spleen and mesenteric lymph nodes of the recipients by FACS for CD45.1+,
NK1.1 +, CD3- cells. Data are displayed as a table of total donor NK cells found in all organs, by number
and percentage of originally injected cells, on days 1-7 after NK cell transfer.
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CHAPTER 6.
CONCLUSIONS AND FUTURE DIRECTIONS
The contents of this chapter were written by Olga Sobolev, with editing by Richard Hynes.
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Summary of results
Tumor immunoediting is a complex process, many aspects of which remain poorly understood.
Among many remaining questions about how the immune system detects and suppresses
malignancies, this thesis focuses on two:
1. What is the role of adhesion molecules in immune surveillance?
2. What is the role of innate immune cells in immune surveillance?
Adhesion molecules must play an important role in immune cell interactions with tumors. In
order to find and eliminate a tumor, immune cells must be able to enter the tissue to reach a
developing solid tumor, interact with tumor cells directly in order to recognize and eliminate
them, exit the tumor into the lymphatic circulation, and traffic to the draining lymph node in
order to activate the adaptive immune response to tumor. Adhesion molecules are key for all of
the above steps. While the adhesion molecules involved in leukocyte traffic in cases of infection
are well studied, few data are available on adhesion events that guide leukocyte traffic in
immune response to malignancy.
Innate immune cells are known to play an important role in immune surveillance. There is
clinical and experimental evidence to implicate macrophages [Vakkila J et. al., 2004; Allavena P
et. al., 2008], mast cells [Conti P et. al., 2007; De Nardo DG et. al., 2007], eosinophils [Lowe D
et. al., 1981], DCs [Kim R et. al., 2007] and NK cells [Diefenbach A et. al., 2001; Cerwenka A
et. al., 2001] in interactions with tumors. However, it isn't clear whether these innate immune
cells protect against tumors or promote tumor growth. Evidence of both functions exists at least
for mast cells [Coussens LM et. al., 2002; Ribatti D et. al., 2003], macrophages [Mantovani A et.
al., 1977; Coussens LM et. al., 2002; Mantovani A et. al., 2002; Balkwill F et. al., 2005] and
DCs [Mahnke K et. al., 2002; Wakkach A et. al., 2003; Ghiringhelli F et. al., 2005; Kim R et. al.,
2007].
Previous work in the laboratory provided an experimental model where it seemed possible to
address both the role of adhesion molecules and the role of innate immune cells in tumor
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immune surveillance. It was found that mice missing selectins, a family of adhesion molecules
important for leukocyte recruitment from blood into tissue and lymphoid organs [Ley K et. al.,
2007], have increased subcutaneous tumor growth [Taverna D et. al., 2004]. This suggested that
selectins are normally important for immune suppression of tumors. Since the experiments were
performed in Rag2 "' " mice that lack the adaptive immune system, and the tumor phenotype
largely transferred with bone marrow transplants, this also implied that an innate immune cell is
important for eliminating tumors. We hypothesized that in selectin-deficient mice, some
tumoricidal innate immune cell fails to migrate appropriately because of the absence of selectins
and therefore fails to control the growth of the tumor.
We began our studies by moving from the original model, which used subcutaneous injection of
human cell lines into Rag2 "' selectin-deficient and selectin-replete mice, to a model using
subcutaneous injection of syngeneic murine cell lines into fully immune-competent selectin-
deficient and selectin-replete mice. The reason for this transition was two-fold. First, the original
mice were of mixed background, and the selectin-deficient and control colonies have been
breeding separately for several years, raising concern that our control mice were no longer a
good comparison for the selectin-deficient animals. We therefore wanted to switch to using
purebred mouse lines. Second, this transition would allow us to analyze tumor growth in the
context of an intact, unmanipulated immune system.
In the process of establishing the new model, we tested several syngeneic tumor cell lines of
different origin (melanoma, colon carcinoma, lung carcinoma, teratocarcinoma) in several mouse
backgrounds (original mixed, C57BL/6, Balb/c, 129S4). In all cases but one we observed
increased tumor growth in selectin-deficient mice, indicating that selectin-dependent tumor
suppression is a real and important phenomenon, at least in the context of subcutaneously
injected tumors. We also confirmed that in our models, as reported previously for human tumor
cell lines [Taverna D et. al., 2004], L-selectin contributed the most to tumor suppression, P-
selectin contributed somewhat, and E-selectin did not contribute significantly. Finally, we
confirmed that in our model the absence of the adaptive immune system (nude mice on Balb/c
background; Rag2- mice on C57BL/6 background) did not lead to increased tumor growth,
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verifying that selectin-dependent tumor suppression is unlikely to be mediated by the adaptive
immune system but probably depends on the innate immune system.
Selectins play a role in immune cell recruitment to tissues and to lymphoid organs. The lymphoid
organ traffic is more important for the adaptive immune system activation than for activation of
innate immune cells. Since the adaptive immune system did not appear to contribute to tumor
suppression in our system, we hypothesized that, in this case, selectins may be necessary for
innate immune cell infiltration into the tissue, namely into the tumor itself. To establish which
immune cell fails to be recruited to the tumor in the absence of selectins, we captured and
analyzed tumor-infiltrating immune cells using Matrigel. This assay led to several essential
findings. First, we established that in all mice, regardless of the presence or absence of selectins,
there is a tumor-specific immune response. The initiation of tumor growth in our system is
coupled to significant tissue injury from the injection of tumor cells, therefore it was particularly
important to ascertain that the immune response we observed is due to the tumor and not simply
to injury. Second, we determined that the tumor-specific immune response is particularly
apparent on days 5-7 after tumor injection, and begins to wane by day 10. Third, we found that
the tumor-specific immune response is defective in selectin-deficient mice. In particular, fewer
macrophages, dendritic cells and NK cells were recruited to the tumor in the absence of selectins.
The most severe and consistent defect we observed was in the recruitment of NK cells. In the
absence of either all three selectins or of L-selectin alone, only half as many NK cells entered the
tumor on day 7 after tumor injection. Since NK cells are also the most abundant tumor-specific
infiltrating immune cells on day 7 (30-35% of infiltrating leukocytes), are known to be
tumoricidal, and fail to infiltrate the tumor in the absence of selectins, they became our top
candidate for mediating selectin-dependent tumor suppression.
To exclude the possibility that not only NK cell migration but also other aspects of NK cell
function are affected by the absence of selectins, we characterized selectin-deficient NK cells in
detail. We established that NK cells in selectin-deficient mice are present in normal numbers and
that their development is unaffected. We also found that selectins are not necessary for NK cell
killing of tumor target cells in in vitro cytotoxicity assays, and that selectin-deficient NK cells
are capable of normal cytokine secretion in response to several stimuli. Overall, NK cells in
219
Chapter 6
selectin-deficient mice appeared normal and functional apart from their defect in entering the
tumors in vivo.
In light of these results, we focused on the role of selectins in NK cell migration. We first
confirmed that NK cells indeed express L-selectin and the main selectin ligand, PSGL-1, as has
been previously reported [Frey M et. al., 1998; Andre P et. al., 2000]. Next we attempted to
establish the possible ligands for L-selectin or receptors for PSGL-1 (E-selectin, P-selectin) in
tumor endothelium by staining thin tumor sections. These experiments did not yield any useful
data, possibly because the tumor vascular ligand for L-selectin may well be different from the
currently established ones and we could only stain for the known ones. Taking a different
approach, we used the NK cells themselves to test for selectin-dependent binding to tumor
vasculature in Stamper-Woodruff assays. This approach did not prove successful, for a different
reason. NK cells bound very strongly and quickly to the tumor cells themselves, thus frustrating
our efforts to observe binding to the vasculature.
As investigation of the role of selectins in NK cell interaction with tumor sections in vitro failed
for technical reasons, we proceeded to explore the role of NK cells and their selectins in tumor
suppression in vivo. First we demonstrated that NK cells are required for suppression of
subcutaneous tumors. Growth of several subcutaneously injected tumor cell lines was enhanced
in the absence of NK cells. This finding was true for two different NK-deficient models: mice
acutely depleted of NK cells with the TM-131 antibody [Tanaka T et. al., 1993], and GrzA-
Ly49A transgenic mice with a genetic NK cell deficiency [Kim S et. al., 2000]. The defect in
tumor clearance in GrzA-Ly49A transgenic mice that we observed confirms the previous report
that these mice are more susceptible to experimental B 16 cell lung metastases and subcutaneous
RMA-S lymphoma tumors [Kim S et. al., 2000]. Overall, NK cells are clearly important for
tumor elimination in our model.
Having established that NK cells are important for tumor suppression in our system, we
proceeded to determine whether selectins are necessary for NK-dependent tumor elimination.
First, we tested whether NK cell depletion and selectin deficiency synergize in potentiating
tumor growth. We did not see any additional effect on tumor growth when both NK cells and
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selectins were removed. This lack of synergy suggested that selectins and NK cells act in the
same pathway in tumor elimination. However, other explanations were possible, for example that
we have reached the detection limit of our system and tumors physically could not grow any
faster than we observed in the absence of either selectins or NK cells.
To test the function of NK cells in selectin-deficient mice more directly, we used matched cell
lines, one that is relatively resistant to NK-mediated killing and the other that is specifically
targeted by NK cells due to expression of a ligand (Rael E) for an NK cell activating receptor
NKG2D [Cerwenka A et. al., 2001; Diefenbach A et. al., 2001]. While the resistant cell variant
should grow in all mice and serve as a positive control for tumor cell injection efficiency, the
NK-susceptible cell variant should only grow in mice where NK cell function is defective. We
confirmed that the cell lines we generated were behaving as expected by testing them in mice
depleted of NK cells with the TM-p 1 antibody, and GrzA-Ly49A transgenic mice. The resistant
cell line gave rise to tumors in all animals, while the NK-susceptible tumors only grew in NK-
deficient mice but not in control animals (treated with an isotype control antibody, or matched
siblings without the transgene, respectively). Having tested the system and established that it did
report clearly on the functionality of NK cells in live mice, we proceeded to test our selectin-
deficient animals. NK-susceptible tumors grew in all triple selectin-knockout mice. Of the single
selectins, similar to our previous observations on tumor growth in selectin-deficient animals, L-
selectin and P-selectin both contributed to NK-dependent tumor elimination, while E-selectin did
not contribute significantly. This establishes that selectins are necessary for NK cell elimination
of tumor targets in a live animal.
Taken together, our data provide evidence that selectins are necessary for tumor elimination, that
NK cells are necessary for tumor elimination, and that NK cells require selectins to clear tumor
targets in vivo. We also found that, in the absence of selectins, NK cells are normal and
functional but defective in entering the tumor. The simplest model suggested by these findings is
that in our system NK cells require selectins, particularly L-selectin, and selectin ligands on their
surface in order to interact with the tumor vasculature, enter the tumor, and eliminate it. There is
some support in the literature for this model. One paper has demonstrated that NK cells use L-
selectin to enter lymph nodes and eliminate melanoma cells there in a mouse model [Chen S et.
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al., 2005]. Our findings do not address NK cell traffic to the lymph nodes, which may well
depend on different cell adhesion mechanisms than traffic to non-lymphoid tissues. However,
this at least supports that idea that NK cells use L-selectin-dependent migration in vivo. The
second publication is more relevant, demonstrating that in L-selectin-deficient mice,
subcutaneous melanoma growth and experimental lung metastasis are enhanced and NK cell
numbers around primary or metastatic tumors are reduced on day 14 after subcutaneous or tail-
vein injection of tumor cells [Yamada M et. al., 2006]. This would support the idea that in a
model similar to ours NK cells use L-selectin for migration into the tumor.
Future work
The work described in this thesis raises interesting questions that need to be addressed. We are
still pursuing some of them. One important caveat to the proposed model is that we have not
actually demonstrated that the defect in NK cell function observed in selectin-deficient mice is
cell-intrinsic and not due to the failure of some other selectin-dependent cell that regulates NK
cell recruitment or function. In a similar vein, we have not demonstrated that NK cells are the
only innate immune cell type affected by the absence of selectins. Indeed, our data would argue
the opposite, since we also observed some defects in tumor-specific recruitment of macrophages
and dendritic cells in the absence of selectins. Thus, NK cells and their recruitment may be
necessary but not sufficient to explain selectin-dependent tumor suppression. To address some of
these issues, we are performing NK cell adoptive transfer experiments (some preliminary data
are presented in Appendix C). Transfer of selectin-deficient or selectin-replete NK cells into
NK-depleted mice, followed by injection of NK-susceptible tumor cells, would establish whether
the NK cell functional defect in the absence of selectins is cell-intrinsic. It would also be
interesting to see whether the transfer of selectin-replete NK cells into selectin-deficient mice
can rescue selectin-dependent tumor suppression. If so, a defect in NK cell migration would be
sufficient to explain enhanced tumor growth in the absence of selectins.
Conversely, we have not demonstrated that selectins are the only adhesion molecules that are
required for NK cell migration to the tumor. From the classic model of leukocyte recruitment,
chemokines and chemokine receptors, and integrins, should play a role as well. At present it is
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not clear what molecules are necessary for NK cell recruitment to tumors. This thesis implicates
selectins in NK cell migration to tumors. Of the chemokines, CX3C chemokine (fractalkine) and
its receptor CX3CR1 are at present the only ones that have been definitively implicated in NK
cell tumor recruitment [Lavergne E et. al., 2003; Xin H et. al., 2005]. Of the integrins, one
publication showed that ICAM-1 is important for control of subcutaneous tumor growth and for
NK cell recruitment to the tumor 14 days after tumor injection [Yamada M et. al., 2006]. This
suggests that aLP32 and aMP2 integrins, which are the receptors for ICAM-1, may be involved
in NK cell recruitment to tumors. Previous work from our laboratory indicated that 33 and P5
integrins are important for controlling subcutaneous tumor growth; however, in that case it is
unclear whether the effect depends on the immune system or is due to other factors such as
angiogenesis [Taverna D et. al., 2004]. Overall, it is unclear which integrins are important for
NK cell migration and trafficking in different situations, although it is known that many integrins
are expressed on NK cells [Morris MA et. al., 2004; Gregoire C et. al., 2007]. We have
confirmed the expression of some of the integrins on freshly isolated and cytokine-activated NK
cells (Appendix D). In our laboratory we have many integrin-deficient mouse models, as well as
reagents and methods for analyzing NK cell function in tumorigenesis. It would be interesting to
use these resources to explore the role of integrins in NK cell infiltration of tumors.
In the case of directly investigating the interaction of NK cells with the tumor vasculature we
were unsuccessful, due to technical difficulties. However, the questions remain about the precise
mechanism and timing of NK cell recruitment to tumors, as well as their behavior in the tumor. It
might be informative to use intravital microscopy methods to observe directly the recruitment
process of NK cells into the tumor, and alterations to this process in the presence or absence of
selectins and other adhesion molecules. In this regard it would be particularly helpful to have a
mouse model where NK cells were specifically labeled with fluorescent molecules, or where
adhesion molecules could be removed only in NK cells. To address this issue we attempted to
generate an NK-specific Cre mouse model, using a reportedly NK-specific Granzyme M
promoter [Smyth MJ et. al., 1992; Kelly JM et. al., 1996; Sayers TJ et. al., 2001]. Unfortunately,
our attempt was unsuccessful, as is recorded in Appendix E. Recently a mouse has been
generated that expresses green fluorescent protein in NK cells under the control of an NK
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receptor NKp46 promoter [Walzer T et. al., 2007]. This model looks very promising as a tool for
microscopy studies of NK cell migration.
Lastly, it would be useful to extend our work on the role of selectins and NK cells in tumor
suppression to spontaneous tumor models. As mentioned already, our method of inducing tumors
is necessarily concurrent with tissue damage and resulting inflammation. While we showed that
the tumor-specific immune response is still clearly detectable over the response to the injury, it is
still possible that the quality of the immune response is different from what it would be in case of
a naturally arising tumor. Also the process of tumor growth itself in our model is not particularly
physiological. We inject fully transformed, rapidly growing cells, that give rise to sizeable
tumors within a month of injection. A naturally arising tumor that proceeds through all stages of
transformation slowly may well interact differently with its microenvironment and be treated by
the immune system in a different way than what we observe in our system. To address the role of
selectins in spontaneous tumors, we have crossed our selectin-deficient mice to a mouse model
carrying a stop cassette flanked by LoxP sites (LSL) in front of an oncogenic kRas allele
[Jackson EL et. al., 2001]. In this model, adenoviral delivery of Cre to the tissue results in the
Cre-mediated excision of the stop cassette and kRas expression, leading to formation of
spontaneous tumors [Jackson EL et. al., 2001; Dinulescu DM et. al., 2005]. We will use this
model to induce lung tumors in selectin-deficient and control animals and investigate the role of
selectins in the growth of, and immune response to, spontaneously arising lung cancer. The LSL-
kRas mice and help with adenoviral lung infections are kindly provided by the Jacks lab (MIT).
Concluding remarks
The results from this thesis have contributed a small piece of knowledge towards a more
complete understanding of tumor immunology, particularly in the poorly understood areas of
immune cell migration in cancer and of innate immune response to cancer. We have examined
the role of one family of adhesion molecules, the selectins, in a mouse model of tumorigenesis,
and determined that this family contributes to tumor immune surveillance in our experimental
system. We have also uncovered some of the mechanism by which selectins control tumor
growth by demonstrating that NK cell recruitment and in vivo tumor-suppressive functions are
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defective in the absence of selectins. Understanding the migration and recruitment mechanisms
of immune cells in cancer, while challenging, is both scientifically interesting and possibly
clinically valuable in the future. Immune cell transfers for T cells, DCs and NK cells are
currently in clinical trials as anti-cancer therapy methods [June CH, 2007; Kawakami Y et. al.,
2008; Woan K et. al., 2007]. Knowing something of the molecular mechanisms that guide
immune cell migration to tumors may perhaps allow us to target the immune response
specifically to the tumor some day.
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CELL LINES
Unmanipulated cell lines
LS180 human adenocarcinoma, B 16 C57BL/6 melanoma, LL/2 C57BL/6 Lewis lung carcinoma,
CT26 Balb/c adenocarcinoma, and F9 129S4 teratocarcinoma cells were obtained from the
American Type Culture Collection (ATCC, Manassas, VA). MC38GFP C57BL/6 cells were
obtained from the laboratory of Dr. Ajit Varki (UCSD). All tumor cell lines were cultured in
Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% of heat-inactivated
fetal bovine serum (FBS), glutamine and penicillin/streptomycin (100X stock from Gibco-
Invitrogen). Cells were passaged approximately every 3 days and released with Versene or
Versene supplemented with 0.25% Trypsin (Gibco-Invitrogen).
TM- 31 hybridoma cells were obtained from the lab of Dr. Tanaka (Osaka University, Japan),
and the RR4-7 hybridoma cells were a kind gift from the lab of Dr. Herman Eisen (MIT, Boston,
MA). Hybridoma cells were cultured in RPMI medium supplemented with 10% of heat-
inactivated fetal bovine serum (FBS), glutamine and penicillin/streptomycin (100X stock from
Gibco-Invitrogen). In the cases where hybridoma supernatants were later used for antibody
purification, the 10% FBS was replaced by 4% IgG-depleted FBS.
Yac-l lymphoma cells for use in the NK cell cytotoxicity assays were obtained from the
American Type Culture Collection (ATCC, Manassas, VA) and cultured in RPMI medium
supplemented with 10% of heat-inactivated fetal bovine serum (FBS), glutamine and
penicillin/streptomycin (100X stock from Gibco-Invitrogen).
For all cell types, cell freezing was accomplished by resuspending cells in 95% FBS and 5%
dimethyl sulfoxide (DMSO) Hybri-Max (Sigma-Aldrich, St. Louis, MO).
LL/2 cells expressing Renilla luciferase
Renilla luciferase was cloned by PCR and inserted into Mid7 viral vector. VSVG-pseudotyped
retrovirus containing the Renilla construct was generated in Human Embryonic Kidney 293
(HEK 293) cells by Dr. Patrick Stern and was used to infect LL/2 cells. Stably infected cells
were selected with neomycin (100X stock from Gibco-Invitrogen). The resulting stable LL/2-
Renilla cell line was tested for Renilla expression by cell lysate luminescence in the presence of
the substrate, coelentrazine (Biotium), and by whole cell luminescence in the presence of
substrate by microscopy (NightOwl imaging system and WinLight32 software, Brethold
Technologies).
B16 cells expressing the NKG2D ligand Raele
The MSCV-Raele vector was kind gift from Dr. David Raulet at UC Berkeley. Rae 1E was
transferred by cloning into an in-house lentiviral vector developed by Dr. Partick Stern. He
generated lentivirus containing either Rae ~E and puromycin selection cassette, or the puromycin
selection cassette alone, in HEK 293 cells. Two 100mm plates of B 16F0 cells of the same
passage number were infected in parallel with either Raele-puro or puro-alone lentivirus, and
subsequently selected, also in parallel, with puromycin (100X stock from Gibco-Invitrogen).
Resulting stable cell lines, designated B 16-puro Rael 8 and B 16-puro, were tested for Rae ls
expression by FACS using the pan-specific anti-mRael antibody (R&D Systems).
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MICE
Selectin-null mice
Mice missing all combinations of selectins were created and bred in our laboratory [Mayadas TN
et. al., 1993; Arbonds ML et. al., 1994; Labow MA et. al., 1994; Frenette PS et. al., 1996;
Robinson SD et. al., 1999].. The animals were originally made on a mixed C57BL/6 and 129S4
background. They were subsequently back-crossed for 8-9 generations into C57BL/6, Balb/c, or
129S4 backgrounds. Animals for back-crossing were obtained from Taconic. The mice are
maintained as pure-breeding knockout lines, since they are viable and fertile in that state.
However, all the breeding pairs are genotyped to ensure the purity of the colony. The following
primers are used for genotyping:
E-selectin: Esel (F) 5'-GGACTGTGTAGAGATTTACATTC-3'
Esel (R) 5'-GCAGGTGTAACTATTGATGGT-3'
Esel (R2) 5'-CACGAGACTAGTGAGACGTG-3'
L-selectin: Lsel
Lsel
Lsel
(F)(R)(R2)
5'-GGGAGCCCAACAACAAGAAG-3'
5'-CACCAGCAGGAACAAACAAA-3'
5'-CACGAGACTAGTGAGACGTG-3'
P-selectin: Psel (F) 5'-TTGTAAATCAGAAGGAAGTGG-3'
Psel (R) 5'-AGAGTTACTCTTGATGTAGATCTCC-3'
Psel (R2) 5'-CACGAGACTAGTGAGACGTG-3'
Starting with 1001tM primer stocks, the primer mixes for each selectin are made by combining
4.2UtL of the forward (F) primer with 2.1 tL of each of the reverse primers (R and R2) and
91.6[tL of water. The final PCR reaction, using DNA obtained from an -0.25cm 2 piece of mouse
ear dissolved in 200[pL TE buffer, and the Quiagen HotStar PCR kit, is as follows:
10X PCR buffer 2.5[tL
MgCl 2
dNTP
l1lL
21tL
The PCR conditions
selectin primer mix 3E L
dH20O 14.375[tL
Taq HotStar 0.125[1L
DNA 1itL
that give good results for any of the selectin reactions are:
Step 1. 95 0C, 15min.
Step 2. 94 0C, 30sec.
Step 3. 55°C, 45sec.
Step 4. 720 C, 1min.
Step 5. Repeat steps 2-4, 35 cycle
Step 6. 720C, 20min.
The expected products are:
For E-selectin, the WT band is 664bp and the knockout band is 300bp.
For L-selectin, the WT band is 810bp and the knockout band is 343bp.
For P-selectin, the WT band is 322bp and the knockout band is 479bp.
s
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Rag2'" mice
Immune-deficient mice missing the recombination activating gene 2 (Raf2-) on C57BL/6
background were obtained from the laboratory of Dr. Chen (MIT). Rag2" mice were used in
crosses with selectin-null animals and were genotyped by the following PCR protocol:
Rag2 primers: Rag2-2 (F) 5'-AGCCTGCTTATTGTCTCCTG-3'
Rag2-1 (R) 5'-TCTCCCAGAACTTCAGGATG-3'
Rag2-Neo (R2) 5'-GGCACCGGACAGGTCGGTCTTGAC-3'
Primer stocks were diluted to the concentration of 20pmole/[LL for use. The final PCR reaction,
using DNA obtained from an -0.25cm 2 piece of mouse ear dissolved in 200[tL TE buffer, and
the Quiagen HotStar PCR kit, is as follows:
10X PCR buffer 2.5RtL
MgCl 2  0.5[tL
dNTP 2tpL
Rag2-2 2[L
RAG2-1 1ctL
Rag2-Neo 1 [iL
dH20 14.875[L
Taq HotStar 0.125 jL
DNA 1j L
The following PCR conditions were used:
Step 1. 95*C, 15min.
Step 2. 95 0C, Imin.
Step 3. 550C, Imin.
Step 4. 72*C, 2min.
Step 5. Repeat steps 2-4, 32 cycles
Step 6. 720C, 15min.
The expected products are: the WT band is 420bp and the knockout band is 620bp.
Granzyme A-Ly49A transgenic mice
Immune-deficient mice where the development of NK cells is disrupted by the insertion of the
Ly49A NK receptor under the control of the Granzyme A promoter (Granzyme A-Ly49Atg)
backcrossed to the C57BL/6 background were obtained from the laboratory of Dr. Yokoyama
(Washington University St. Louis). The mice have been maintained as a heterozygous colony, as
the homozygous transgenic is lethal. Also, due to the importance of NK cells for proper
placentation, breeding pairs should ideally consist of Granzyme A-Ly49Atg" females and
Granzyme A-Ly49Atg ÷ males. Mice were genotyped by the following PCR protocol:
Rag2 primers: NKD-S (F) 5'-GCTGATTGGGGTGGGAGAG-3'
NKD-A (R) 5'-CTCTCTTTGCACTGCAGACT-3'
Primer stocks were diluted to the concentration of 10 Opmoles/JtL for use. The final PCR reaction,
using DNA obtained from an -0.25cm 2 piece of mouse ear dissolved in 200[L TE buffer, and
the Quiagen HotStar PCR kit, is as follows:
10X PCR buffer 51AL
MgCl 2  2.5[1L
dNTP 4[tL
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NKG-A 2itL
NKG-S 2[tL
dH20 33.25RL
Taq HotStar 0.25tL
DNA iiL
The following PCR conditions were used:
Step 1. 950C, 15min.
Step 2. 95 0C, Imin.
Step 3. 54°C, 1.5min.
Step 4. 720 C, 1.5min.
Step 5. Repeat steps 2-4, 32 cycles
Step 6. 720C, 15min.
The expected product is a 1kb band if the transgene is present.
SUBCUTANEOUS TUMORS
Tumor cell preparation for subcutaneous injection
Tumor cells were grown to near confluence in 100mm dishes, then treated with 2mL of Versene
at 370 C for 5 min, dissociated from the plate, supplemented with 8mL of warm complete
medium and pelleted by centrifugation at 200rcf for 5min. The medium was completely removed
and the cells washed twice (200rcf, 5min.) with chilled Hank's Balanced Salt Solution (HBSS,
Gibco-Invitrogen). The cells were then counted and diluted with HBSS to the final concentration
of 5x104cells/mL in 5mL polystyrene round-bottom tubes (Beckton Dickinson). In the cases
where tumor cells were injected with Matrigel, the final dilution was done in 50%HBSS/50%
growth factor-reduced Matrigel (BD Biosciences). From the final dilution until injection the cells
were kept on ice in all cases.
Tumor injection
8- to 12-week-old mice were anesthetized with an intraperitoneal injection of
avertin/tribomethanol (Sigma). The cell suspension was mixed by inverting the tube 3 times, and
drawn up into the barrel of a 1 mL syringe, which was subsequently capped by a 26-gauge
needle. Anesthetized mice were laid on their side on a clean paper towel and the fur was moved
aside with a wet finger to expose the skin on the flank, just above the pelvis. The needle was
inserted under the skin and 200uL of cell suspension (1x104 cells) was injected. The formation of
a "bump" created by the cell suspension under the skin was indicative of a successful injection.
Monitoring tumor growth
In the cases where tumor growth was monitored, beginning on day 14 after tumor injection mice
were monitored every 2-3 days by palpation for the presence of any masses at the injection site.
If such a mass was detected, its length and width were measured with calipers and recorded.
Tumor surface area was calculated by multiplying the length of the tumor by its width.
Measurements were continued until either the tumor surface area approached 400mm 2, at which
point the mouse was euthanized to prevent undue pain or distress to the animal, or until the end
of the experiment (28 days post tumor injection).In the cases tumor size was only compared at
the final time point (3 weeks post tumor injection), this was accomplished by dissecting the
animals, carefully removing the tumor mass, and weighing it.
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Further processing of tumor samples
Tumor samples were subsequently processed in several ways, depending on the experiment. For
future protein, DNA or RNA extraction, small pieces of the tumor were placed inside 1.5mL
Eppendorf tubes and flash-frozen in liquid nitrogen. For frozen sections, tumor samples were
placed into a mould, completely covered with O.C.T. Compound (Tissue-Tek), and frozen on dry
ice. Alternatively, tumor samples were fixed overnight in 3.7% formalin buffered in PBS, or in
Zinc Fixative IHC solution (Becton Dickinson) and subsequently stored in 70% ethanol until
sectioning.
Immune cell extraction from Matrigel samples
In Matrigel timecourse experiments, Matrigel "plugs" were dissected from the animals on days
1, 3, 5, 7, and 10 after injection. Between 4 and 7 mice of each genotype (C57BL/6, L-, ELP"/')
were analyzed at every time point. Care was taken to dissect the entire piece of Matrigel and at
the same time make sure that other tissues were excluded. The entire sample was immediately
placed into an Eppendorf tube containing 0.2% auto-digested collagenase I (Worthington
Biochemical Corporation) in PBS and mechanically dissociated into fine pieces with scissors.
The samples were digested with agitation at 37*C for 2 hours, then strained through a 70ýtm
nylon sieve. Any remaining larger pieces were mashed through the sieve with the rubber-capped
end of a plunger from a 3.5mL syringe. The sieve was then washed with 2mL of FACS buffer
(0.5% BSA and 2mM EDTA in PBS) to collect all the cells. A 100[tL sample was taken out for
counting the total cell number in the sample at this point. The cells were pelleted by
centrifugation, and treated as any other FACS sample from this point on (see cell preparation
for FACS).
ANTIBODIES USED
CD3, CD4, CD8, NKI.1, Grl, PECAM-1, CD62E (E-selectin), CD62L (MEL14, L-selectin),
CD62P (P-selectin), PNAd (MECA-79), CD 162 (PSGL-1), DX5 (a2 integrin), CD1 la (LFA-1;
aL integrin), CD 1 lb (Mac- 1; aM integrin), CD 11 c (aX integrin), aV integrin, a4 integrin, a5
integrin, aE integrin (CD 103), a4P7 integrin, P2 integrin, I3 integrin, P37 integrin, rat isotype
controls and goat anti-rat secondary antibodies, as well as fluorophore-conjugated steptavidin (in
cases where a biotinylated primary antibody was used) were obtained from BD Biosciences.
Anti-mouse H-2Db, H-2D d, H-2Kb and H-2Kd antibodies were obtained from Biolegend. Pan-
specific anti-mRael antibody was obtained from R&D Systems. TM-P31 NK-depleting and RR4-
7 control antibodies were generated in the lab (see Appendix B for methods) from hybridoma
supernatants. The hypridomas were provided by, respectively, Dr. Tanaka (Osaka University,
Japan), and Dr. Herman Eisen (MIT, Boston, MA).
THIN SECTION STAINING
5ptm thin frozen sections were cut from tumor samples, prepared as described above (see
Further processing of tumor samples). Alternatively, sections of freshly isolated spleen and
lymph nodes frozen in O.C.T. compound by the same method were prepared. Sections were cut
by Denise Crowley, KI histology facility. Sections were thawed at room temperature, rehydrated
in PBS for 5min. and fixed in cold 10% acetone on ice for 10min. Sections were then washed,
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blocked for 10min. in appropriate 10% normal serum in PBS, and stained for 30min. and room
temperature with primary antibody diluted in PBS (1:50 dilution for anti-P selectin, anti-E
selectin and anti-PNAd antibodies; 1:10 dilution of anti-PECAM- 1 antibody). Where
appropriate, a second blocking step and secondary antibody staining was performed for 45min. at
room temperature (1:100 dilution of goat anti-rat antibody; 1:100 dilution of streptavidin-PE if a
biotinylated primary antibody was used). The sections were then washed 3x5min. in PBS and
mounted with Vectashield-DAPI hard-set mounting medium (Vector Laboratories). Sections
were examined for staining on a DeltaVision deconvolution microscope (Applied Precision).
FLOW-ASSISTED CELL SORTING (FACS) ANALYSIS
Immune cell isolation for FACS from blood
In experiments where immune cells were monitored or assayed in the blood, blood was collected
by making a small incision with a sterile blade on the tail of an appropriately restrained mouse.
The incision was made across one of the lateral tail veins, and several drops of blood (-20-50[tL
total) were collected into 10tL of 1U/tL heparin solution (Sigma). The tail wound was treated
with the KwikStop (Gimborn) anesthetic/styptic/disinfecting compound prior to returning the
mouse to its cage, to ensure that the bleeding has stopped. The blood samples were diluted with
100[tL of FACS buffer (0.5% BSA and 2mM EDTA in PBS) and layered over ImL of density
gradient Lympholyte M solution (Cedarlane Laboratories) in a 1.5mL Eppendorf tube. The
samples were then centrifuged at 750-800rcf for 30min. with no brake at room temperature to
remove the red blood cells, which pellet to the bottom of the tube, while the leukocytes remain in
suspension in the density gradient. The leukocyte suspension was removed from the tubes,
washed with 2mL of cold FACS buffer by centrifugation for 8min. at 700rcf, and the resulting
cell pellet was treated as any other FACS sample from this point on (see cell preparation for
FACS).
Immune cell isolation for FACS from bone marrow
In experiments where immune cells were monitored or assayed in the bone marrow, the femur
was removed from a freshly euthanized mouse, cleaned with ethanol-disinfected paper towels,
and placed into cold RPMI medium. The ends of the femur were removed, and the marrow
flushed out using a 5mL syringe filled with RPMI medium and a 27-gage needle. The marrow
was resuspended in RPMI by pipetting, strained through a 70[pm nylon sieve to remove large
tissue clumps, and then pelleted by centrifugation. To remove red blood cells, the bone marrow
pellet was resuspended in FACS buffer (0.5% BSA and 2mM EDTA in PBS) and centrifuged
over Lympholyte M, as described above for blood samples. After collection and washing of the
leukocyte layer, the resulting cell pellet was treated as any other FACS sample from this point on
(see cell preparation for FACS).
Immune cell isolation for FACS from spleen and lymph nodes
In experiments where immune cells were monitored or assayed in the spleen or in the lymph
nodes, the tissue of interest was removed from a freshly euthanized mouse under sterile
conditions, and placed into cold FACS buffer (0.5% BSA and 2mM EDTA in PBS). 10mL of
FACS buffer were used for a spleen and 3mL for a lymph node. Frosted glass slides were then
used to dissociate the tissue by rubbing it between the frosted ends of buffer-moistened slides.
The resulting cell suspension was then strained through a 70itm nylon sieve to remove large
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tissue clumps, and pelleted by centrifugation. For lymph node samples, the resulting cell pellet
was at this point ready for FACS staining (see cell preparation for FACS). The spleen samples
were further processed by centrifugation over Lympholyte M to remove red blood cells, as
described above for blood samples. After collection and washing of the leukocyte layer, the
resulting cell pellet was treated as any other FACS sample from this point on (see cell
preparation for FACS).
Cell preparation for FACS
For FACS staining, cells were counted with a hemocytometer and resuspended in FACS buffer
(0.5% BSA and 2mM EDTA in PBS) at -1-5x1 06 cells/100[tL. The cell suspension was placed
into a 4mL polystyrene round-bottom FACS tube and centrifuged to reduce the sample volume
in cases where the cells were few. The cell pellet was resuspended in 100[tL of 10% normal
serum in FACS buffer. The blocking serum was selected to match the origin of the staining
antibody (in our case, usually normal rat serum). The samples were blocked for 5min. at room
temperature, and then 100L of 1:100 dilution of the staining antibody in FACS buffer was
added. The samples were incubated with the antibody at 40C in the dark for 25-30min., then
washed with FACS buffer. In cases where a biotinylated or an unlabeled primary antibody was
used, this was followed by a second 30min. incubation in the same conditions with 100[1L of
1:100 dilution of labeled streptavidin or secondary antibody, followed by washing in FACS
buffer. In cases where the analysis was to be performed the next day, cells were fixed at this
point by addition of lmL of 4% paraformaldehyde in PBS, followed by dilution with lmL of
PBS after 10min. of fixation. The samples were then stored at 4*C in the dark until analysis.
Incases where the analysis was performed immediately, washed cells were resuspended in 100[tL
of FACS buffer, usually containing 2l[g/mL propidium iodide in order to exclude dead cells. The
cells were assayed on FacsScan or FacsCalibur (BD Biosciences) machines for live cells stained
with antibody. Cells labeled with isotype control antibodies were used to set the gating
parameters. Data were analyzed and plotted using the FlowJo software.
NK CELL ISOLATION FROM SPLEEN
Isolation using positive selection
To isolate NK cells by positive selection, cell suspensions were prepared from spleens of freshly
euthanized 8-12-week-old selectin-sufficient or selectin-deficient mice. Cell preparation was the
same as described above (see Immune cell isolation for FACS from spleen and lymph nodes)
up to the wash after the Lympholyte M density centrifugation. Isolated leukocytes were treated
from this point on according to the protocol provided with the DX5 MicroBeads for NK cell
isolation (Miltenyi Biotech). Briefly, the leukocyte suspension is mixed with paramagnetic beads
coated with the DX5 antibody, washed, and passed through a magnetic column (XS, LS or MS,
Miltenyi Biotech MACS products). The cells that bound to the DX5 beads are retained on the
column, while unlabeled leukocytes pass through it. After washing, the bound fraction can be
eluted.
Isolation using negative selection
We used two methods of NK cells isolation using negative selection. In the first method,
suspensions of spleen leukocytes from the spleens of age- and sex-matched selectin-sufficient
and selectin-deficient mice were prepared as described above for positive selection. NK cells
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were then isolated followinf the protocol provided for the NK cell isolation kit (Miltenyi
Biotech). Briefly, the leukocyte suspension is labeled with a biotinylated antibody cocktail to
label every cell but the NK cells, washed, incubated paramagnetic beads coated with anti-biotin
antibody, washed, and passed through a magnetic column (XS, LS or MS, Miltenyi Biotech
MACS products). The cells that bound to the anti-biotin beads are retained on the column, while
unlabeled leukocytes (enriched for NK cells) pass through it and are collected for use.
In the second method, suspensions of spleen leukocytes from the spleens of age- and sex-
matched selectin-sufficient and selectin-deficient mice were prepared as described above (see
Immune cell isolation for FACS from spleen and lymph nodes) through the tissue
dissociation step. The protocol for the SpinSep mouse NK cell enrichment kit (Stem Cell
Technologies) was then followed. Briefly, the leukocyte suspension is labeled with a biotinylated
antibody cocktail to label every cell but the NK cells, washed, incubated density beads coated
with anti-biotin antibody, washed, and centrifuged over a density gradient. The cells that bound
to the anti-biotin beads are denser and therefore sink to the bottom of the tube, as do the red
blood cells, while unlabeled leukocytes (enriched for NK cells) remain suspended in the gradient
and are collected for use.
NK cell adoptive transfer
NK cels isolated by any of the above methods were counted using a hemocytometer to establish
cell numbers, and a small sample was analyzed by FACS for NKl.1 +, DX5+, CD3Y live
leukocytes to establish the purity of the preparation. The cells were then resuspended in Hank's
Balanced Salt Solution (HBSS) at -lx10 6 -5x105 NK cells/100IxL. 100tL of this suspension was
injected into live anesthesized recipient mice, either through the lateral tail vein or intraorbitally.
NK CELL IN VITRO FUNCTIONAL ASSAYS
Colorigenic cytotoxicity assay
NK cells isolated by the positive selection method described above were cultured overnight ( 18
hours) in 6-well plates at -1x10 6 NK cells/well in RPMI medium supplemented with 10% of
heat-inactivated fetal bovine serum (FBS), glutamine and penicillin/streptomycin (100X stock
from Gibco-Invitrogen), 125U/mL IL-2 (BD Biosciences) and 75ng/mL IL-15 (Sigma). The cells
were collected the following morning, counted using a hemocytometer to establish cell numbers,
and a small sample was analyzed by FACS for NK1.1 ÷, DX5+, CD3" live leukocytes to establish
the purity of the preparation. NK cells and target cells of interest (Yac-1, LL/2) were then mixed
at varying effector:target ratios in a 96-well plate. To create the ratios, variable numbers of NK
cells were added to a constant number of target cells (xl 104 Yac-1 cells/well; 2x10 3 LL/2 or other
tumor cells/well). The cells were co-incubated in RPMI medium supplemented with 5% of heat-
inactivated fetal bovine serum (FBS), glutamine and penicillin/streptomycin (100X stock from
Gibco-Invitrogen) for 4 hours 370C in C02 incubator, and the supernatants were then assayed for
target killing using the CytoTox Non-Radioactive Cytotoxicity assay (Promega). In cases where
L-selectin blocking was used, NK cells were blocked with 1:100 dilution of the L-selectin
blocking antibody MEL 14 (BD Biosciences), and then added to the assay with the antibody, so
that the blocking antibody was present throughout the assay. % target killing was calculated as:
= experimental cytotoxicity - effector spontaneous cell death - target spontaneous cell death x100
target maximum cell death - target spontaneous cell death
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Interferon gamma ELISA
The supernatants were collected from the NK cells cultured overnight (-~18 hours) for
cytotoxicity assays (see above). Supernatants were then analyzed for interferon gamma content
using the DuoSet ELISA Development System for IFNy (R&D Systems). The final results were
adjusted to accurately reflect the number of NK cells that produced the cytokine (calculated from
number of NK cells in the well at the time of medium collection). Medium containing no NK
cells was used as a baseline for the assay, while the standard curve was set using dilutions of
IFNy standard provided with the kit.
Interferon gamma intracellular staining and FACS analysis
6-well plates were coated with lmL of 0.5-2jig/mL anti-NK1.1 antibody (BD Biosciences) in
PBS for lhr. 20min. at 37"C, then rinsed 3 times with PBS. Freshly isolated total splenocytes
were prepared from selectin-deficient and selectin-sufficient mouse spleens as described above
(see Immune cell isolation for FACS from spleen and lymph nodes) up to the wash after the
Lympholyte M density centrifugation. Cells were counted and resuspended at 1x10 7 cells/mL in
cold RPMI medium. ImL of cell suspension was added to each well of the 6-well antibody-
coated plate prepared above, and the cells were incubated for 45 min. at 370C in C02 incubator.
10 L of the 1:100 dilution of the stock Brefeldin A solution (Cytofix/Cytoperm Kit, BD
Biosciences) was added per well and mixed by gentle swirling, then the plates were incubated at
the same conditions for additional 6-8hrs. The stimulation was stopped by the addition of 5mL of
cold FACS buffer (0.5% BSA and 2mM EDTA in PBS) per well. The cells were harvested by
pipetting up and down vigorously about 30 times using a 5 ml pipette, pelleted by centrifugation,
and stained for NK1.1 +, IFNy+, CD3" live leukocytes following the instructions provided with the
Cytofix/Cytoperm Kit. Staining was detected on FacsCalibur flow cytometer (BD Biosciences)
and analyzed using FlowJo software.
STAMPER-WOODRUFF ASSAY FOR CELL ADHESION
10 Om thick frozen sections were cut from tumor samples, prepared as described above (see
Further processing of tumor samples). Alternatively, sections of freshly isolated spleen and
lymph nodes frozen in O.C.T. compound by the same method were prepared. Sections were cut
by Denise Crowley, KI histology facility. Sections were thawed at room temperature, rehydrated
in PBS for 5min. and fixed in cold, freshly made 4% paraformaldehyde on ice for 10min. Slides
were then washed 3x5min. with PBS and, where appropriate, incubated for 30min. with control
or selectin-blocking antibodies. Freshly isolated (see Isolation using positive selection) or
cytokine-stimulated (see Colorigenic cytotoxicity assay) NK cells at 3x1 07 cells/mL were
incubated for 30min. at 37"C in C02 incubator with 20g/mL of either isotype control or L-
selectin blocking antibody (MEL 14) and 0.15g1L/mL of 2jiM CFSE dye (Molecular Probes) in
unsupplemented RPMI. The cells were then washed in RPMI supplemented with 10% of heat-
inactivated fetal bovine serum (FBS), glutamine and penicillin/streptomycin (100X stock from
Gibco-Invitrogen). Cells were resuspended in supplemented RPMI at 3x1 07 cells/mL, and 1001gL
of the NK cell suspension was overlaid on the tissue sections prepared above. Slides were
incubated in a humidified chamber on a rotating table (60-70rpm) for 30min. at room
temperature. Slides were then washed by dipping each slide into PBS 30 times, and fixed with
10% cold acetone in PBS for 10min. on ice. The blood vessels were then stained with rat anti-
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PECAM-1 antibody followed by secondary goat anti-rat fluorochrome-conjugated secondary
antibody staining following the protocol described above (see Thin section staining). The slides
were mounted in PBS, as overlaid cells were observed to detach in Vectashiled, and examined
using an Axiovert 200 inverted microscope (Zeiss).
REFERENCES
Arbonds ML, Ord DC, Ley K, Ratech H, Maynard-Curry C, Otten G, Capon DJ, Tedder TF
(1994). Lymphocyte homing and leukocyte rolling and migration are impaired in L-
selectin-deficient mice. Immunity 1(4): 247-260.
Frenette PS, Mayadas TN, Rayburn H, Hynes RO, Wagner DD (1996). Susceptibility to
infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell 84:
563-574.
Labow MA, Norton CR, Rumberger JM, Lombard-Gillooly KM, Shuster DJ, Hubbard J, Bertko
R, Knaack PA, Terry RW, Harbison ML (1994). Characterization of E-selectin-deficient
mice: demonstration of overlapping function of the endothelial selectins. Immunity 1(8):
709-720.
Mayadas TN, Johnson RC, Rayburn H, Hynes RO, Wagner DD (1993). Leukocyte rolling and
extravasation are severely compromised in P selectin-deficient mice. Cell 74(3): 541-554.
Robinson SD, Frenette PS, Rayburn H, Cummiskey M, Ullman-Cullere M, Wagner DD, Hynes
RO (1999). Multiple, targeted deficiencies in selectins reveal a predominant role for P-
selectin in leukocyte recruitment. PNAS 96: 11452-11457.
242
Appendix B
APPENDIX B.
RAT IgG2b ANTIBODY PURIFICATION
FROM HYBRIDOMA SUPERNATANTS
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To perform the NK cell depletion experiments, we required Img of antibody per mouse. Such
large amounts are difficult to obtain commercially, therefore we decided to purify the TM-P31
NK-depleting [Tanaka T et. al., 1993] and the RR4-7 isotype control antibodies ourselves from
hybridoma supernatants. The hybridoma cell lines were a kind gift from, respectively, Dr.
Tanaka (Osaka University, Japan) and Dr. Eisen (MIT).
Several attempts at antibody purification failed before a successful method was discovered. First,
we attempted to purify the antibodies based on charge with diethylaminoethyl (DEAE)-modified
sepharose beads (Sigma). This method did not prove useful, as many serum proteins from the
hybridoma culture medium co-purified with the antibody (Figure 1A). Second, we tried to purify
the antibody by Protein L-conjugated beads (Pierce Biotechnology). This protein binds to
antibodies through the K light chain, and was reported to bind well to rat but not to bovine
antibodies, which would make it particularly useful in antibody purification from bovine serum-
containing hybridoma supernatants [Nilson BH et. al., 1993]. We did find that the beads bound
extremely well and specifically to the antibody, however we could not discover a method that
would allow us to elute the antibody from the beads without destroying it in the process (Figure
IB). Lastly, we tried to purify the antibody using Protein G-coupled beads (BD Biosciences).
They do not bind particularly well to the rat antibody isotype that we were trying to purify
[Akerstr6m B et. al., 1985], but in view of the Protein L experience we felt that might be an
advantage. This method proved to be very successful, giving us good quantities of highly pure
antibody (Figure 2). Because a large volume of hybridoma supernatant was required to obtain the
amount of antibodies that we needed, in the final protocol we developed the Protein G step was
preceded by an ammonium sulfate cut. This both concentrated the antibody and purified it of a
fraction of contaminating serum proteins.
Hybridoma cell culture
Hybridomas were expended in 75mL Falcon tissue culture flasks in RPMI medium
supplemented with 10% of heat-inactivated fetal bovine serum (FBS), glutamine and
penicillin/streptomycin (100X stock from Gibco-Invitrogen). Once the cells have filled the
flasks, they were centrifuged to remove the medium and transferred into 1L glass spinner flasks
in RPMI supplemented with 4% of heat-inactivated IgG-depleted FBS, glutamine and
penicillin/streptomycin (100X stock from Gibco-Invitrogen). The cells were left to grow until
their density exceeded the nutrients in the medium and cells started exhibiting signs of apoptosis.
At this point the cells were centrifuged, the supernatants were collected, filtered, and stored at
40 C in sterile flasks until further use.
Ammonium sulfate cut
When 2-4 liters of hybridoma supernatants have been collected, we proceeded to the antibody
purification. Saturated ammonium sulfate was added dropwise to tissue culture supernatants to
the final concentration of 55% v/v. This step was typically performed overnight at 4VC with
constant stirring of the supernatant. As the antibody precipitated with addition of the salt, the
solution became cloudy. Once the desired concentration of ammonium sulfate has been reached,
the supernatant was centrifuged for 30min. at 4500rcf in sterile 500mL bottles. The supernatant
was discarded and the yellow-orange antibody-containing pellets were stored at 4°C until further
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use. We typically collected ammonium sulfate precipitates from 8-10 liters of hybridoma
supernatants before proceeding with the experiments.
Protein G antibody purification
Ammonium sulfate precipitates were resuspended in the smallest possible volume of PBS and
dialyzed into 0. 1M sodium acetate, pH 5. The dialyzed solution was spun down at top speed in
the benchtop centrifuge to remove any debris before proceeding. The dialyzed antibody solution
was then passed through a column containing 5mL of Protein G-coupled sepharose beads (BD
Biosciences). As the binding capacity of Protein G-coupled sepharose beads is reported to be
18mg of antibody for 1 mL of beads, this volume should be sufficient for most large-scale
antibody purifications. The column was washed with 6 column volumes of running buffer (0.1M
sodium acetate, pH 5) and eluted with 7 column volumes of 0.1M glycine, pH 3. The 5mL
elution fractions were collected into 300[tL 1.5M Tris, pH 8.8, in order to neutralize the solution
and limit any possible pH damage to the antibody. The flowthrough and wash fractions were
passed through the Protein G column a second time to recover any antibody that might have
escaped. The wash and elution steps were repeated and the eluent fractions collected. Thus every
purification yielded a total 80mL of antibody solution. The 14 eluent fractions were analyzed by
Western blot for antibody content and by silver stain gels for purity. The fractions that were
found to contain the most antibody (typically fractions 3-6 of 7 in every elution) and the least
contamination were pooled, dialyzed into dH20, frozen and lyophilized.
Antibody preparation for injection
Lyophilized antibody was resuspended in sterile PBS and assayed for protein content first
approximately by absorbance at 280nm (lmg/mL = 1.8Abs) and subsequently more accurately
by the BCA Protein Assay kit (Pierce). Final antibody amount was calculated from the total
protein concentration in the sample by the BCA assay and the % whole antibody in the sample
by silver stain densitometry. The samples were then diluted to 2mg/mL of whole antibody,
aliquoted at 500[pL (1mg) per Eppendorf tube and stored at -400C until injection.
The antibody samples were also assayed for endotoxin content using the Endpoint Chromogenic
Limulus Amebocyte Lysate (LAL) analysis kit (Charles River). The permitted levels of
endotoxin are > 10ng/mouse, and toxicity is possible at higher doses. Our antibody preparations
were consistently 10-100 times below this limit in their endotoxin content, therefore we were
satisfied that the preparations posed no danger to our animals, and that our antibody purification
method was reasonably sterile.
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Antibody purification using DEAE beads
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Figure 1. DEAE and Protein L beads are not optimal for rat IgG b antibody purification. (A)
DEAE purification of TM-P 1 rat IgG2b antibody from hybridoma supernatant was not successful,
because many serum proteins co-purified with the antibody as can be seen on this silver-stained gel. A
commercially available rat antibody of the same isotype was used as a positive control. (B) Protein L-
coupled beads bind the TM-p1 rat IgG2 b antibody very well, as can be seen in this Western blot (probed
with goat anti-rat HRP-conjugated antibody). The antibody is completely captured by the beads (left
lane) and vary little remains in the supernatant (middle lane). However, the method is not useful because
the antibody cannot be eluted from the beads subsequently (right lane).
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A Western blot record of rat IgG2 b antibody purification
with protein G-coupled beads
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Silver stain record of rat IgG2b antibody purification
with protein G-coupled beads
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Figure 2. Protein G-coupled bead purification of rat IgG2b antibodies results in good antibody
yield and high purity. Protein G-coupled beads were used for purification of TM -P1 and RR4-7 rat
IgG2 b antibodies from hybridoma supernatants concentrated by ammonium sulfate. Despite highly
impure starting material (see hybridoma supernatant and flowthrough lanes), this method resulted in
successful purification of large amounts of whole (A) and very clean (B) antibodies. As a positive
control, commercially available pure rat antibody of the same isotype was used throughout the antibody
purification experiments.
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ADOPTIVE TRANSFER OF NK CELLS
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Our data demonstrate that both selectins (Chapter 2) and NK cells (Chapter 5) are necessary
for the suppression of subcutaneous tumors. However, the data do not directly show that
selectins on NK cells themselves rather than on some interacting immune cell are important, or
that NK cells are the only immune cell involved in selectin-dependent tumor suppression. We
started a series of adoptive transfer experiments to address these questions. The preliminary data
from the adoptive transfer experiments are presented here.
Adoptive transfer of NK cells isolated using positive selection
To determine whether the presence of selectins on NK cells is sufficient to prevent tumor
growth, we isolated NK cells from the spleens of either C57BL/6 mice or of ELP'" mice by using
DX5-coated beads (Miltenyi Biotech) and transferred them immediately after isolation into
GrzA-Ly49tg+NK-deficient recipient mice [Kim S et. al., 2000; Kim S et. al., 2006]. The cells
were injected into the tail vein at 5*105 cells/mouse. GrzA-Ly49tg- littermate recipients were
used as a negative control. LL/2 cells were injected into the flank three days after NK cell
transfer and allowed to grow as usual. Tumors were dissected and weighed 3 weeks after tumor
injection, in order to analyze whether the presence of transferred NK cells affected tumor growth
in the recipients. Unfortunately, all GrzA-Ly49tg+recipients developed tumors equally well,
regardless of NK cell transfer (Figure lA). The experiment was repeated several times, with no
improvement in the results.
We hypothesized that perhaps the number of NK cells we transferred was insufficient to have a
measurable impact on tumor growth, since we saw no reduction in tumor growth even in the
mice that have received C57BL/6 selectin-sufficient NK cells. From preliminary experiments we
also knew that transferred NK cells do not survive for much longer than a week in the recipient
(Chapter 5). Perhaps the timing of our initial transfers, three days prior to tumor injection, did
not allow transferred NK cells to survive long enough to make a difference to tumor growth. To
improve transfer efficiency, in the next experiment NK cells were transferred every 2-3 days,
beginning three days prior to tumor injection and continuing for two weeks after tumor injection.
Each mouse received a total of- 0*10 6 NK cells in six tail vein injections. This protocol both
boosted the overall number of transferred NK cells, and extended the period when tumors were
exposed to NK cells. Tumors were dissected and weighed 3 weeks after tumor injection. Again,
NK cell transfer did not prevent LL/2 tumor growth in any of the GrzA-Ly49tg+ recipients
(Figure IB).
Adoptive transfer of selectin-replete C57BL/6 NK cells into GrzA-Ly49tg+ recipients was our
positive control; this transfer procedure should have produced an equivalent of a normal
C57BL/6 mouse, capable of rejecting tumors. Since we could not reconstitute wild-type NK cell
function even with our best transfer protocol, we could not assay the function of selectins on NK
cells by this method.
Adoptive transfer of NK cells isolated using negative selection
New impetus for the adoptive transfer experiments was provided by a recent publication, which
indicated that our method of isolating NK cells may be at fault for the previous failure. The
method we used to isolate NK cells was positive selection with DX5-binding beads. In this
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procedure, the DX5 biotinylated antibody binds to the a2 integrin (CD49b) on NK cells, and the
cells are then isolated by binding to streptavidin-coated paramagnetic beads (Mintenyi Biotech).
It is known that the DX5 antibody does not activate NK cells upon binding to its integrin target
[Arase H et. al., 2001]. However, the crosslinking of integrins by the streptavidin bead in the
positive selection protocol does lead to integrin activation, much reduced NK cell motility, and
increased NK cell adhesion to collagen, which causes the majority of NK cells isolated by the
positive selection method to remain in the tissue, such as the lung, rather than enter the
circulation [Garrod KR et. al., 2007].
We therefore repeated the NK transfer experiments, this time using a negative selection approach
in which every cell but NK cells is labeled and depleted. We also made the assay more sensitive
by using the B 16-puro and B 16-Rae 1E tumor cells rather than the LL/2 cells. As described in
Chapter 5, B16- Rael tumor cells are specifically sensitive to NK cell killing. GrzA-Ly49tg+
NK-deficient mice were reconstituted by intraorbital injection with negatively selected (NK cell
negative selection kit, Miltenyi Biotech) NK cells isolated from spleens of C57BL/6 or from
ELP"/ mice, and injected with B16-puro and B16- Rael tumor cells. NK cells were isolated to
-90% purity as assessed by FACS analysis and transferred twice, 3 days prior to tumor injection
and 4 days after tumor injection, at a total number of 1*106 cells/mouse. The result was
unexpected. In mice reconstituted with C57BL/6 NK cells, B 16-puro tumors grew in all animals,
whereas B 16- Rael tumors grew in 4/8 mice while 4/8 rejected the tumor. Our positive control,
while not perfect in this initial experiment, at least gave the expected outcome of B 16-Rae 1
tumor rejection in half the cases. Surprisingly, mice reconstituted with ELP" NK cells rejected
3/4 B 16-puro tumors and all B 16-Rael E tumors (Figure 2A). All of our previous work had led us
to believe that NK cell in vivo function is defective in the absence of selectins. These results
indicated that their function is instead dramatically improved.
The experiment was repeated using NK cells from C57BL/6 or L' mice, isolated once again by
the depletion method but with a different kit (SpinSep NK cell enrichment kit, Stem Cell
Technologies). The purity of isolated NK cells as assayed by FACS at the time of transfer was
similarly good, at -90% of isolated cells being NK1.+, CD3". The NK cell transfer protocol and
the numbers of transferred cells were the same as in the above experiment. Results were similar
regarding the transfer of L" NK cells; this transfer led to complete rejection of both B 16-puro
and B16-Raele tumors. However, in this case the positive control failed, as the C57BL/6 NK
cells did not reject any of the B16-RaelE tumors (Figure 2B).
At this time we are somewhat skeptical about these new NK transfer data, for several reasons.
One is, the positive control in the first experiment worked in only half the cases, and failed
altogether in the second experiment, indicating that something may be wrong with the
experiment technically. These data also contradict previous results that demonstrate defective
NK cell recruitment to tumors (Chapter 3) and defective NK cell function in tumor rejection in
the absence of selectins (Chapter 5). However, if one were to accept these new data as valid,
and consider their implications, several interesting possibilities arise.
One possibility is that P-selectin and L-selectin can compensate for each other in NK cell
recruitment to tumor. We have some evidence suggesting that NK cells from selectin-deficient
mice are slightly hyperactivated. They are a bit better at killing Yac-1 target cells, secrete
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slightly more IFNy, and some subsets of them (although not the circulating NK cells, which are
the most likely candidates for reaching the tumor) express more NKG2D receptor, which could
make them better killers of B 16-Rae 1 E cells (Chapter 4). If these slightly more functional NK
cells used P-selectin to reach the tumor, they could well be better at tumor elimination than
selectin-replete NK cells. To test this hypothesis, we will use NK cells lacking the main selectin
ligand PSGL-1, or both PSGL-1 and L-selectin, in adoptive transfer experiments. These studies
are in progress. One caveat to this hypothesis is that we did not see less NK cell recruitment to
Matrigel tumors in the ELP"/" than in the single knockout L " mice (Chapter 3). However, P-
selectin could be important for some other aspect of NK cell function, since in actual tumor
growth assays the ELP- " mice are always affected more severely than any of the single selectin
knockouts (Chapters 2 and 5).
A second possibility is that something in the selectin-deficient mice is suppressing NK cell
function in vivo, and once NK cells are removed from that suppressive environment they are
perfectly capable of anti-tumor activity. The suppressing factor could be a cell; as mentioned in
the introduction to Chapter 5, regulatory T cells and myeloid-derived suppressor cells are both
known to suppress NK cell functions. It is somewhat difficult to imagine how the absence of
selectins, which reduces immune cell adhesion and migration, would promote such suppression
though. It seems that in the absence of selectins, any immune cell has less chance to enter the
tissue and contact other immune cells, whether to activate or to suppress them. A more likely
possibility is a soluble NK-suppressing factor. Selectin-deficient mice, particularly mice lacking
endothelial selectins, are known to have altered levels of circulating cytokines [Frenette PS et.
al., 1996]. These changes have never been studied systematically; we are planning to test
circulating cytokine levels in various selectin-deficient mice and correlate any changes in
cytokine levels with what is known about cytokine suppression of NK cells. If any such soluble
factors are found, their role in NK-dependent tumor suppression can be tested in vitro in NK cell
function assays and in vivo by injecting them into C57BL/6 mice and looking for a reduction in
the rejection of Bl6-Rael tumors.
The most interesting explanation for dramatically enhanced tumor rejection by NK cells from
selectin-null mice could be that the defect in NK cell recruitment in selectin-deficient mice is not
NK cell-intrinsic. If the selectin-dependent defect in NK cell rejection of tumors were not cell-
intrinsic, and the selectin-dependent NK cells were truly more functional in some manner, one
could imagine several scenarios. In one, NK cells would be activated by a selectin-dependent
cell. For instance, if NK cell function or recruitment to the tumor depended on prior recruitment
of macrophages to the tumor in a selectin-dependent manner, in a selectin-replete recipient
mouse the slightly hyperactive NK cells could well be more functional in tumor killing than
normal NK cells. Alternatively, NK cells could activate a selectin-dependent cell. For example,
transferred hyperactive selectin-deficient NK cells would reach the tumor (where their enhanced
function would compensate for lower numbers) and activate the DCs there. The activated DCs
would then migrate to the lymph node in a selectin-dependent manner that usually fails in the
selectin-deficient mice, and activate robust T cell response. This particular possibility is less
likely, as we could never detect any role for T cells in our system, but not impossible.
Any such models imply that NK cells interact with some other immune cell to mediate tumor
suppression. This is a very exciting possibility, since so little is known about NK cell interactions
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with other immune cells, particularly in vivo and in the context of tumors. However, the lack of
knowledge also makes any further study in this direction extremely challenging. The work would
have to be done by depleting various cell types and observing the effect on NK-dependent tumor
rejection. Since we never saw an effect of removing adaptive immune cells on NK-dependent
tumor suppression, it is most likely that the interacting partner is an innate immune cell.
Unfortunately, that means a long list of possible candidates, including various macrophage
subsets, DCs, mast cells, eosinophils, neutrophils, and so forth. Most of these cells are rather
difficult to deplete thoroughly and specifically.
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Adoptive transfer of NK cells isolated with DX5 beads
into GrzA-Ly49tg mice does not prevent LL/2 tumor growth
First NK transfer Second NK transfer
Repeated adoptive transfer of NK cells isolated with DX5 beads
into GrzA-Ly49tg mice does not prevent LL/2 tumor growth
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Figure 1. Adoptive transfer of NK cells isolated by DX5 beads does not prevent LU2 tumor growth.
A. NK cells were isolated from the spleens of either C57BL/6 mice or of ELP-/- mice by using DX5-coated
beads (M iltenyi Biotech). The cells were then injected at 5* 105 cells/mouse into the tail veins of GrzA-
Ly49tg+ recipients. GrzA-Ly49tg littermate recipients were used as a negative control. LL/2 cells were
injected into the flank three day s after NK cell transfer and allowed to grow as usual. Tumors were
dissected and weighed 3 weeks after tumor injection. All GrzA-Ly49tg+ recipients developed tumors
equally well, regardless of NK cell transfer. B. To improve transfer efficiency, NK cells were transferred
every 2-3 day s, beginning three day s prior to tumor injection and continuing for two weeks after tumor
injection. Each mouse received a total of 10* 106 NK cells in six tail vein injections. Tumors were dissected
and weighed 3 weeks after tumor injection. Again, NK cell transfer did not prevent LL/2 tumor growth in
any of the GrzA-Ly49tg + recipients. Data are presented as tumor weights in individual animals; the
horizontal black bars indicating the mean value for the data set.
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C57BL/6 NK cells prevent B16-Raele tumor growth in some mice,
while ELP-/" NK cells prevent growth of all tumor cells
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Figure 2. NK cells from selectin-deficient mice are more effective at in vivo tumor suppression
than wild-type NK cells. A. GrzA-Ly49tg+ NK-deficient mice were reconstituted by intraorbital
injection with NK cells isolated from spleens of C57BL/6 or from ELP-/ mice, and injected with B16-puro
and B16-Raele tumor cells. NK cells were isolated by depletion of all other cell types (NK cell isolation
kit, Miltenyi Biotech) to -90% purity as assessed by FACS analysis and transferred twice, 3 days prior
to tumor injection and 4 days after tumor injection, at the total number of 1*106 cells/mouse. In mice
reconstituted with C57BL/6 NK cells, B16-puro tumors grew in all animals, while B16- Rael tumors
grew in 4/8 mice while 4/8 rejected the tumor. Surprisingly, mice reconstituted with ELP-/ NK cells
rejected 3/4 B16-puro tumors and all B16- RaelE tumors. Data are presented as average tumor growth
curves±SEM. B. The experiment was repeated using NK cells from C57BL/6 or L-'- mice, isolated with a
different kit (SpinSep NK cell enrichment kit, Stem Cell Technologies), with similar results. C57BL/6 NK
cells failed to promote tumor rejection, L-"/ NK cell transfer led to complete rejection of all tumors.
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APPENDIX D.
FACS ANALYSIS OF INTEGRIN EXPRESSION
IN NATURAL KILLER CELLS
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Integrins are a large family of ap-dimeric cell adhesion molecules that are key for matrix
adhesion, migration, signaling and survival in many cells (Figure 1) [reviewed by Hynes RO,
2002]. As reviewed in Chapter 4, NK cells express many integrins, some of which vary in
interesting ways during NK cell development, and some of which, such as a2 integrin, DX5, are
widely used as NK cell markers (Figure 1). In the process of analyzing NK cells in C57BL/6
mice, we also looked by FACS for integrin expression on either freshly isolated or cytokine-
activated splenic NK cells. This appendix reports our findings.
32 family of leukocyte integrins
Fresh and cultured C57BL/6 splenic NK cells express all members of the P2 family, as has been
reported previously [Morris MA et. al., 2004; Gr6goire C et. al., 2007]. These integrins are
expressed at uniformly high levels on all NK cells and were downregulated slightly upon
cytokine activation (Figure 2). Since 32 family integrins are important for NK cell binding to and
direct cytotoxicity against target cells, this finding is interesting and might imply that, similarly
to what has been reported for human NK cells, with activation NK cells may lose cytotoxicity
but gain migratory properties and the ability to activate DCs and T cells instead [Mailliard RB et.
al., 2005; Martin-Fontecha A et. al., 2004].
P31 family and aV family integrins
Splenic C57BL/6 NK cells, either fresh or cultured, express P31-associated a5 and a2 integrin
subunits (Figure 3). Fresh and cultured NK cells also express aV-associated 33 integrin subunit,
which is expressed on the same cells as aV. aV and 33 integrin expression increases slightly on
cytokine-activated NK cells (Figure 3). The aV33 and aVP5 integrin expression on NK cells are
particularly interesting because in the original subcutaneous tumor growth experiments
performed by Dr. Taverna, 3-3/- and P33p55/ mice were also observed to have increased tumor
growth [Taverna D et. al., 2004]. It isn't at all clear that tumor growth is related to immune cell
involvement in this instance. However, if ctV integrin expression were necessary for proper NK
cell function, either by regulating NK cell development in the bone marrow [Kim S et. al., 2002],
or by upregulation on activated NK cells, the resulting NK cell defect could contribute to the
tumor phenotype.
17 integrin family
Splenic C57BL/6 NK cells, either fresh or cultured, express 37-associated a4 but not aE integrin
subunits. ua4P7 integrin is expressed on the same subset of NK cells and its expression does not
alter with NK cell activation with cytokines (Figure 4). a4 integrin also interacts with the p31
integrin subunit, which may explain the cells that express a4 but no 37 integrin. It is interesting
that a4P7 but not aEP7 integrin is expressed on NK cells, because these two integrins have been
associated with, respectively, lymphocyte homing to skin and gut [Marelli-Berg FM et. al.,
2008]. This might suggest that splenic NK cells are particularly primed for homing to some
tissues but not to others.
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Figure 1. Integrin expression on NK cells . Integrins are a large family of ap-dimeric cell adhesion
molecules. This figure (adapted from Hynes RO, 2002) shows the existing clp subunit combinations and
subdivides the integrins into subfamilies based on their cell expression pattern and substrate binding.
Circled in black are the integrins that have been detected on NK cells. In the following figures, we
assayed fresh or cytokine-activated NK cells isolated from spleens of C57BL/6 mice for the expression
of some of the above integrin family members.
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Figure 2. All members of the $2 family of leukocyte integrins are expressed on C57BU6 mouse
NK cells . NK cells were isolated from spleen of C57BL/6 mice. Cells were either analyzed directly or
activated overnight by culturing in the presence of IL-2 and IL-15. Cells wrere stained with antibodies and
analyzed by FACS for expression of leukocyte-specific 02 family integrins. Fresh and cultured
C57BL/6 NK cells expressed all members of the P2 family and seemed to downregulate them slightly
upon cytokine activation. Data are displayed as representative histogran~ and FACS plots of integrin
expression, gated on live NK1.1+, CD3- leukocytes.
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Figure 3. Some jP1 family and aV family integrins are expressed on C57BU 6 mouse NK cells.
Splenic C57BL/6 NK cells, either fresh or cultured, express P31-associated a5 aid a2 integrin subunits.
Fresh and cultured NK cells also express aV-associated P3 integrin subuit, which is expressed on the
same cells as aV. aV and P3 integrin expression increases slightly on cytbkine-activated NK cells. Data
are displayed as representative histograms and FACS plots of integrin expressidn, gated on live NK1.1+,CD3- leukocytes.
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Figure 4. a4P7 but not aE47 integrin is expressed on C57BIJ6 splenic NK cells . Splenic C57BL/6
NK cells, either fresh or cultured, express P7-associated a4 but not aE integrin subunits. a447 integrin
is expressed on the same subset of NK cells and its expression does not alter with NK cell activation
with cytokines. a4 integrin also interacts with the Pl integrin subunit, which may explain the cells that
express a4 but no P7 integrin. Data are displayed as representative histograms aid FACS plots of
integrin expression, gated on live NK1.1+, CD3- leukocytes.
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APPENDIX E.
NK CELL-SPECIFIC CRE EXPRESSION
USING A GRANZYME M PROMOTER
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Currently there is no mouse model where Cre recombinase is expressed specifically in NK cells.
Having such a mouse would be extremely useful for our experiments in NK cell migration, and
for the field of NK cell biology generally. We therefore attempted to create such a mouse.
The difficulty thus far has been that it isn't trivial to find a promoter that would function in all
NK cells but not in any other immune cell subset. Many genes that are expressed in NK cells,
such as most granzymes (proteases contained in the cytolytic granules), are also expressed in
cytotoxic T cells or NKT cells. On the other hand, purely NK-specific molecules, such as NK
receptor family members, are often only expressed by a subset of NK cells and do not cover the
whole population. In searching through the literature for a likely candidate, we came across a
few publications describing a new member of the granzyme family, granzyme M, which was
reported to be expressed exclusively in NK cells in rat [Smyth MJ et. al., 1992], mouse [Kelly
JM et. al., 1996], and human [Smyth MJ et. al., 1993; Sayers TJ et. al., 2001].
We cloned the reported functional promoter of the granzyme M gene (a 3.3 kb segment of 5'
sequence flanking the mouse granzyme M gene) [Kelly JM et. al., 1996] from freshly isolated
C57BL/6 splenocytes, and created a construct that consisted of a human interferon P scaffold
attachment region (SAR) element, followed by the granzyme M promoter, followed by Cre
recombinase containing an intron from the mouse P-globin gene. The SAR element is reported to
effectively prevent transgene silencing in stem cells and immune cells [Ma Y et. al., 2003;
Cooper LJ et. al., 2004], while insertion of an intron into Cre recombinase sequence leads to a
30-fold enhancement in mRNA production [Lacy-Hulbert A et. al., 2001]. The intron-containing
Cre was provided by Dr. Lacy-Hulbert in our laboratory, while the SAR element and generous
cloning advice were provided by Dr. Stern, also in our laboratory. Pronuclear injections were
performed by Peimin Qi, MIT Division of Comparative Medicine.
From the pronuclear injections we recovered 3 founder mice. Mice were genotyped by PCR for
the presence of Cre in tail genomic DNA. The founders were crossed to a Cre-inducible
ubiquitous EGFP reporter strain [Mao X et. al., 2001] obtained from Jackson Labs. Two
founders gave offspring, while the third could not be induced to breed. The offspring were also
genotyped for the presence of Cre by genomic PCR, and assayed by FACS for GFP expression
in immune cells. No GFP expression was detected in Cre+ animals as compared to their Cre-
siblings in any immune cell subset. Thinking that perhaps the granzyme M promoter may only be
functional in activated but not in resting NK cells, we induced inflammation by 3 injections
spaced 2 days apart of 250ýtL of polyl:C intraperitoneally, by a method previously described [Ni
H et. al., 2003]. This did not result in any induction of GFP expression in any immune cell types.
Finally, we isolated splenic NK cells from Cre+ and Cre- mice, and analyzed either fresh or
cytokine-activated NK cells for Cre mRNA content by RT-PCR. No Cre mRNA was detected.
Our method ultimately did not generate any useful animals. It is possible that the promoter
region we used, while functional in vitro, is not sufficient in vivo. However, another laboratory
used targeted Cre insertion into the granzyme M gene and also could not detect Cre expression in
any immune cell [Pao LI et. al., 2005]. A recent publication describes a more promising
approach using the promoter of the NKp46 NK receptor [Walzer T et. al., 2007]. It was
demonstrated to drive efficient expression of GFP and diptheria toxin specifically in NK cells.
No Cre mouse has been generated yet in that model, but one is likely forthcoming.
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